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Abstract 
There is evidence that dopaminergic dysfunction plays a role in the symptoms of bipolar 
disorder although the precise abnormality is unclear. In addition clysregulation of corticosteroid 
secretion characterised by a flattened diurnal circadian rhythm has been observed across mood 
states in bipolar disorder. As a result it has been hypothesised that corticosteroid 
hypersecretion underlies the dopaminergic dysfunction. Here the endocrine regulation of 
mesocorticolimbic doparninergic neurotransmission was investigated with the hope of bettering 
our understanding of the pathology of bipolar disorder. 
Immunocytochemical studies established that around half of dopaminergic neurones in the 
ventral tegmental area (VTA) express the low affinity glucocorticoid receptor (GR), whilst all of 
these neurones express the high affinity mineralocorticoid receptor (MR). This indicated that 
corticosteroids can directly modulate dopaminergic neuronal function. 
By administering corticosterone to rats in their drinking water a flattened circadian profile of 
corticosteroid secretion similar to that seen in bipolar disorder was modelled. In situ 
hybridisation histochemistry in the VTA revealed that corticosterone treatment increased the 
transcription of mRNA for tyrosine hydroxylase, the vesicular monoamine transporter and the D2 
receptor, whilst decreasing expression of the 5-HT2c receptor and the GluRl subunit of the 
AMPA receptor. 
In vivo microdialysis in the medial prefrontal cortex demonstrated increased doparnine release 
under both basal and stimulated conditions in corticosterone treated animals. This effect did not 
appear to be the result of altered D2 autoreceptor function or a change in the firing rate of 
cloparninergic neurones. In light of the in situ hybridisation data it is hypothesised that flattening 
the diurnal profile of corticosteroid secretion increases prefronto-cortical doparnine release by 
upregulating dopamine synthesis and vesicular uptake. 
These studies demonstrate that corticosteroid dysrhythmia of the type seen in bipolar disorder 
can alter doparninergic neurotransmission and furthermore they indicate specific aspects of 
dopaminergic function which might be altered. Thus circadian rhythm abnormalities in the HPA 
axis may play a role in the aetiology of bipolar disorder via clysregulation of dopaminergic 
neurotransmission. 
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Chapter 1. Introduction 
Bipolar affective disorder is an illness which has a devastating effect on the lives of those who 
suffer with it. The aetiology of this disorder is poorly understood and current drug therapies, in 
the most part discovered serendipitously, treat symptoms rather than targeting the underlying 
pathology. A better understanding of this disease offers the possibility of developing more 
effective therapies which will not only benefit individuals but reduce the burden of this chronic 
illness on society as a whole. 
The following thesis is based on an integrative hypothesis of bipolar disorder which provides a 
link between observed abnormalities in the hypothalamic-pituitary-adrenal axis and changes in 
brain function related to doparninergic neurotransmission. These studies have been carried out 
to investigate aspects of the endocrine regulation of dopaminergic neuronal systems, and the 
effect that alterations in HPA axis function have on these systems. Thus it is hoped to better our 
understanding of these systems as they relate to bipolar disorder 
1.1. Bipolar Disorder 
1.1.1. Symptoms and diagnosis 
The affective disorders, which include bipolar disorder, are a group of illnesses primarily 
characterised by clysregulation of emotion. The inappropriate emotional responses 
characteristic of affective disorders "do not reflect a realistic appraisal of the environment at the 
time" (Feldman et al. 1997) and result in significant impairment to behavioural and cognitive 
function. Compared to other psychiatric disorders, affective disorders are highly prevalent with 
estimates suggesting that 5% of the UK population (- 3.25 million people) suffer from mood 
disorders (Ohayon et al. 1996), whilst 10-20% of the population of the US can expect to suffer a 
significant affective episode at some point during their lives (Feldman et al. 1997) 
According to current classifications (DSM-IV, American Psychiatric Association 1994), 
affective disorders fall into two broad categories, unipolar depression (with major depressive 
disorder as it's archetype) and bipolar disorder. Bipolar disorder is characterised by episodes of 
2 
Chapter 1 
both elevated and depressed mood, with mood states categorised according to specific 
diagnostic criteria (see table 1.1. ). Different combinations of these mood states allows for the 
diagnosis of a number of related disorders classified as bipolar I disorder, bipolar 11 disorder, 
and cyclothymia (for review see Manning et al. 1998). 
It is the case however, that diagnosis in bipolar disorder is difficult due to the variability in 
presenting symptoms and the reliance on accurate recall of previous affective episodes (see 
Cassano et al. 1999; reviewed by Perlis 2005). High rates of comorbidity with other psychiatric 
disorders (reviewed by Krishnan, 2005; Hirshfeld and Vornik, 2005; Pini et al. 2005) further 
complicate the picture. 
Due to the variability in presenting symptoms, and the shortcomings of making diagnoses 
based on rigid criteria, in recent years there has been a trend towards viewing bipolar disorder 
as a continuum of phenotypes ranging from cyclothymia to predominantly mania (Muller- 
Oerlinghausen et al. 2002). Indeed some have proposed that the affective disorders as a whole 
represent a continuum ranging from predominantly manic bipolar disorder to major depressive 
disorder, with bipolar mixed states as a kind of halfway point between the two (Akiskal, 2002). 
Such a theory suggests a common underlying pathology across DSM-lV bipolar subtypes, 
however it may be the case that whilst these disorders share common symptoms they differ in 
their aetiology. This uncertainty makes research into the biological basis of bipolar disorder 
particularly difficult. 
1.1.2. Prevalence and disease burden of bipolar disorder 
The current lifetime prevalence of bipolar I disorder in the general population is thought to be 
1-2% (Avissar and Schreiber, 2002; Muller-Oerlinghausen et al. 2002, Pini et al. 2005) and 
affects men and women equally (Feldman et al. 1997; Pini et al. 2005). If all bipolar spectrum 
disorders are included in the analysis then the prevalence increases to around 6% (Pini et al. 
2005). The World Health Organisation has ranked bipolar disorder as sixth on a list of the 
leading causes of disability worldwide (Avissar and Schreiber, 2002; Hirshfeld and Vornik, 
2005). This can be attributed to the chronic nature of the disorder (Angst, 1978; Ten Have et al. 
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Chapter 1 
Bipolar I Disorder Bipolar 11 Disorder Cyclothymia 
The patient is currently (or most recently was) One or more major depressive episodes is or For at least 2 years, the presence of numerous 
in a manic, mixed, or major depressive has been present. periods with hypomanic symptoms and 
episode. numerous periods with depressive symptoms 
At least one hypomanic episode is or has been that do not meet criteria for a Major Depressive 
At least one previous manic, mixed or major present. Episode. Note: In children and adolescents, 
depressive episode has occurred which is fits the duration must be at least 1 year. 
the criteria for a mood state different to the The symptoms cause clinically significant 
one the patient is currently in. distress or impairment in social, occupational, During the above 2-year period (11 year in 
or other Important areas of functioning. children and adolescents), the person has not 
been without the symptoms in Criterion A for 
more than 2 months at a time. 
No Major Depressive Episode, Manic Episode, 
or Mixed Episode has been present during the 
first 2 years of the disturbance 
Note: After the initial 2 years (1 year in children 
and adolescents) of Cyclothymic Disorder, 
there may be superimposed Manic or Mixed 
Episodes (in which case both Bipolar I 
disorder and Cyclothymic Disorder may be 
diagnosed) or Major Depressive Episodes (in 
which case both Bipolar 11 Disorder and 
Cyclothymic Disorder may be diagnosed) 
The symptoms cause clinically significant 
distress or impairment in social, occupational, 
or other Important areas of functioning. 
Table 1.2. Criteria for diagnosis of bipolar disorder subtypes (adapted from DSM-lV criteria, 
APA, 1994; Manning et al. 1998) 
2003; Morgan et al. 2005) and the high comorbidity with other DSM-lV axis I disorders 
(reviewed by Krishnan, 2005; Hirshfeld and Vornik, 2005; Pini et al. 2005). Furthermore the 
disease carries a significant risk of mortality due to high rates of attempted and completed 
suicides (Chen and Dilsaver, 1996; Baldessarini et al. 2006). 
In addition to the burden for the individual, bipolar disorder represents a significant cost to 
society. Direct costs resulting from emergency treatment, hospitalization, psychiatric treatment 
and medication in the United States were estimated at $7 billion in 1991, whilst indirect costs 
result from impaired productivity, welfare costs, and criminality associated with the disease were 
estimated at $38 billion. Lost productivity due to suicide alone represented a significant 
proportion of this cost at $8 billion (Hirshfeld and Vornik, 2005). 
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1.1.3. Genetics of bipolar disorder 
Studies have demonstrated a high degree of heritability in bipolar disorder with first degree 
relatives of patients having higher rates of bipolar and unipolar disorders than the general 
population (Gershon et al. 1987). Further evidence comes from studies in twins where it has 
been shown there is much greater concordance for bipolar disorder in monozygotic twins than 
dizygotic twins (79% vs. 24% respectively) (Bertelsen et al. 1977). Interestingly the rate of 
concordance in monozygotic twins is much higher than it is for unipolar depression (where the 
rate of concordance is 54%) suggesting that there is a strong genetic predisposition to the 
disorder. 
1.1.4. Environmental risk factors 
Whilst there is a high degree of heritability in bipolar disorder, environmental factors play a 
significant role in triggering the condition. Chief amongst these factors is stress, such that 
adverse life events have been associated with first onset of symptoms (see reviews by Paykel, 
2003 and Tsuchiya et al. 2003) whilst a positive relationship has been shown between stress 
and recurrent bipolar episodes. In one study patients with bipolar I disorder who experienced 
episodes of illness showed greater total stress levels in the preceding months than those 
patients without episodes (Hammen and Gitlin, 1997). Furthermore, developmental adaptations 
to stress induced by early life adversity (physical or sexual abuse in childhood or adolescence) 
have been found to correlate with earlier onset of illness, faster cycling frequencies, increased 
suicide rates, more co-morbidities and greater total time ill than bipolar patients without a history 
of early life adversity (Post et al. 2001). 
1.1.5. Pharmacotherapy for bipolar disorder 
Current UK guidelines for the pharmacological management of bipolar disorder recommend 
the use of three principal classes of drug - mood stabilisers, antipsychotics and/or 
antidepressants (UK NICE guidelines, 2006). The following section provides a brief introduction 
to these drugs and the circumstances under which they are used. 
6 
Chapter 1 
1.1.5.1. Mood stabilisers 
The mood stabilisers are a group of drugs which include the monovalent ion lithium, and the 
anticonvulsant drugs valproate, carbamazepine and lamotrigine. These drugs are the mainstay 
of prophylactic treatment for bipolar disorder and are, for the most part, efficacious in the acute 
treatment of mania. There is evidence to suggest that while lamotrigine has prophylactic 
efficacy, it has greater utility for the treatment of acute depressive episodes than for acute 
mania (Fountoulakis et al. 2007). At the present time mood stabilisers are indicated for the first- 
line treatment of all phases of bipolar disorder (UK NICE guidelines, 2006). 
The first drug of this class was lithium, whose mood stabilising properties were recognised 
during the late 1940's to early 1950's (Atack et al. 1995). The mechanism by which lithium alters 
neuronal function to produce its mood stabilising effect is unclear, however it has been 
observed that lithium is a potent inhibitor of the intracellular enzyme inositol monophophatase 
(Atack et al. 1995; Lenox and Frazer, 2002; Brunello, 2004). This enzyme performs a key step 
in the regeneration of phosphoinositicle required for G-protein mediated signal transcluction, with 
the result that lithium inhibits agonist stimulated lP3/DAG signalling. One consequence of this is 
that protein kinase C (PKC) activity is reduced following long-term lithium treatment which has 
the potential to alter neuronal excitability, neurotransmitter release, and produce long-term 
alterations in gene expression and plasticity (Lenox and Fraser 2002; Brunello, 2004). Lithium 
also modulates the cAMP signal transduction pathway by reducing the receptor-coupled 
stimulation of adenylyl cyclase and increasing basal cAMP levels (Lenox and Frazer, 2002; 
Brunello, 2004; Montezinho et al. 2007). As cAMP modulates neuronal function via protein 
kinase A (PKA) this is an additional means by which lithium might modulate neurotransmission. 
A further property of lithium is its ability to increase Na+/K+ ATPase activity (Lenox and Frazer, 
2002). This results in a decrease in intracellular sodium and, because calcium concentrations 
largely parallel those of sodium, a concomitant decrease in intracellular calcium. Given that 
these two ions play a critical role in neuronal excitability and neurotransmitter release, this is a 
further mechanism by which lithium may regulate neuronal function. 
The remaining mood stabilisers valproate, carbamazepine and lamotrigine are anticonvulsants 
that inhibit sodium channels, particularly those with a high rate of activity (Ragsdale and Avoli, 
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1998). Carbarnazepine and valproate have also been shown to inhibit adenylyl cyclase activity 
(Montezinho et al. 2007), whilst valproate has been shown to inhibit PKC activity in a similar 
fashion to that produced by lithium (Brunello, 2004). Thus it is likely that these drugs produce 
their therapeutic effect via the modulation of ion permeability ad intracellular signalling pathways 
in neuronal cells. Further discussion of the functional effects of these drugs on dopaminergic 
cells can be found in section 1.1.6.4 (c). 
1.1.5.2. Antipsychotics 
Antipsychotics are efficacious for both the acute treatment of mania and long-term mood 
stabilisation, with some atypical (see later) antipsychotics showing acute efficacy in the 
depressive phase of the illness (Brambilla et al. 2003; Surja et al. 2006). Current UK guidelines 
recommend the use of antipsychotics for the treatment of mania, although the atypical 
olanzapine is considered an option for long-term management of bipolar disorder (UK NICE 
guidelines, 2006). 
Antipsychotics were discovered in the late 1940's when it was noted that various substances 
including promethazine produced tranquilising properties without sedation (Stip, 2002). 
Subsequent developments based on modifications to the phenothiazine structure of these drugs 
produced chlorpromazine, the antipsychotic effect of which was discovered in the early 1950's 
(Stip, 2002). A defining property of these early antipsychotic drugs, including haloperidol, 
thoridazine and flupenthixol, was their induction of so-called extra-pyramidal side-effects such 
as dystonia, akathisia, parkinsonism and tardive clyskinesia (Meltzer, 2002; Hood and Nutt, 
2004). With the subsequent development of antipsychotics which do not produce these extra- 
pyramidal effects, the notion of atypical (as opposed to classical) antipsychotics was introduced. 
Examples of atypical drugs are clozapine, olanzapine, riperidone and quetiapine. 
By the 1960's significant steps had been made towards elucidating the mechanism of action of 
the classical antipsychotics with the discovery that they antagonise dopamine receptors 
(Carlsson and Linqvist, 1963). Specifically antipsychotics bind to D2-like receptors which are 
expressed at presynaptic sites on dopaminergic neurones, and at postsynaptic sites (see 
section 1.3.1.6. ). The antipsychotic efficacy of both classical and atypical antipsychotics has 
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been correlated with their binding affinity at the D2 receptor (Wilson et al. 1998; Kapur and 
Mamo, 2003). Whilst the lack of extra-pyramidal side-effects is the principal distinguishing 
feature of atypical antipsychotics, at a pharmacological level some of these drugs, such as 
olanzapine, risperidone and clozapine share a high affinity for the 5-HT2A receptor (Stip, 2002; 
Meltzer, 2002). This property is not shared with the classical antipsychotic drugs and this 
distinction has been proposed as a further means of defining classical vs. atypical 
antipsychotics. Further discussion of the functional pharmacology of these drugs in relation to 
doparninergic hypotheses of bipolar disorder can be found in section 1.1.6.4. (c). The role of D2 
receptors in the regulation of dopaminergic neurotransmission is also discussed in greater detail 
in section 1.3.5. 
1.1.5.3. Antidepressants 
Antidepressants as a class of drugs are useful in the treatment of the depressive phase of 
bipolar illness. These drugs produce their therapeutic effect by increasing monoaminergic 
neurotransmission in the CNS. This occurs via three principal mechanisms: 1) reuptake 
inhibition which has the effect of increasing synaptic monoamine concentrations and increasing 
post-synaptic neuronal stimulation; 2) inhibition of monoamine neurotransmitter metabolism, 
which has a similar effect to reuptake inhibition in that neurotransmitter inactivation is reduced; 
and 3) presynaptic autoreceptor inhibition resulting in increased neurotransmitter release 
(Artigas et al. 2002). 
Some of the earliest agents to be employed as antidepressants were the tricyclic 
antidepressants (TCA's) such as imipramine and amitryptiline. These drugs potentiate 
serotonergic and noradrenergic neurotransmission by blocking nerve terminal reuptake of the 
neurotransmitter following release and this is thought to underlie their therapeutic efficacy 
(Artigas et al. 2002; Lenox and Frazer 2002). The other principal class of antidepressants 
discovered around this time were the monoamine uptake inhibitors (MA01s) such as iproniazid 
and tranylcypromine which inhibit the oxidative metabolism of serotonin, noradrenaline, and 
cloparnine. Again, the potentiation of monoamine neurotransmission is thought to underlie their 
therapeutic effect (Artigas et al. 2002; Lenox and Frazer 2002). 
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The discovery of these drugs contributed greatly to the monoamine hypothesis of depression, 
and subsequent refinements to this hypothesis led to the development of drugs which target 
specific monoamines such as serotonin and noradrenaline. Perhaps the best example of this 
would be the development during the 1970's of the selective serotonin reuptake inhibitors 
(SSRIs) such as fluoxetine, paroxetine and sertraline. The principal advantage of these drugs 
over the earlier TCA's is their improved side-effect profile such as fewer anticholinergic effects, 
and a better safety profile (Artigas et al. 2002; Lenox and Frazer 2002). More recently 
developed drugs include the selective noradrenaline reuptake inhibitors (SNRIs) such as 
reboxetine, the seroton in-norad renal ine reuptake inhibitors such as venlafaxine and the 
noradrenaline and cloparnine reuptake inhibitor bupropion (DeVane 1998; Artigas et al. 2002; 
Tremblay and Blier 2006). 
Similar refinements have been made to drugs which inhibit monoamine oxidase such that 
moclobernide, a drug which reversibly inhibits the MAO-A isoform of monoamine oxidase is 
available. This has significant advantages over the traditional irreversible MAOI's in terms of 
safety (Fulton and Benfield, 1996). One of the key drawbacks of monoamine oxidase inhibitors 
is the risk of a so-called 'cheese reaction' resulting from the inhibition of the breakdown of 
dietary tyramine, the symptoms of which include severe hypertension and, potentially, 
intracranial haemorrhage. Reversible inhibition of the enzyme greatly reduces the risk of this 
side-effect occurring. 
The final class of antidepressant, are the drugs acting directly at neurotransmitter receptors. At 
the present time the only drug of this type in common clinical use is mirtazepine, an a2 
adrenergic receptor antagonist which increases noradrenergic neurotransmission via 
presynaptic autoreceptor inhibition (Tremblay and Blier 2006). 
Current UK guidelines for the treatment of bipolar disorder recommend the use of 
antidepressants only in conjunction with an anti-manic drug such as a mood stabiliser (UK NICE 
guidelines 2006). This is due to the risk of inducing a switch to mania in patients receiving 
antidepressants alone. The guidelines also recommend the monitoring of bipolar patients for 
signs of prolonged akathisia or agitation which might be indicative of the early stages of mania. 
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1.1.6. Pathophysiology of bipolar disorder 
The high degree of heritability in bipolar disorder indicates that there is some underlying 
biological deficit which predisposes individuals to the condition. Despite a huge amount of 
research carried out in the field of affective disorders this underlying cause is yet to be found, 
although a number of biological systems are currently under investigation. 
1.1.6.1. Monoamine systems in bipolar disorder 
One of the most enduring hypotheses regarding the aetiology of affective disorders has been 
the "monoamine hypothesis" which was first postulated in the mid-1960's (Schildkraut, 1965). 
This hypothesis was derived from the observation that drugs affecting central monoamine 
function can significantly alter mood. The serendipitous discovery of the monoamine oxidase 
inhibitors in the 1950's demonstrated that drugs which increase monoamine levels in the brain 
have mood elevating properties, whilst drugs which deplete central monoamines such as 
reserpine were found to induce depression in a manner which was, at that time, thought to be 
clinically indistinct from that seen in depressed patients. Initially Schildkraut postulated that 
noradrenaline was the neurotransmitter of crucial importance (1965), whilst others focused on 
the role of serotonin (Coppen, 1969). Subsequently the importance of dopamine was 
recognized as the clinical evidence began to be formulated into a hypothesis during the 1970's 
(see for example Barbeau, 1970). The vast majority of research based on the monoamine 
hypothesis has been carried out in major depressive disorder, and serotonin in particular has 
been the focus of many studies. This is principally due to the fact that the majority of effective 
antidepressants act on this neurotransmitter system. The study of dopamine is perhaps more 
pertinent to bipolar disorder due to its potential role in the distinguishing feature of this disorder, 
mania which can be induced by drugs which increase dopaminergic transmission (reviewed by 
Silverstone, 1985). In addition there has been increased interest in the role of dopamine in 
emotional regulation as a result of the role of the mesolimbic clopamine system in reward and 
motivational behaviour (reviewed by Willner, 1995), deficits of which may account for the 
anhedonia and amotivational states present during depressive episodes. There follows a review 
of the literature concerning monoamine neurotransmitter systems in bipolar disorder. 
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1.6.2. Evidence for serotonergic dysfunction in bipolar disorder 
Serotonin has enjoyed a central position in the monoamine hypothesis of affective disorders in 
the 30 years since the discovery that selective serotonin reuptake inhibitors can be effective in 
the treatment of major depressive disorder. A huge body of literature exists regarding the role of 
serotonin in major depression and there is general agreement that deficits in central 
serotonergic transmission play a role in this condition (Mahmood and Silverstone, 2001). As far 
as the role of serotonin in bipolar disorder goes the body of evidence is much smaller with few 
studies looking specifically at this disease. 
Some of the earliest studies concentrated on measurements of the 5-HT metabolite 5-HIAA 
(5-hydroxyindole acetic acid). These were, on the whole, inconclusive with one study 
demonstrating lower CSF levels of 5-HIAA in melancholic bipolar patients than in healthy 
controls (Asberg et al. 1984), a finding which a later study failed to replicate (Redmond et al. 
1986). In a similar study looking at manic patients an increase in CSF 5-HIAA was found only in 
female subjects (Swann et al. 1983). Despite these findings decreased levels of 5-HIAA have 
been associated with increased suicide risk as evidenced by findings in post mortem brains of 
bipolar depressed suicides (Traskmann et al. 1981; Young et al. 1994) providing some evidence 
to support the serotonergic hypothesis. 
Alterations to 5-HT transporter (5-HTT) function in bipolar patients have been demonstrated. 
Thus in studies using platelet 5-HT uptake as an indicator of central 5-HT uptake, decreases in 
5-HT transport have been shown in both bipolar depression (Meltzer et al. 1983) and bipolar 
mania (Marazziti et al. 1991). More recently Oquendo et al. (2007) demonstrated decreases in 
5-HTT binding in various brain regions in bipolar depressives whilst post-mortern studies have 
shown lower concentrations of citalopram binding in bipolar subjects who died whilst depressed 
(Leake et al. 1991). These findings are challenged, however, by another recent study which 
reports increased 5-HT transporter binding in the thalamus and a number of cortical regions, 
and decreased binding in the midbrain in unmedicated bipolar patients (Cannon et al. 2006) 
making it difficult to draw conclusions from the literature. 
Changes in 5-HT receptor expression have been found in post-mortern tissue from bipolar 
patients, with decreases in 5-HT2A receptor mRNA levels in the prefrontal cortex and increases 
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in 5-HT1B and 5-HT2A transcripts in the hippocampus (Lopez-Figueroa et al. 2004). Further 
evidence for changes in the expression of the 5-HTlA receptor is provided by a PET imaging 
study of 5-HTIA ligand binding in which decreases were found in the raphe and mesiotemporal 
cortex of bipolar depressed patients (Drevets et al. 1999). However a study looking at post- 
mortem hippocampal tissue from bipolar patients found no differences in 5-HT1A binding (Dean 
et al. 2003). Due to its easy accessibility, calcium mobilization by the platelet 5-HT2A receptor 
has been used as an indicator of receptor function in psychiatric disorders. Studies in bipolar 
depressed patients have shown that calcium mobilization by serotonin is markedly elevated 
compared to normal controls and subjects with unipolar diagnoses (Kusumi et al. 1994; Suzuki 
et al. 2001) and in a more recent study this was associated with increased protein kinase C 
activity resulting from receptor activation rather than an increase in receptor expression (Suzuki 
et al. 2003). Overall there is some evidence that 5-HT receptor expression and function is 
altered in bipolar disorder however further work is required to clarify the nature of these 
alterations. 
The ability of mood-stabilising and antidepressant drugs to modulate the serotonergic system 
provides circumstantial evidence for the involvement of this system in bipolar disorder. Lithium 
has been shown to increase serotonin release in various regions of the rat brain (Treiser et al. 
1981; Friedman and Wang, 1988; Baptista et al. 1990; Pei et al. 1995), whilst in bipolar patients 
lithium treatment increases plasma 5-HT levels (Artigas et al. 1989). Furthermore, the use and 
efficacy of selective serotonin reuptake inhibitors in combination with mood stabilisers for the 
treatment of severe or treatment resistant bipolar depressive episodes (see Thase, 2005) 
implies that there is a serotonergic component to these states. The ability of antidepressants to 
induce a switch to mania has been reported in around 20-40% of bipolar patients and has been 
reported for SSRI's as well as all other major classes of antidepressant (reviewed by Goldberg 
and Truman, 2003). Serotonergic dysfunction may therefore play a role in manic states, a 
hypothesis supported by the demonstrated efficacy of atypical antipsychotics with high affinities 
for the 5-HT2A receptor in treating these episodes (Cousins and Young, 2007) 
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1.1.6.3. Evidence for noradrenergic dysfunction in bipolar disorder 
Noradrenaline was originally considered to be central to the monoamine hypothesis of mood 
disorders as postulated by Schildkraut (1965). In more recent times its position has been 
supplanted by serotonin, however a limited number of studies have looked at the role of this 
neurotransmitter in bipolar disorder. A number of early studies demonstrated significantly lower 
urinary levels of the noradrenaline metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) in 
bipolar patients compared to unipolar or control subjects (reviewed by Schatzberg and 
Schildkraut, 1995), however a more recent study has failed to replicate these findings 
(Grossman and Potter, 1998). Studies of plasma and urinary noradrenaline levels have shown 
more consistent results with elevations of plasma NE in bipolar and unipolar depressed patients 
following orthostatic challenge being greater than those seen in controls (Rudorfer et al. 1985; 
reviewed by Schatzberg and Schildkraut, 1995), whilst urinary NE has been found to be greater 
in unipolar and bipolar patients compared to controls (Grossman and Potter, 1999). 
Changes to adrenoceptor function have not been consistently demonstrated in bipolar 
disorder. Studies have shown a decrease in P-adrenergic receptor binding associated with 
bipolar disorder (Wright et al. 1984; Wood et al. 1986) although other studies have failed to 
replicate these findings (Berrettini et al. 1987; Kay et al. 1993; Young et al. 1994), whilst 
decreased P-adrenoceptor function as measured by stimulated cAMP production has been 
reported in lymphocytes of manic and depressed patients (Extein et al. 1979). A trend towards 
increased platelet a2-adrenoceptor density has also been reported in bipolar patients (Karege et 
al. 1992). 
The role of noradrenaline in the action of mood stabilising drugs has been investigated, and 
studies have demonstrated that high doses of lithium can induce the release of NE from cortical 
and hippocampal slices (Gross and Hanft, 1990) whilst in a peripheral model lithium has been 
found to decrease the release of NE (Mantelli and Ledda, 1989) although this has not been 
replicated (Finberg et al. 1992). Valproate has been found to have little effect on noradrenaline 
release in cortical slices (de Boer et al. 1982), however increases in NE in-vivo have been found 
following valproate treatment in the rat hippocampus and brainstern with a concurrent decrease 
in the hypothalamus (Baf et al. 1994a). Valproate has also been shown to increase tyrosine 
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hydroxylase mRNA in the locus coeruleus of rats following chronic treatment (Sands et al. 
2000). Elevations in NE levels have been shown in the motor cortex and cerebellum of rats 
following carbarnazepine treatment (Baf et al. 1994b), whilst increases in C12 adrenoceptor 
sensitivity have also been demonstrated (Dilsaver et al, 1993). Overall there is some evidence 
that these drugs can affect noradrenergic function, but as with the rest of the literature 
concerning the role of noradrenaline in bipolar disorder, there is currently not enough data to 
draw any conclusions. 
1.1.6.4. Evidence for dopaminergic dysfunction in bipolar disorder 
The clinical evidence that dopamine plays a role in bipolar mood states began to be 
recognized during the 1970's (see Barbeau, 1970) leading to the formulation of a hypothesis 
implicating dopaminergic hyperfunction in mania and hypofunction in depression (Bunney and 
Garland, 1982). There is now compelling evidence for this hypothesis with a large body of 
literature available implicating the mesolimbic dopamine system in motivational and reward 
behaviour (see later) providing a link with the anhedonic states characteristic of depression, 
whilst the behaviour produced by dopamine releasing drugs implicates this system in manic 
states. In addition the ability of doparnine to alter cognitive function via projections to the 
prefrontal cortex (see later) suggests that neurocognitive deficits present in the disease (see 
Quraishi and Frangou, 2002; Savitz et al. 2005) may be the result of dopaminergic dysfunction. 
(a) Dopamine metabolites in bipolar disorder 
CSF levels of the dopamine metabolite homovanillic acid (HVA) have been reported to be 
elevated in manic bipolar patients (Swann et al. 1983; Gerner et al. 1984; Tandon et al. 1988), 
and decreased in depressed bipolar patients (Asberg et al. 1984; Reddy et al. 1992, Bottiglieri 
et al. 2000). These studies indicate that dopamine metabolite levels are a state marker for 
bipolar disorder, however this may be an oversimplification. It has been suggested that CSF 
HVA levels are indicative of motor activity rather than mood as a result of the dense 
cloparninergic innervation of the basal ganglia and its close proximity to the ventricles (Willner et 
al. 1995). Consequently these studies may not provide an accurate measure of neuronal 
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function in doparninergic systems implicated in mood and cognitive regulation such as the 
mesolimbic and mesocortical systems. 
(b) Bipolar symptoms and clopaminergic drugs 
It has been observed that a variety of drugs which stimulate dopamine release, or directly 
stimulate dopamine receptors can induce mania. Perhaps the most obvious example of this is 
amphetamine which in healthy subjects produces a behavioural syndrome very similar to that 
seen in mania (Silverstone, 1985) and has been shown to precipitate manic episodes in bipolar 
patients (Van Karnmen and Murphy, 1975; Gerner et al. 1976). Further evidence for 
doparninergic dysfunction in mania is provided by the observation that amphetamine produces 
an exaggerated behavioural response in bipolar patients compared to healthy controls (Anand 
et al. 2000) although the evidence for this is inconsistent (see also Numberger et al. 1982). 
Although amphetamine induces the release of both dopamine and noradrenaline it has been 
shown that doparnine antagonists are able to block its behavioural effects (Jonsson, 1972; 
Silverstone et al., 1980) implicating dopamine as the mediator of its manic effects. The idea that 
mania is the result of a hyperclopaminergic state is given further support by the ability of 
dopamine receptor agonists such as piribedil (Gerner et al. 1976), bromocriptine (Vlissides et al. 
1978; Brook and Cookson, 1978; Kemperman and Zwanikken, 1987) pramipexole and ronpirole 
(Singh et al. 2005) to induce mania. Furthermore the dopamine precursor L-DOPA has been 
shown to induce mania in bipolar depressives (Goodwin et al. 1972; Murphy, 1973) whilst L- 
DOPA therapy in Parkinson's disease has been associated with an increased incidence of 
mania (Harsch et al. 1985; Black et al. 2005), an effect which is believed to occur as result of 
increased dopamine synthesis. 
Reducing dopamine synthesis by dietary depletion of tyrosine (the amino acid precursor of 
dopamine) has been shown to reduce the symptoms of mania in bipolar subjects (McTavish et 
al. 2001), thus giving further evidence for a hyperdoparninergic state in mania. Moreover 
tyrosine depletion induces disrupted affect/reward characteristics in healthy subjects which 
parallel those seen in bipolar depressive states (McLean et al. 2004). This builds on earlier work 
showing that reserpine induced depletion of monoamines (including doparnine) depresses 
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mood, an observation which contributed to the original monoamine hypothesis of affective 
disorders (Schildkraut, 1965). Later analysis of the original reserpine studies revealed that 
reserpine did not actually produce true depressive states in the majority of individuals but a 
66pseudodepressive" state lacking the cognitive features of major depression (Willner et al. 
1995). Despite this, there is a significant body of evidence that drugs interfering with 
doparninergic transmission can induce mood states similar to those seen in bipolar disorder. 
(c) Therapeutic drug effects on doparninergic systems 
A variety of drugs with efficacy in bipolar disorder interact with dopaminergic systems in the 
brain. In particular, the ability of antipsychotic drugs to treat the symptoms of mania and 
potentially depression (Brambilla et al. 2003; Surja et al. 2006; Wijkstra et al. 2007) provides 
good evidence for a doparninergic mechanism in bipolar disorder. The therapeutic potency of 
typical antipyschotics has been correlated with their affinity for binding at D2 receptors (reviewed 
by Wilson et al. 1998) and whilst atypical antipsychotics have much lower affinities for this 
receptor, D2 antagonism is required for therapeutic effect (Kapur and Mamo, 2003). 
Whilst all antipsychotic drugs antagonise D2 receptors, their exact mechanism of action is 
currently unclear. Administration of these drugs to rats produces increases in dopamine release 
in the nucleus accumbens and striatum (Moghaddam and Bunney, 1990; Volonte et al. 1997; 
Kuroki et al. 1999; Rollema et al. 2000) an effect consistent with the blockade of presynaptic 
autoreceptors, but seemingly at odds with the hypercloparninergic hypothesis of mania. 
Furthermore typical and atypical antipsychotics appear to differ in their effects on dopamine 
release in the prefrontal cortex. A number of studies have found no significant effect of acute 
typical antipsychotic administration on prefrontocortical dopamine release (Moghaddam and 
Bunney, 1990; Volonte et al. 1997; Gessa et al. 2000; Westerink et al. 2001; Ago et al. 2005), 
whilst others have found that typical antipsychotics are less efficacious at increasing dopamine 
release in the prefrontal cortex than in the nucleus accumbens or striaturn (Rollema et al. 2000; 
Westerink et al. 2001). In contrast, acute administration of atypical antipsychotics has 
consistently been shown to increase doparnine release in the prefrontal cortex, nucleus 
accumbens and striaturn (Volante et al. 1997; Kuroki et al. 1999; Gessa et al. 2000; Ichikawa et 
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al. 2001; Jaskiw et al. 2001). Overall it is currently unclear how the regional differences relate to 
therapeutic effect. 
As mentioned previously, the consistent finding of increased dopamine release upon acute 
administration of antipsychotics would appear to be at odds with a hype rdopam inerg ic 
hypothesis of mania. One possible explanation is that blockade of postsynaptic doparnine 
receptors, thereby reducing doparninergic neurotransmission, is responsible for their therapeutic 
effect. If this is the case, acute increases in dopamine release may well be anomalous as far as 
the anti-manic action of these drugs is concerned. 
Whilst increased dopamine release may not explain the anti-manic properties of these drugs, it 
may explain the blockade of spontaneous doparninergic cell firing in the ventral tegmental area 
induced by chronic administration of both typical and atypical antipsychotics (Bunney and 
Grace, 1978; Chiodo and Bunney, 1983; White and Wang, 1983; Todorova and Dimpfel, 1994). 
This effect is likely to be responsible for the decrease in doparnine release in the prefrontal 
cortex, nucleus accumbens and striaturn which has been found to occur following chronic 
treatment with the atypical clozapine or the typical antipsychotic haloperidol (Morrow et al. 
1999). Further evidence of changes to doparninergic function with chronic administration of 
antipsychotic medication is provided by the ability of clozapine to decrease tyrosine hydroxylase 
(TH, the rate-limiting enzyme in dopamine synthesis) mRNA expression in the VTA and 
substantia nigra and TH protein levels in the nucleus accumbens and striaturn (Tejedor-Real et 
al. 2003). These data suggest that in the long-term, antipsychotics decrease doparninergic 
neurotransmission by a presynaptic mechanism, an effect which might correlate with their long- 
term anti-manic efficacy. 
Whilst antipsychotic drugs are particularly effective in the treatment of mania, other 
doparninergic drugs have shown efficacy as antidepressants in bipolar disorder. Early studies 
reported that the D2/D3 receptor agonist bromocriptine is an effective antidepressant with 
greater efficacy in bipolar compared to unipolar depressives (Colonna et al. 1978; Silverstone et 
al. 1984). Furthermore a number of studies have shown that the D3 preferring agonist 
pramipexole has antidepressant efficacy in bipolar disorder (Perugi et al. 2001; Lattanzi et al. 
2002; Zarate et al. 2004; Goldberg et al. 2004). The antidepressant efficacy of these agonists 
18 
Chapter 1 
suggests that dopaminergic neurotransmission is reduced in bipolar depression, however this 
interpretation may be oversimplistic. Systemic administration of pramipexole has been shown to 
decrease the release of dopamine in the striatum (Crater and Muller, 1991) presumably as a 
result of activating presynaptic autoreceptors. Such a mechanism of action is inconsistent with a 
hypodoparninergic hypothesis of depression. Another study found, however, that bromocriptine 
and pramipexole induce locomotor activity following intra-striatal administration but attenuate 
the locomotor stimulating effects of a calcium channel agonist (Maruya et al. 2003). Thus under 
conditions of low dopamine release these drugs may potentiate doparninergic 
neurotransmission, but when cloparninergic neurotransmission is elevated, these drugs have an 
anti-doparninergic effect. Thus if bipolar depression is characterised by a hypodopaminergic 
state bromocriptine and pramipexole may well augment dopamine neurotransmission to rectify 
the deficit. 
A major group of drugs used in the prophylactic treatment of bipolar disorder are the mood 
stabilising drugs which include lithium, carbarnazepine and valproate. Whilst these drugs do not 
interact directly with dopamine receptors, there is evidence, although inconsistent, that they 
modulate dopaminergic neurotransmission. Some studies in rats have shown that chronic 
lithium treatment increases doparnine synthetic activity (Koyama et al. 1987; Gudelsky et al. 
1988) and basal levels of doparnine and its metabolites in the nucleus accumbens (Koyama et 
al. 1987; Baptista et al. 1993) whilst others have shown no effect on synthesis or release in this 
region (Reches et al. 1984; Ferrie et al. 2006). In the study of Ferrie et al. (2006) no effect of 
chronic lithium was seen on basal dopamine levels, however potassium stimulated dopamine 
release was significantly attenuated in lithium treated animals. 
In the prefrontal cortex two studies have found evidence for increased doparnine synthesis 
following chronic lithium treatment (Koyama et al. 1987; Gudelsky et al. 1988), however 
measurement of levels of dopamine and its metabolites have led to conflicting results. One 
study found increased levels (Koyama et al. 1987), one study found a decrease (Baptista et al. 
1993) and another found no effect (Reches et al. 1984). 
In the striatum results have been more consistent with a number of groups finding increased 
dopamine and dopamine metabolite levels following chronic lithium treatment (Hesketh et al. 
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1978; Otero-Losada and Rubio, 1985; Koyarna et al. 1987; Gudelsky et al. 1988), although 
again one study found no effect (Reches et al. 1984). 
In a similar fashion to the effect of lithium found by Koyama et al. (1987) carbamazepine and 
valproate treatment have been shown to increase prefrontocortical dopamine release (Ichikawa 
and Meltzer, 1999; Ichikawa et al. 2005), whilst carbamazepine has also been shown to 
increase doparnine release in the striatum and hippocampus (Okada et al 1997). 
Whilst it is evident that mood-stabilisers can modulate doparninergic neurotransmission it is 
unclear how this relates to their therapeutic effect. Although the balance of evidence points to 
an upregulation of basal dopaminergic activity by mood-stabilisers, it is interesting that Ferrie et 
al. (2006) showed an attenuation of stimulated dopamine release by lithium treatment. If lithium 
does in fact elevate basal dopamine levels when they are low but decrease dopamine levels 
under stimulated conditions this may account for its mood-stabilising effect. It could thus be 
speculated that mood-stabilisers attenuate the hyperdopaminergic state of bipolar mania whilst 
potentiating dopamine release during the bipolar depressive phase. 
An important point which relates to all classes of drugs used in the treatment of bipolar 
disorder is that our knowledge regarding their mechanism of action comes largely from studies 
in (presumably) healthy animals. It may be the case that the effects of these drugs on 
dopaminergic function differ in bipolar disorder, thus extrapolating the mechanism of their 
therapeutic action from these studies may not be possible. Despite this caveat there is 
considerable evidence that modulation of doparninergic neuronal function may underlie their 
therapeutic effects. 
(d) Markers of central dopaminergic function in bipolar disorder 
Thus far studies investigating markers of dopaminergic function in the brain have yielded 
conflicting results, however the available data provide some evidence that doparninergic 
function is altered in bipolar disorder. 
An interesting finding, which relates directly to the results of this thesis, is the demonstration of 
increased vesicular monoamine transporter 2 (VMAT2) binding in the thalamus and ventral 
brainstern of euthymic bipolar disorder I patients compared to schizophrenics and healthy 
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controls (Zubieta et al. 2000; 2001). This suggests that vesicular dopamine content may be 
increased in biPOlar disorder and this may lead to an increase in dopamine release (see section 
1.3.1.2. ). Conflicting somewhat with this interpretation are the results of a PET imaging study 
which showed that the rate constant for [18 F]-DOPA uptake in the striaturn is unaltered in manic 
subjects, a finding which has been taken as evidence that dopamine synthesis and vesicular 
uptake (of [18 F]-dopamine) is unaltered in mania (Yatham et al. 2002a). It would appear 
however, that this is a rather indirect measure of vesicular uptake, given that this method only 
demonstrates the accumulation of labelled DOPA in the region of interest. 
One PET study has shown that in bipolar subjects (but not unipolar subjects) DAT binding is 
unilaterally increased in the right striaturn (Amsterdam and Newberg, 2007), suggesting that 
post-synaptic dopaminergic function may be decreased (as a result of greater dopamine re- 
uptake) in these patients. 
In terms of dopamine receptors, one clinical PET study has shown a decrease in D, receptor 
binding in the frontal cortex of bipolar disorder subjects (Suhara et al. 1992) suggesting a down- 
regulation of receptor expression in this region, however a study of D, mRNA expression in 
post-mortern hippocampal tissue found increased expression in the CA2 (but not CAl or CA3) 
region (Pantazopoulos et aL 2004). This suggests that there may be regional differences in 
cloparninergic regulation in the disease. 
Studies looking at the D2 receptor have been similarly inconsistent. Studies have shown 
increased D2 receptor binding in neuroleptic-nai've psychotic manic subjects but not in non- 
psychotic manic subjects (Pearlson et aL 1995; Yatham et al. 2002b), whilst a further study 
found no difference in striatal D2/D3 binding between euthymic bipolar subjects (half of whom 
were unmedicated) and controls (Anand et aL 2000). Somewhat in contrast to these results 
however, are the findings of a study which examined D2 mRNA expression in post-mortem 
tissue from bipolar subjects showing a decrease in expression in the prefrontal cortex (Knable et 
al. 2001) and another study which found that D3 mRNA is decreased in peripheral lymphocytes 
of bipolar subjects (Vogel et al. 2004). Again, the available data on D2 and D3 receptors in 
bipolar disorder suggests there may be regional differences in receptor abnormalities. 
Overall, it is difficult to formulate from these data a generalised hypothesis of dopaminergic 
21 
Chapter 1 
dysfunction in bipolar disorder. Increased VMAT2 binding in the thalamus and brainstem, and 
decreased D, receptor binding and D2 mRNA expression in the frontal cortex are consistent with 
an upregulation of dopaminergic neurotransmission in these regions. In contrast, however, 
increased DAT binding in the striaturn and increased D, mRNA expression in the hippocampus 
are consistent with a decrease in dopamine release in these areas. As such one could 
speculate that in bipolar disorder there are fundamentally different alterations in doparninergic 
neurotransmission between brain areas. 
(e) Linkage studies of genes related to doparninergic function in bipolar disorder 
Genetic linkage studies have failed as yet to produce any replicable results for candidate 
genes related to bipolar disorder and doparninergic function. Initial studies implicating the 
doparnine receptor DRD2,3 and 4 genes in bipolar disorder have not been replicated, although 
association with the DRD1 gene has been shown in a number of studies (reviewed by Kato et 
al. 2007). Importantly several studies have reported no linkage between the tyrosine 
hydroxylase gene and bipolar disorder (reviewed by Craddock et al. 2001). 
Overall there is much evidence for a doparninergic component in the pathology of bipolar 
disorder, although its exact nature remains unclear. The evidence from metabolite studies and 
the effects of doparninergic drugs on behaviour suggests a hyperdoparninergic state in mania 
and a hypodopaminergic state in bipolar depression, however our knowledge of the effects of 
therapeutic drugs on doparninergic neurotransmission is not entirely consistent with this 
hypothesis. Furthermore, clinical imaging and post-mortem studies in bipolar disorder suggest 
that the nature of the dopaminergic dysfunction may differ between the various doparninergic 
projection systems and consequently a generalised hypothesis regarding dopamine is likely to 
be an oversimplification. 
In more general terms there is no evidence that changes to monoamine systems are the 
underlying cause of bipolar disorder. It is likely that affective disorders, and bipolar disorder in 
particular, result from of a combination of genetic and environmental factors and as such 
hypotheses focussing on a single neurotransmitter system are an oversimplification. Progress in 
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understanding the aetiology of this condition requires a broadening of perspective to investigate 
how various bodily systems interact to produce the underlying pathology. 
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1.2. The HPA axis 
I. Overview 
The hypothalamic-pituitary-adrenal (HPA) axis is a system consisting of a number of 
component tissues, the overall function of which is to provide neuronal control over the release 
of endocrine signals from the adrenal cortex (see figure 1.1, also; McQuade and Young 2000). 
Activation of the HPA axis produces a cascade of events, ultimately leading to the release of 
corticosteroid hormones from the adrenal glands into the systemic circulation. 
Corticosteroid hormones are a group of related compounds synthesized from cholesterol 
which includes the glucocorticoids cortisol and corticosterone, and the mineralocorticoid 
aldosterone (see figure 1.2. ). There are species differences in the secretion of glucocorticoids 
such that humans predominantly secrete cortisol in a ratio of 7: 1 with corticosterone, whilst rats 
almost exclusively secrete corticosterone (Ganong, 2001). These hormones play an important 
role in homeostasis and interact with a wide variety of systems in the body and CNS. 
The HPA axis signaling cascade originates in a number of brain regions and is coordinated in 
the paraventricular nucleus of the hypothalamus (PVN). Stimulation of the PVN releases 
corticotropin-releasing hormone (CRH) and arginine-vasopressin (AVP) into the hypophyseal 
portal blood via which they are transported to the anterior pituitary. CRH acts on the pituitary to 
induce transcription of the proopiomelanocortin (POMC) gene (Gagner and Drouin, 1985), a 
precursor for adrenocorticotropic hormone (ACTH), and furthermore, in concert with AVP, 
stimulates the release of ACTH from the pituitary (Gillies et al. 1982; Rivier et al. 1982; Donald 
et al. 1983; Rivier and Vale, 1983; Canny et al. 1992). ACTH is then transported in the systemic 
circulation to the adrenal glands where it induces the synthesis of corticosteroid hormones 
(Holzbauer and Vogt, 1957). Under normal physiological conditions activity within the HPA axis 
is tightly regulated by corticosteroid-mediated negative feedback which inhibits secretory activity 
in the PVN and pituitary, as well as at sites in the central nervous system (see figure 1.1. ). 
24 
Chapter 1 
Amygdala 
+ve Hippocampus 
4 MR/GR 
PVN of P V of 
Hypothalamus 
G r- D R 
CRH 
AVP 
-ve 
Pituitary 
Cit 
ita: 
1 11 
-ve I GR 
ACTH 
-ve 
CAdrenal 
Cort x Cortex 
Y 
CIRCULATING 
CORTISOL 
Figure 1.1. The HPA axis 
+ve 
Medulla 
Brain stem nuclei 
Suprachiasmatic 
nucl eus 
25 
Chapter 1 
n 
0 
CH20H 
Figure 1.2. Chemical structure of the corticosteroids: Cortisol 1 = CH3 2=H 
Corticosterone 1 = CH3 2=OH 
Aldosterone 1 =CHO 2=H 
C: 
0 
(D 
C) 
c 
0 
C) 
0 
L) 
CIO 
E 
cn 
Time 
Figure 1.3. Circadian rhythm of cortisol secretion in humans. Black bar indicates waking 
period. 
26 
00 h 06 h 12 h 18 h 24 h 
Chapter 1 
In healthy individuals the release of corticosteroids exhibits a circadian rhythm with peak 
cortisol levels occurring around the time of waking, and a nadir around the time of sleep onset 
(see figure 1.3). This pattern is true for both diurnal and nocturnal animals, thus in humans, 
cortisol levels peak in the morning, whilst in rats corticosterone levels peak in the evening. 
Disruption of the sleep-wake cycle, for example in night shift workers or airline staff, has been 
shown to cause major disturbances to this pattern of secretion (Hennig et al. 1998; Richardson 
and Tate, 2000). The corticosteroid rhythm has it's origins in the suprachiasmatic nucleus of the 
hypothalamus (SCN) which controls HPA axis activity directly via projections to the PVN, and 
indirectly via projections to GABAergic cells of the sub-paraventricular zone which in turn 
synapse with CRF neurones of the PVN (Pecoraro et al. 2006). In addition the SCN controls 
adrenal sensitivity to ACTH via autonomic projections to the adrenal gland (Buijs et al. 1999) 
resulting in reduced ACTH sensitivity during the nadir in plasma corticosteroid levels. 
This diurnal cycle modulates the homeostatic functions of glucocorticoids to meet changing 
requirements throughout the day. Of particular importance is the regulation of energy 
metabolism with corticosteroids increasing glycogenesis and gluconeogenesis (reviewed in 
Rang et al. 2002) resulting in an increase in overall energy availability. The importance of 
glucocorticoids in this role is perhaps best demonstrated by the observation that in adrenal 
insufficiency, fasting produces potentially fatal hypoglycaemia. Glucocorticoids are therefore 
essential for maintaining energy availability during periods of restricted calorific intake. 
In addition to its homeostatic role the HPA axis is intrinsically involved in the body's stress 
response. Plasma ACTH and glucocorticoid levels increase rapidly upon exposure to a stressor 
(see for example Dayas et al. 1999; Herman et al. 2005) and this stress response is regulated 
by a variety pathways converging on the hypothalamus. Examples of excitatory pathways 
include those from the amygdala (Beaulieu et al. 1986; 1987; Roozendaal et al. 1991; Van de 
Kar et al. 1991; Dayas et al. 1999; Bhatnagar et al. 2004) and peripheral pain pathways 
(Pecoraro et al. 2006), whilst inhibitory projections include those from the hippocampus 
(Sapolsky et al. 1984; Jacobson and Sapolsky, 1991; Herman et al. 1995; Chrapusta et al. 
2003). Overall these signalling pathways provide sensory and cognitive input to the HPA axis 
allowing appropriate endocrine responses to perceived threats. 
27 
Chapter 1 
Peripherally, raised glucocorticoid levels following exposure to stress facilitate the ability to 
cope with and recover from the stress via catabolic and metabolic effects which increase energy 
availability. Central effects, on the other hand, promote learning and memory as well as long- 
term adaptive responses to stress. Thus in the short term, raised corticosteroid levels are 
beneficial to the health of the organism however there is increasing evidence that long-term 
exposure to high levels of corticosteroids can have detrimental effects on a wide variety of 
bodily systems. 
1.2.2. Corticosteroid receptors 
Corticosteroid actions are mediated by two types of receptor - the mineralocorticoid receptor 
(MR) and the glucocorticoid receptor (GR). Both are soluble intracellular proteins that act as 
ligand inducible transcription factors, binding to DNA to alter gene expression. They share 57% 
homology, with 94% homology in the DNA binding domain and bind to the same response 
element present in DNA consisting of the 15 nucleotide sequence AGAACAnnnTGTTCT 
(Funder, 1997). This is referred to as the glucocorticoid response element or GRE. The two 
receptors differ chiefly in their ligand binding properties, with MR binding cortisol, corticosterone 
and alclosterone with approximately equal, and high, affinity (Kd - 0.5-2 nM) whilst GR shows a 
lower affinity for cortisol and corticosterone (Kd - 10-20 nM) and little affinity for alclosterone 
(Reul and de Kloet, 1985; de Kloet et al. 1998). Receptor binding studies performed by Reul 
and de Kloet (1985) found that whilst MR is tonically activated by normal circulating levels of 
corticosteroids, GR is activated only during periods of elevated corticosteroid release and 
consequently the GR is responsible for the pathological sequelae of raised corticosteroid levels 
(Reul and de Kloet, 1985). This observation perhaps accounts for the far greater body of work 
investigating GR signalling in the central nervous system compared with that for MR, however it 
is not universally accepted. It has been suggested that due to their methodology, Reul and de 
Kloet (1985) overestimated the occupancy of the MR and that a significant proportion of MR is 
available for binding particularly during the circadian nadir (Pace and Spencer, 2005). Thus it 
may be the case that pathological sequelae of elevated corticosteroid levels result from both MR 
and GR binding. 
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It should be noted here that the term mineralocorticoid receptor is somewhat misleading in the 
context of the majority of tissues in which it is expressed. Mineralocorticoid activity is confined to 
tissues such as the kidney where MR selectivity for aldosterone is achieved by enzymatic 
breakdown of cortisol and corticosterone by type 2 11 -p-hydroxysteroid dehydrogenase (Rang, 
Dale and Ritter, 1999; Buckingham, 2006). In other tissues, such as those of the CNS, 
glucocorticoid binding to MR predominates due to the much higher circulating levels of cortisol 
and corticosterone compared to aldosterone (100-1000 times higher see Ahima et al. 1991). As 
a result MR and GR have been referred to as the type-1 and type-2 corticosteroid receptors to 
avoid any suggestion of MR selectivity for aldosterone however the common nomenclature 
remains MR and GR. 
1.2.2.1. Corticosteroid receptor signalling 
An overview of corticosteroid receptor signalling can be seen in figure 1.4. Unliganded 
corticosteroid receptors are present in the cytoplasm where they exist in heteromeric complexes 
with the heat shock proteins hsp90, hsp70, hsp40, p60 and p23 (Pratt and Toft, 1997; 
Schoneveld et al. 2004). These complexes are essential for hormone binding, with 
uncomplexed receptors showing greatly diminished ligand affinity (Pratt and Toft, 1997). Upon 
ligand binding the heat shock proteins dissociate and conformational changes expose binding 
sites allowing for active transport into the cell nucleus (Nishi and Kawata, 2006). Ligand bound 
MR and GR form dimeric or even multimeric complexes (Savory et al. 2001) prior to DNA 
binding. There is some debate over where this takes place with some studies showing 
cytoplasmic dimerisation (Savory et al. 2001) whilst others have presented evidence that DNA 
binding is required for the formation of stable complexes (Truss and Beato, 1993). The 
traditional view has been that MR and GR form homodimers, however the co-expression of 
these receptors in individual cells in tissues such as the hippocampus (van Eekelen and de 
Kloet, 1992; Han et al. 2005) has prompted investigations revealing that functional MR/GR 
heterodimers are also possible (Trapp et al. 1994; Liu et al. 1995; Ou et al. 2001). This is 
thought to allow for greater diversity in the regulation of corticosteroid responsive genes in 
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response to changing levels of endogenous ligand (Trapp and Holsboer, 1996; Nishi and 
Kawata, 2006). In some genes receptor binding to the GRE alone may be sufficient to regulate 
transcription. Other genes however require a glucocorticoid response unit (GRU) comprising of 
the bound receptor in a complex with other co-factors. This dependence on the presence of 
other co-factors allows for potential tissue specificity in the response of a given gene to 
corticosteroids. The transcriptional response to glucocorticoids can be either positive or 
negative, with some GRE's increasing transcription whilst others decrease transcription. 
Additionally, negative regulation may be achieved via a competitive mechanism at the 
regulatory site. In such a mechanism GR binding prevents the binding of transcriptional 
promoters at sites adjacent to the GRE thus decreasing gene transcription. In genes which do 
not have a GRE glucocorticoid receptors may regulate transcription by binding to transcriptional 
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factors rather than the DNA itself. These mechanisms allow for both positive and negative 
regulation of a wide variety of genes (for reviews see Buckingham 2006; Schoneveld et al. 
2004). 
1.2.2.2. Corticosteroid receptor expression in the CNS 
Of the two receptors MR and GR, the GR has received the most attention as a potential 
mediator of pathology in the CNS. The earliest attempt to map GR in the rat CNS was carried 
out in a series of papers by Fuxe et al. (1985a, b; 1987). This work demonstrated a widespread 
distribution of GR in the CNS, whilst subsequent work allowed quantitative comparison of GR 
immunoreactivity between brain regions (Ahima and Harlan, 1990; Cintra et aL 1994; Morimoto 
et al. 1996). These studies have shown that high densities of GR are present in cortical regions 
such as the motor cortex, anterior cingulate cortex, somatosensory area, and piriform cortex 
and limbic areas such as the hippocampal CA1, CA2 and dentate gyrus, and the amygdala. 
High densities have also been found in the thalamus and the hypothalamus (particularly the 
paraventricular and dorsomedial nuclei), the serotonergic dorsal raphe nucleus and the 
noradrenergic locus coeruleus, whilst the dopaminergic substantia nigra and ventral tegmental 
area express low and moderate levels respectively. 
Mapping of MR in the CINIS has been less comprehensive than for GR, with only one study 
looking at MR expression across a large number of brain regions (Ahima et aL 1991). This work 
demonstrated that MR, similar to GR, has a very widespread distribution, and furthermore that 
regions of high MR density generally correspond with regions of high GR density as reported in 
previous work by the same authors (Ahima and Harlan, 1990). This is particularly true of 
hippocampal, thalamic and hypothalamic regions and whilst the majority of cortical regions were 
excluded from analysis, the piriform cortex was found to contain a high density of MR. 
Monoarninergic nuclei such as the dorsal raphe and locus coeruleus were also found to express 
'high levels' of MR, whilst the substantia nigra and VTA contained 'low to moderate levels', 
again reflecting the pattern seen with GR. More recent studies looking at MR immunoreactivity 
have been somewhat restricted in their scope, however they confirm the presence of MR in the 
hippocampus and hypothalamus (Agarwal et al. 1993; Ito et al. 2000; Han et al. 2005). Of some 
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importance to the present work are the findings of the study by Agarwal et aL (1993) which 
show an absence of MR immunoreactivity in the midbrain, septum and striaturn - thereby 
contradicting the findings of Ahima et al. (1991). Thus, given the mesencephalic location of the 
majority of dopaminergic cell groups, the literature is unclear on the presence of MR in these 
regions. 
The hypothesis initially postulated by Reul and de Kloet (1985) that MR and GR act as high 
and low affinity binding sites for corticosteroids, with MR tonically active and GR active under 
conditions of elevated corticosteroids, suggests that these receptors might be expressed in the 
same cells. Whilst the theory stands without making this assumption, receptor co-expression 
offers the simplest mechanism for complex regulation of neuronal function as plasma 
corticosteroid levels fluctuate. Furthermore in-vivo receptor heterodimerisation would be 
impossible without the presence of both MR and GR. So far co-expression has been 
demonstrated in the hippocampus (van Eekelen and de Kloet, 1992; Han et al. 2005) and the 
hypothalamus (Han et al. 2005). It is likely that co-expression occurs in other regions of the 
brain, however at the current time there is a lack of data to support this. 
1.2.3. Hypothalamic Pituitary Adrenal axis function in bipolar disorder 
As previously discussed (see section 1.1.4) environmental stress plays a role in the onset of 
bipolar disorder in a significant number of individuals. This arouses suspicion that 
corticosteroids and the HPA axis are in some way involved in bipolar disorder. Further to this, 
therapeutic use of corticosteroids has been associated with significant psychopathology and 
has been associated with the onset of bipolar symptoms. One study examining records from 
-2000 patients referred to a psychiatric unit found seven cases where recurrent bipolar disorder 
developed following corticosteroid treatment, with five of these patients initially presenting with 
mania or hypomania (Wada et al. 2001). This finding is supported by a number of single case 
reports of mania following corticosteroid therapy (Pies, 1981; Ur et al. 1992; Abouesh, 1998). A 
further study has shown that in ophthalmic patients treated with corticosteroids for 8-days, 
symptoms of hypomania occurred in about a third of patients, whilst one in ten developed 
depressive symptoms (Naber et al. 1996). Furthermore, chronic corticosteroid therapy has been 
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associated with an increase in depressive symptoms (Bolanos et al. 2004), with 60% of patients 
in this study meeting the criteria for a therapy-induced mood disorder. Findings such as these 
suggest that an underlying dysregulation of corticosteroid secretion may be involved in the 
aetiology of bipolar disorder. 
Clinical studies have found that a common feature of unipolar affective disorders is disruption 
to the diurnal pattern of HPA axis activation, producing an elevated basal level, and a flattening 
of the rhythmic variation in plasma cortisol levels (Yehuda et al. 1996; Deuschle et al. 1997). 
This abnormality has also been observed in bipolar disorder (see figure 1.5. ) where patients 
experiencing depressed, euthymic and hypomanic mood states exhibit an increased basal level 
of cortisol secretion, and reduced diurnal variation compared to controls, which is particularly 
evident during the daily nadir in cortisol levels (Cervantes et al. 2001). 
Evidence for elevated cortisol secretion over 24 hours has been found in patients experiencing 
manic symptoms (Sachar et al. 1975; Akesode et al. 1976; Linkowski et al. 1994) compared to 
normal controls, with the latter two studies showing some evidence of a flattening of the diurnal 
rhythm. More limited studies which have examined daytime (Cookson et al. 1985) and night- 
time (Platman and Fieve, 1968; Carpenter and Bunney, 1971; Cookson et al. 1985; Linkowski et 
al. 1994) plasma cortisol levels have found increases in manic subjects compared to healthy 
controls. Increased free urinary and CSF cortisol levels in manic patients have also been 
reported (Swann et al. 1992). 
In depressed bipolar patients elevations in 24 free urinary cortisol have been found (Rubinow 
et al. 1981) whilst more detailed studies in unipolar and bipolar depressives have shown that 
the 24 hour profile of plasma cortisol is elevated (Linkowski et al. 1985) whilst another study 
found a correlation between blunted amplitude and depression rating scores (Souetre et al. 
1989). These findings are supported by data showing elevated daytime and night-time ACTH 
levels in melancholic depressed (including bipolar) subjects and a significant increase in 
morning cortisol compared to healthy controls (Moffoot et al. 1994). 
Although there is evidence for a flattened cortisol rhythm in all bipolar mood states there is the 
question of whether relative cortisol levels vary with mood state. Whilst figure 1.5. (Cervantes et 
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Figure 1.5. Circadian rhythm of cortisol secretion in bipolar disorder. Mean 24-h cortisol 
secretion of normal controls (circles) and patients with bipolar disorder in 
depressed (black circles), hypornanic (asterisks) and euthymic (open triangles) 
phases of their illness (reproduced from Cervantes et al. 2001) 
al. 2001) suggests that this is not the case, data from two patients in the study for whom cortisol 
measurements were obtained in all of the three mood states demonstrated that levels of cortisol 
secretion were highest during the hypomanic phase and lowest during the euthymic phase. This 
is in contrast with a number of studies which have shown higher cortisol levels during bipolar 
depressive phases than during mania (Bunney et al. 1965; Carroll et al., 1976; Joyce et al. 
1987; Gann et al. 1993; Joyce et al. 1995) and evidence that in some patients cortisol levels are 
higher during the euthymic phase than in mania (Joyce et al. 1987). Thus currently the evidence 
for a consistent correlation between mood state and cor-tisol secretion is lacking. 
The fact that cortisol levels in euthymia (Joyce et al. 1987) were generally higher than those 
seen in manic phases suggests that hypercortisolaemia is a trait marker for bipolar disorder, a 
notion supported by the data from Cervantes (2001) which shows elevated levels compared to 
controls in euthymic phases of the disease. It is however unfortunate that more studies including 
euthymic patients and healthy controls have not been performed, leaving the question of 
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whether the HPA circadian profile represents a trait marker in bipolar disorder largely 
unresolved. 
The origin of abnormalities in circadian cortisol secretion is currently unknown, however it has 
been suggested that they are the result of dysfunctional negative feedback control in the HPA 
axis, for which there is mounting evidence in bipolar disorder. The ability of dexamethasone (a 
synthetic glucocorticoid) to suppress the release of cortisol over a 24-hr period post- 
administration (the dexamethasone suppression test or DST) is used to probe negative 
feedback regulation in the HPA axis. Abnormalities of dexamethasone suppression have been 
found in a significant proportion of bipolar patients across all mood states. In manic patients 
non-suppression occurs in around 45% of cases (Graham et al. 1982; Cassidy et al. 1998) with 
a similar rate in bipolar depression (Feinberg and Carroll, 1983; Rush et al. 1996) whilst in 
mixed episodes non-suppression rates are as high as 86% (Swann et al. 1992; Cassidy et al. 
1998). It is interesting to note that rates of non-suppression are much higher in bipolar 
depression than unipolar depression (Rush et aL 1996). 
Another interesting finding is that in bipolar patients successfully treated with lithium, non- 
suppression still occurs in up to a fifth of patients (Deshauer et al. 1999) implicating non- 
suppression as a trait marker for the illness. Further evidence for this is the finding that euthymic 
patients have significantly higher post dexamethasone cortisol levels than healthy controls 
(Watson et al. 2006) and observations that healthy non-suppressors have a significantly higher 
morbid risk of affective disorders (based on their family histories), particularly for mania and 
hypomania (Coryell and Zimmerman, 1987). Overall the data suggest that glucocorticoid 
negative feedback is impaired in a significant subset of bipolar patients and may represent a 
trait marker for the illness. It should be noted however that successful suppression in the DST 
by bipolar patients does not necessarily mean that there is no abnormality in HPA axis function. 
A study looking at the salivary cortisol response to waking has shown that bipolar patients 
demonstrate an enhanced response compared to controls even when there is no abnormality in 
the afternoon clexamethasone response (Deshauer et al. 2003). 
A further refinement of the DST is the combined dex/CRH test in which administration of 
dexamethasone is followed by a CRH challenge 24 hours later. In healthy subjects 
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dexamethasone restrains the increase in cortisol following the CRH challenge via its action at 
negative feedback sites. Bipolar patients have been shown to respond to post-dexamethasone 
CRH challenge with an increase in ACTH and cortisol levels greater than that seen in healthy 
controls (Watson et al. 2004) implying that negative feedback is reduced at the level of the 
pituitary. This abnormality appears to be independent of mood state having been observed in 
studies comparing both manic (Schmider et al. 1995) and depressed (Rybakowski et al. 1999) 
patients with healthy controls. Further to this, cortisol responses to dex/CRH remain constant in 
rapid cycling subjects irrespective of mood state (Watson et al. 2005). That this abnormality is a 
trait marker is suggested by studies demonstrating its presence in remitted patients (Schmider 
et al. 1995; Watson et al. 2005) and furthermore by a study showing that 20-30% of first degree 
relatives of patients with affective disorders (bipolar and unipolar) have an aberrant response to 
the dex/CRH test (Krieg et al. 2001). Overall the data from the DST and combined dex/CRH 
studies show that negative feedback is impaired in a significant number of bipolar patients, and 
this may account for the altered cortisol secretion profile which has been observed in the 
disorder. 
Further abnormalities in the HPA axis have been found in the corticotropin releasing hormone 
test which measures the ability of the pituitary to respond to CRH. It has been shown that 
following injections of CRH, the ACTH response is blunted in remitted bipolar patients who went 
on to experience a depressive relapse (Vieta et al. 1997) however the same group found that 
euthymic patients who demonstrate a higher AUC for ACTH following CRH are at greater risk of 
manic episodes in the following six months (Vieta et al. 1999). This indicates that pituitary 
responsiveness to CRH can predict the types of relapse patients are susceptible to, however 
further studies are required to confirm this. Blunting of the ACTH response to CRH has been 
demonstrated in depression, and in some studies an inverse relationship between baseline 
cortisol levels and post-CRH ACTH secretion has been found. From this it has been concluded 
that circulating cortisol is responsible for blunting the ACTH response (Holsboer, 2000), 
however this hypothesis contrasts with the evidence from DST and dex/CRH studies showing 
reduced negative feedback in such patients. Furthermore the studies in bipolar disorder (Vieta 
et al. 1997,1999) suggest that euthymic patients vary in their response to CRH challenge 
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despite evidence that cortisol levels remain elevated in this mood state (Cervantes et al. 2001), 
thus it is unclear how pituitary responsiveness and circadian cortisol secretion are related. 
In conclusion, a number of abnormalities in HPA axis function have been found in bipolar 
disorder including cortisol hypersecretion and impaired glucocorticoid feedback regulation. The 
evidence for an altered cortisol rhythm is considerable having been demonstrated in euthymic, 
manic and depressive mood states (Akesode et al. 1976; Linkowski et al. 1985; Linkowski et al. 
1994; Souetre et al. 1991; Cervantes et al. 2001) and it is hypothesised that this plays a role in 
the aetiology of the disease through its effects on central neuronal function. 
The widespread distribution of corticosteroid receptors in the CNS (see section 1.2.2.2. ) 
suggests that a large number of neuronal systems are likely to be prone to clysregulation by the 
kind of changes to HPA axis function observed in bipolar disorder. As the focus of this thesis is 
the mesocorticolimbic dopamine system, the mapping studies which have demonstrated GR 
expression in doparninergic nuclei support the notion that cells projecting from these regions 
may also be affected by HPA axis circadian rhythm alterations. As far as the potential role for 
MR in these pathological processes, it is currently unclear whether this receptor is expressed in 
dopaminergic cells. The following section introduces the mesocorticolimbic dopamine system 
and provides evidence that corticosteroids can modulate aspects of its function. 
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1.3. Doparninergic Neurotransmission in the CNS 
Whilst today dopamine is well accepted as a neurotransmitter, prior to the pioneering work of 
Carlsson in the late 1950's it had been thought of merely as a precursor of noradrenaline and 
adrenaline. Carlsson postulated a role for cloparnine as a neurotransmitter in 1958 having 
demonstrated its presence in the brain of rabbits (Carlsson et al. 1958) and based on studies 
showing that the akinetic effects of reserpine could be reversed by administration of the 
catecholamine precursor DOPA (3,4-dihydroxyphenylalanine) (Carlsson et al. 1957). DOPA 
treatment resulted in a recovery of dopamine but not noradrenaline levels in the brain and thus 
it was proposed that doparnine acted as a neurotransmitter in its own right within the central 
nervous system. An overview of doparninergic neurotransmission is given in figure 1.6. and 
discussed in detail in the following section. 
1.3.1. Dopaminergic neuronal function 
1.3.1.1. Dopamine synthesis 
Dopamine is a catecholamine neurotransmitter sharing a similar structure and initial synthetic 
pathway with noradrenaline and adrenaline (see figure 1.7. ). The starting point in the clopamine 
synthetic pathway is L-tyrosine, an amino acid which is transported across the blood brain 
barrier by the large neutral amino acid transporter (LAT1) in competition with other large neutral 
amino acids such as tryptophan and phenylalanine (Kanai et al. 1998; Prasad et al. 1999; 
Hawkins et al. 2006). Tyrosine is hydroxylated in catecholamine neurons to produce L-DOPA by 
the enzyme tyrosine hydroxylase (TH) (see figure 1.8. ), the activity of which was first 
characterised by Nagatsu et al. in 1964. L-DOPA is subsequently clecarboxylated by the 
enzyme DOPA decarboxylase to form dopamine. These processes occur principally in the 
neuronal cytoplasm, however membrane bound forms of TH have been found in nerve terminal 
regions which suggest that the initial step in the pathway may take place in the vicinity of the cell 
membrane (Kuczenski et al. 1972). 
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DOPA decarboxylase exhibits fast kinetics and as a consequence TH is the rate-limiting 
enzyme in dopamine synthesis (Nagatsu et aL 1964). Because TH determines the rate of 
formation of dopamine it is a principal determinant of dopamine availability. As such 
manipulation of TH activity is the key means by which regulation of dopamine synthesis occurs. 
This regulation can take the form of end-product inhibition (Nagatsu et al. 1964) which inhibits 
enzyme activity in the short term. In the medium term protein kinase dependent phosphorylation 
of TH can take place at a number of sites resulting in increased enzyme activity (Joh et al. 1978; 
Yamauchi and Fujisawa, 1979; Mallet, 1996; Lew et al. 1999) and by this mechanism a variety 
of receptors can control dopamine synthesis. In the long term changes in the transcription of TH 
mRNA affect enzyme availability and thus long term changes in dopamine synthesis can be 
achieved by this means (Cho et al. 1996; Hadjiconstantinou et al. 1996; Young et al. 1998). 
1.3.1.2. Vesicular uptake 
Following synthesis, cytoplasmic dopamine is packaged into synaptic vesicles in preparation 
for release and to prevent its breakdown by metabolic enzymes (see figure 1.9. ). The transport 
of dopamine into vesicles is performed by the vesicular monoamine transporter VMAT2 (Peter 
et al. 1995; Nirenberg et al. 1996; Hoffmann et al. 1998) utilizing a proton antiport mechanism 
(Eiden et al. 2004). The required proton concentration within vesicles is derived from the activity 
of an ATPase which translocates H+ across the vesicular membrane to produce a pH gradient 
and transmembrane potential which drives the uptake of dopamine by VMAT2. 
Vesicular and cytoplasmic pools of dopamine exist in a dynamic equilibrium with passive 
vesicular leakage countering VMAT2 activity (Floor et al. 1995; Eisenhofer et al. 2004). VMAT2 
is therefore the principal determinant of vesicular content (Colliver et al. 2000) and this in turn 
governs the quantity of cloparnine released during exocytosis (see below and Pothos et al. 
2000). As a consequence VMAT2 activity is an important determinant of doparninergic neuronal 
function. 
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1.3.1.3 Dopamine release 
Release of dopamine occurs following the invasion of the nerve terminal by an action 
potential which causes depolarisation of the terminal membrane. This induces vesicular fusion 
with the terminal membrane leading to exocytosis of dopamine. The prevailing view of 
neurotransmitter release has been that an action potential produces fusion of an invariable 
number of vesicles and hence dopamine release is quantal being directly proportional to 
impulse activity (reviewed by Bennett and Kearns, 2000). This view is challenged however by 
the finding that in dopamine neurons phasic burst firing (characterized by short trains of high 
frequency firing) produces a supralinear increase in the release of dopamine, an effect which 
has been demonstrated in the nucleus accumbens and striaturn (Gonon and Buda, 1985; 
Wightman and Zimmerman, 1990; Suaud-Chagny et al. 1992). It is thought that the supralinear 
increase in DA release may be a result of the increased efficiency and probability of presynaptic 
release in burst firing neurons compared to lower frequency firing neurons (Miles and Wong, 
1986; Lisman, 1997; Snider et al., 1998). It may be the case however that saturation of uptake 
(Chergui et al. 1994), slow metabolism (Michael et al. 1995), or delayed autoreceptor activation 
(Chergui et al. 1994) contribute to the elevated extracellular levels. 
A further problem with the quantal release theory is that as originally postulated, the theory 
requires vesicular content to remain constant (at least in the short term) - the original theory 
arose from measuring postsynaptic evoked potentials at the neuromuscular junction where it 
was found that synaptic neurotransmitter concentrations were quantal, thus vesicular content 
must have been constant. Recent research in dopaminergic neurones has shown that changes 
in vesicular content governed by VMAT2 activity allow for some variability in the amount of 
doparnine released despite the fact that vesicular fusion itself is quantal (Pothos et al. 2002). 
These findings suggest that the classic view of neurotransmitter release is an oversimplification 
as far as doparninergic neurones are concerned. 
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1.3.1.4 Dopamine uptake 
Following release into the synaptic cleft doparnine is cleared via active uptake back into the 
pre-synaptic terminal. The protein responsible for this is the dopamine transporter (DAT) which 
belongs to a superfamily of Na+ dependent monoamine transporters including the serotonin and 
noradrenaline transporters (see reviews by Hoffman et al. 1998; Chen & Reith 2000). DAT is 
present at perisynaptic sites in the neuronal membrane and utilizes the transmembrane Na+ 
electrochemical gradient maintained by the Na+-K+ ATPase pump to transport dopamine across 
the presynaptic membrane. The sodium -potassium pump is therefore an important determinant 
of DAT activity, which in turn is a major determinant of dopamine concentrations at post- 
synaptic sites. DAT activity has been shown to affect the time course of removal of dopamine 
from the synapse and its ability to diffuse to extrasynaptic sites (Benoit-Marand et al. 2000; 
Wayment et al. 2001; Cragg & Rice, 2004). 
N. B. DAT transports both cloparnine and noradrenaline although it has a ten-fold higher affinity 
for DA than NE. Conversely the noradrenaline transporter (NET) has around a four-fold higher 
affinity for dopamine than its proper substrate noradrenaline, and has a higher affinity for 
cloparnine than DAT (reviewed by Masson et al. 1999). Uptake of clopamine by NET has been 
demonstrated in the prefrontal cortex (Moron et al. 2002) and as a consequence NET may play 
an important role in cloparninergic neurotransmission. 
1.3.1.5. Dopamine metabolism 
Dopamine metabolism occurs via two principal pathways, one intraneuronal and the other 
extraneuronal (see figure 1.9. ). Intraneuronal metabolism involves clopamine present in the 
cytoplasmic pool which is composed of both newly synthesised doparnine and doparnine which 
has been released and undergone uptake from the synapse. The enzyme responsible for this is 
monoamine oxidase A (MAO-A) one of two isoforms of the monoamine oxidase enzyme in the 
central nervous system (the other being MAO-B) (Gesi et al. 2001; Shih 2004). Whilst dopamine 
is a substrate, and has equal affinity for both isoforms (Youdim and Bakhle, 2006), MAO-A is 
thought to be the principal isoform responsible for DA metabolism. This has been demonstrated 
in studies which have found that selective MAO-A inhibition leads to a reduction in levels of the 
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oxidative metabolite DHPA in cloparninergic terminal regions, whilst MAO-B inhibition has little 
effect (Kato et al. 1986; Gareft and Soares-da-Silva 1990; Fornai et al. 2000). The study of 
Fornyai et al. (2000) also demonstrated that this enzyme is located intra-neuronally, as 
blockade of vesicular uptake in the striaturn increased 3,4-dihydroxyphenylacetaldehyde 
(DHPA) levels which was presumed to result from increased metabolism of cytoplasmic 
doparnine. Blockade of extracellular DAT-mediated uptake failed to elicit such an effect thus 
ruling out extraneuronal metabolism. As the intraneuronal metabolic route is thought to be 
responsible for the majority of dopamine metabolism (Westerink et al 1985; see later) this 
further supports a preferential involvement of MAO-A in clopamine metabolism. 
Regarding the relative roles of the MAO isoforms in dopamine metabolism, it is interesting to 
note that MAO-B inhibitors such as selegiline and rasagiline are efficacious in the treatment of 
Parkinson's disease (PD), a disorder characterized by deficiencies of striatal dopaminergic 
neurotransmission. It might therefore be suggested that MAO-B is a major determinant of 
striatal dopamine levels. This is contradicted by the evidence given above that MAO-B plays 
only a limited role in dopamine metabolism under normal conditions. It has been shown, 
however, that MAO-B inhibitors significantly increase doparnine levels, and reduce dopamine 
metabolism, following administration of exogenous L-DOPA (but not under basal conditions) 
suggesting a significant role for glial MAO-B metabolism during L-DOPA therapy for PID 
(Brannan et al. 1995). This may explain the therapeutic efficacy of these drugs in the treatment 
of PD, although an alternative hypothesis is that MAO-B inhibition actually reduces the 
generation of neurotoxic dopamine metabolites in astroglial cells thus exerting a neuroprotective 
effect (Nagatsu and Sawada, 2006; Youdim and Bahkle, 2006). Currently this matter remains 
unresolved. 
Returning to the mechanisms underlying dopamine metabolism, monoamine oxidase 
oxidatively deaminates dopamine to produce DHPA, an aldehyde intermediate which is 
dehydrogenated extraneuronally to form DOPAC. Around 60% of DOPAC is then metabolised 
by the enzyme catechol-0-m ethyl transferase (COMT) to form homovanillic acid (HVA) 
(Westerink et al. 1985). DOPAC and HVA are then either excreted in urine or undergo 
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sulphonation and are excreted in urine as sulphated conjugates. This pathway is thought to be 
responsible for the majority of clopamine metabolism, with studies in the striatum suggesting 
that around 90% of doparnine is metabolised in this way (Westerink et al. 1985). The other 
metabolic pathway involves the same enzymes, however the first step involves extraneuronal 
0-methylation of dopamine by COMT to form 3-methoxytyramine. This is then metabolised by 
MAO to form MHPA, an aldehyde intermediate, which is subsequently dehydrogenated to form 
HVA and excreted. 
1.3.1.6. Dopamine receptors 
There are five known receptors for dopamine all of which are coupled to G-protein mediated 
signal transduction pathways (see table 1.3). These receptors are broadly categorised into the 
DI-like receptors (Dj and DO which are positively coupled to adenylyl cyclase and 
phospholipase C, and the D2-like receptors (D2, D3 and D4) negatively coupled to adenylyl 
cyclase. In addition D2 receptors are positively coupled to phospholipase C, arachidonic acid 
synthesis and inwardly rectifying potassium channels (GIRKs) and negatively coupled to Ca 2+ 
channels (reviewed by Sokoloff and Schwarz, 1995; Missale et al. 1998). 
D, receptor mRNA is widely expressed in dopaminergic terminal regions such as the cortex, 
striatum, limbic system, olfactory tubercle, hypothalamus and thalamus (Fremeau et al. 1991; 
Meador-Woodruff et al. 1991; Weiner et al. 1991; Mengod et al. 1992; Richtand et al. 1995) but 
is absent from regions containing dopaminergic cell bodies such as the ventral tegmental area 
and substantia nigra (Meador-Wood ruff et al. 1991; Mengod et al. 1992; Richtand et al. 1995; 
Gross et al. 2005). A similar distribution for D, receptor protein is shown by receptor binding and 
immunocytochernical studies with high to moderate levels expressed in the cauclate-putamen, 
nucleus accumbens, olfactory tubercle and amygdala and low levels in the hypothalamus, 
thalamus, frontal cortex and hippocampus (Boyson et al. 1986; Ariano et al. 1989; Mansour et 
al. 1990; Levey et al. 1993; Caille et al. 1996). A significant difference between D, mRNA 
expression and D, binding is however found in the cell body containing regions of the VTA and 
substantia nigra, with particularly high D, binding in the substantia nigra and to a much lesser 
extent in the VTA. The lack of D, mRNA in these regions has been taken as evidence that the 
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Dl-like D2-like 
D, D5 D2 D3 D4 
G-protein Gs/GOLF/Gq Gs Gi/,, /Gq Gi/,, Gi/,, 
coupling 
Second cAMP cAMP cAMP cAMP cAMP 
messenger I P3/DAG IP3/DAG AA 
pathway 
AA 
T K+ 
Ca 2+ 
Table 1.3. Dopamine receptor coupling and second messenger pathways. cAMP = adenosine 
3', 5'-cyclic monophosphate; IP3 -= inositol trisphosphate; DAG = diacylglycerol; AA 
= arachidonic acid (adapted from Jaber et al. 1996; Missale et al. 1998; Alexander 
et al. 2007) 
D, receptor is located at post-synaptic sites but is not present on doparninergic neurones 
themselves. 
In a similar fashion to that seen with D, receptor mRNA, D5 receptor mRNA is not found in the 
ventral tegmental area or substantia nigra, whilst its expression in terminal regions is much 
restricted compared to the D, receptor having been demonstrated only in the hippocampus, 
thalamus and hypothalamus of rats and certain regions of the cerebral cortex and striaturn in 
monkeys (reviewed by Ciliax et al. 2000). 
In contrast to the DI-like receptors D2 and D3 receptors are expressed both pre- and post- 
synaptically with D2 mRNA present in terminal regions such as the prefrontal cortex, striaturn, 
nucleus accumbens and olfactory tubercle, and in DA cell body containing regions such as the 
ventral tegmental area and substantia nigra (Bouthenet et al. 1991; Weiner et al. 1991; Meador- 
Woodruff et al. 1992; Richtand et al. 1995). Autoradiographic binding and immunocytochemical 
studies show a similar distribution for D2 receptor protein (Boyson et al. 1986; Charuchinda et 
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al. 1987; Ariano et al. 1989; Mansour et al. 1990; Levey et al. 1993). There is also evidence 
from immunocytochernical studies for the expression of D2 receptors on doparninergic neurones 
within the VTA and substantia nigra (Diaz et al. 2000). 
mRNA for D3 receptors has been found in the VTA and substantia nigra in addition to terminal 
regions such as the hippocampus and nucleus accumbens (Bouthenet et al. 1991) whilst 
immunocytochernical studies have shown expression of D3 receptors limited to the nucleus 
accumbens and striaturn (Levesque et al. 1992). Similar to the D2 receptor, the D3 receptor is 
expressed by all clopaminergic neurons in the midbrain (i. e. ventral tegmental area, substantia 
nigra etc. ) (Diaz et al. 2000). The D4 receptor also has a limited expression, with mRNA and 
protein detectable principally in terminal regions such as the frontal cortex, thalamus and globus 
palliclus and little expression in the ventral tegmental area or substantia nigra (Ariano et al. 
1997) suggesting that this receptor is only expressed post-synaptically. 
D2 and possibly D3 receptors located on dopamine neurones play an important role in the 
regulation of neuronal function by providing negative feedback control of cell firing (via 
somatodendritic receptors), and dopamine synthesis and release (via presynaptic terminal 
receptors) (O'Hara et al. 1996; White 1996; Centonze et al. 2002; Lindgren et al. 2003). Further 
discussion of the functional role of these autoreceptors can be found in section 1.3.5. 
1.3.2. Dopaminergic cell groups and projections in the CNS 
The development of the Falck-Hillarp formaldehyde histofluorescence technique (Carlsson et 
al. 1962; Falck et al. 1962) allowed the visualisation of catecholarnine and serotonergic cell 
bodies and fibres throughout the brain. Using this technique Dahlstrom and Fuxe (1964) 
identified twelve catecholamine containing cell groups which they named Al-A12. Subsequent 
work revealed a further five catecholamine groups (A13-A17) and three adrenaline synthesising 
cell groups (Cl-C3) (Hokfelt et al. 1984). Of the Al-A17 cell groups Al-A7 are noradrenergic 
whilst A8-A17 are doparninergic. The doparninergic cell groups are primarily located in the 
midbrain and thalamic/hypothalamic areas, and their cells form a number of distinct projections 
innervating a variety of brain regions (see table 1.4 and figure 1.10. ). In terms of cell numbers it 
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Cell Anatomical Projection System 
Major Anatomical 
Group Location Targets 
A8 Retrorubral Nucleus Mesostriatal Ventral caudate-putamen 
Mesostriatal Caudate-putamen, globus pallidus 
---------------------------- Mesolimbic 
----------------------------- 
------------------------------- 
Amygdala, Hippocampus 
------------------------------- 
Mesocortical Prefrontal, cingulate and perirhinal 
A9 Substantia Nigra ---------------------------- 
cortices 
------------------------- Monoaminergic nuclei, superior 
Mesorhombencephalic colliculus, reticular formation, 
----------------------------- 
periaqueductal grey 
--- --------------------------- 
Mesodiencephafic Various thalamic and 
hypothalamic nuclei 
Mesostriatal Anteromedial caudate-putamen 
----------------------------- ------------------------------- 
Nucleus Accumbens, Amygdala, 
Mesolimbic Hippocampus, Olfactory 
---------------------------- 
Tubercle, Septum 
------------------------------- 
A10 
Ventral Tegmental Mesocortical Prefrontal, cingulate, perirhinal, 
Area (VTA) 
----------------------------- 
suprarhinal and piriform cortices 
------------------------------- 
Monoaminergic nuclei, superior 
MesorhombencephaliC colliculus, reticular formation, 
----------------------------- 
periaqueductal grey 
--- --------------------------- 
Mesodiencephalic Various thalamic and 
hypothalamic nuclei 
Dien cephalospin al 
----------------------------- 
Spinal Cord 
------------------------------- 
Periventricular Periaqueductal grey, medial 
thalamus and hypothalamus 
All Periventricular Grey 
----------------------------- ------------------------------- 
Zona incerta, anterior, medial 
Incerfohypothalamic preoptic and periventricular 
hypothalamus 
A12 Arcuate Nucleus Tuberohypophyseal Median eminence, pituitary 
A13 Zona Incerta Incerfoh othalaml .c YP 
Anterior, medial preoptic and 
periventricular hypothalamus 
Periventricular Incertohypothalaml .C 
Zona incerta, anterior and medial 
A14 preoptic hypothalamus 
Hypothalamus ----------------------------- ------------------------------- Tuberohypophyseal Median eminence, pituitary 
A15 Olfactory Bulb Periglomerular Olfactory glomeruli 
A16 Retina Local projections 
Table 1.4. Dopaminergic projection systems in the CNS (see over for diagram) (adapted from 
reviews by Oades et al. 1987; Feldman et al. 1997; Bjorklund and Dunnett, 2007) 
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Figurel. 10. Major dopaminergic nuclei and projection pathways in the rat brain (adapted from 
reviews by Oades et al. 1987; Feldman et al. 1997; Bjorklund and Dunnett, 2007) 
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Figure 1.11. Brain atlas diagram showing the location of the VTA in a coronal section. 
Distance from bregma -5.6 mm (reproduced from Paxinos and Watson, 1997). 
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has been estimated that around 70-75% of clopaminergic neurons in the brain belong to the 
midbrain cell groups of the retrorubral nucleus (M), substantia nigra (A9) and the ventral 
tegmental area (A10) (reviewed by Grillner et al. 2002) and as a result the vast majority of 
studies on doparninergic function have been carried out either in these regions or the regions 
they innervate. 
1.3.3. The Ventral Tegmental Area 
This thesis focuses on the ventral tegmental doparninergic neurones which form the A10 cell 
group in the classification system of Dahlstrom and Fuxe (1964). The VTA contains the cell 
bodies of the majority of neurones which comprise the mesocorticolimbic system, a system 
consisting of the mesocortical and mesolimbic projections. The mesocortical pathway is 
responsible for doparninergic innervation of regions such as the prefrontal, cingulate, perirhinal, 
suprarhinal and piriform cortices, and the mesolimbic pathway innervates structures such as the 
nucleus accumbens, amygdala, hippocampus, olfactory tubercle and septum (see figure 1.10. ). 
The ventral tegmental area is located close to the midline on the floor of the midbrain (see 
figure 1.11. ). Rostral to the VTA are the mamillary nuclei and posterior hypothalamus, with the 
substantia nigra lying laterally. Caudal to the VTA are the pons and hindbrain, and at its caudal 
extent it is situated above the nucleus interpeduncularis. Fibres from brainstern nuclei which 
form the median forebrain bundle (in particular from the raphe nuclei which extend dorsally from 
the caudal border of the VTA) pass through and dorsally to the VTA with mesocortical, nucleus 
ruber and oculornotor fibres situated clorsolaterally (Oades et al. 1987). 
Two main cell types have been identified in the VTA - dopaminergic cells (which are 
immunoreactive for the synthetic enzyme tyrosine hydroxylase), and non-TH positive, non- 
dopaminergic cells. These non-dopaminergic cells are thought to comprise for the most part of 
GABAergic cells (Van Bockstaele and Pickel, 1995; Steffensen et al. 1998; Carr and Sesack, 
2000; Bubar and Cunningham, 2007; Olson and Nestler, 2007), although there is evidence that 
the VTA contains, in addition, glutarnatergic cells (Yamaguchi et al. 2007). Of the 27-29,000 
cells estimated to be located bilaterally in the VTA, 18,000 stain for tyrosine hydroxylase (Oades 
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Neuronal Action Firing In-vitro firing 
Subtype Potential Frequency pattern Duration 
Highly regular 
DA cell >2 msec - 0.5 -4 Hz pacemaker like 
pattern 
non-DA < 1.5 >4 Hz 
Variable - phasic or 
cell msec burst firing 
Table 1.5. Electrophysiological properties of neuronal subtypes in the VTA (data from Grace 
et al. 1989) 
et al. 1987). The evidence that these TH positive cells are doparninergic and not noradrenergic 
is provided not only by the fluorescence histochemistry studies of Dahlstrom and Fuxe (1964) 
who demonstrated the presence of dopamine in this region (dopamine is not present in 
detectable amounts in noradrenergic fibres, see Kitahama et al. 2000), but also by 
immunocytochemistry studies showing that TH positive neurones in the VTA do not express the 
noradrenaline synthesising enzyme dopamine-p-hydroxylase (Swanson and Hartman, 1975; 
Tong et al. 2000). 
In addition to labelling studies, doparninergic and non-doparninergic neurones can be 
distinguished on the basis of their in-vitro electrophysiological characteristics (see table 1.5). It 
should be noted that the regular pacemaker-like firing of dopaminergic neurons in vitro differs 
significantly from the in vivo situation where firing occurs in bursts (see section 1.3.1.3). 
1.3.4. Afferent regulation of VTA dopaminergic neurones 
Afferent projections to the VTA arise in a number of regions and include glutamatergic, 
cholinergic, noradrenergic, GABAergic, and serotonergic projections (Grillner et al. 2002). Table 
1.6. shows the regions of origin, and effect on VTA DA neurone firing rates, of these projections. 
The following discussion focuses on the glutamatergic and serotonergic afferent systems as 
these have been the subject of study in this thesis. Whilst all afferent inputs have a potentially 
important role in regulating dopaminergic function, these two systems were selected as they 
were thought to be likely mediators of any observed changes in neuronal function arising from 
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Neurotransmitter Region of Origin 
Effect on DA cell 
firing 
Prefrontal cortex, subthalarnic 
nuclei, laterodorsal and Excitatory + 
Glutarnate pedunculopontine tegmental Inhibitory 
nuclei (direct effect) 
Acetylcholine Laterodorsal tegmental nuclei 
Excitatory 
(LDTg) (direct effect) 
Noradrenaline Locus coeruleus 
Excitatory 
(direct effect) 
Striaturn, pallidurn, nucleus Inhibitory GABA accumbens, VTA (direct effect) interneurones 
Inhibitory 
5-HT Raphe nuclei (indirect effect on 
GABA interneurones) 
Table 1.6. Afferent projections to the VTA (data from Grillner et al. 2002) 
corticosteroid clysregulation. To summarise the rationale behind this, the glutamatergic system 
was selected due to its central role in the regulation of burst firing within the mesocorticolimbic 
system (see later). This functional property is critical in determining dopamine release at the 
terminal making glutamatergic regulation a prime candidate for investigation. The serotonergic 
system was selected on the basis that it is dysregulated in mood disorders (see section 1), and 
additionally because there is considerable evidence that corticosteroids can modulate 
serotonergic function (see reviews by McAllister-Williams et al. 1998; Bremner, 1999; Chaouloff, 
2000). 
1.3.4.1. Glutamatergic regulation of VTA dopaminergic activity 
Reciprocal connections exist between the VTA, PFC, and the nucleus accumbens, consisting 
of GABAergic and glutarnatergic projection neurons (Carr and Sesack, 1999; Moore et al. 1999; 
Sesack and Carr, 2002). These form a complex feedback mechanism which acts to control tonic 
activation of mesocortical and mesolimbic neurons (Cheramy et al. 1990; Grace, 1991). In 
addition to tonic regulation of dopaminergic cell firing, the phasic burst firing seen in-vivo is 
thought to be regulated by these projections. It has been shown that prefrontocortical afferents 
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play a major role in the conversion of pacemaker-like firing to phasic bursting. Application of 
glutamate to the PFC (Murase et al. 1993) or electrical stimulation of this region (Tong et al. 
1996) results in burst-firing within the doparninergic cells of the VTA, A study by Overton and 
Clark (1997) found that the latency between PFC stimulation and induction of bursting within the 
VTA was not always consistent with a monosynaptic connection between these two regions. It 
has been suggested that excitatory projections from the PFC to the subthalamic nucleus or 
pedunculopontine nucleus activate glutarnatergic efferents from these regions which synapse 
onto dopaminergic cells within the VTA (Overton and Clark, 1997). Overall, the situation is 
currently unclear, however the PFC has been shown to be involved in the induction of burst 
firing and this is likely to be mediated via a mixture of monosynaptic and polysynaptic efferent 
projections to the VTA. 
Glutamate acts on two main classes of receptor - the so called ionotropic receptors which are 
ligand gated ion channels and include the NMDA, AMPA and kainate receptors, and the 
metabotropic (G-protein linked) mGIuR receptors. In terms of the receptor subtypes responsible 
for the regulation of doparninergic function there is evidence for both NMDA and AMPA/kainate 
subtypes of ionotropic glutamate receptors on VTA DA neurons. Immunocytochernical studies 
have shown high levels of the AMPA receptor subunits GluRII-4 in the VTA and substantia 
nigra. In addition, binding studies have demonstrated the presence of NMDA, kainate, and 
AMPA receptors within the VTA (reviewed by Kalivas, 1993). 
Microdialysis studies suggest a tonic activation of AMPA receptors within the VTA, as selective 
AMPA antagonists produce a decrease in doparnine release in the prefrontal cortex (Westerink 
et al. 1998, Takahata and Moghaddarn, 2000). In the study by Takahata and Moghaddarn 
however it was shown that the AMPA antagonist LY293558 produces an increase in doparnine 
release within the nucleus accumbens - the opposite effect to that seen in the PFC which 
suggests that these two projections may be differentially regulated. 
A role for NMDA receptors in the regulation of VTA doparnine neurons is suggested by the 
ability of NMDA selective drugs such as the non-competitive channel blocker phencyclidine to 
antagonise the glutarnate induced excitation of A10 neurons in a midbrain slice preparation 
(Wang et al. 1993). The involvement of NMDA receptors in burst firing is probably their most 
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important functional role within the mesocorticolimbic system. The existence of spontaneously 
bursting DA cells in VTA slices from immature rats has allowed the nature of burst firing to be 
studied in-vitro. One study has shown that spontaneous bursting can be blocked by the 
application of the NMDA antagonist AP-5 (Mereu et al. 1997). In addition this study found that 
spontaneously bursting neurons were more sensitive to NMDA induced spikes in burst firing 
than cells firing in a pacemaker like manner (Mereu et al. 1997). Studies in intact animals have 
also demonstrated that burst firing produced in VTA DA neurones by electrical stimulation of the 
PFC can be blocked by the NIVIDA antagonist CPP (Tong et al. 1996). In this study, the AMPA 
antagonist CNQX had no effect on bursting activity. Overall, it is clear that the NMDA receptor is 
involved in burst firing in these neurones, whilst the contribution of AMPA receptors is less well 
understood. Given the functional role of burst firing in increasing the efficiency of doparnine 
release, it would appear that glutamatergic signalling plays a central role in regulating 
doparninergic neuronal function in the VTA. 
1.3.4.2. Serotonergic regulation of VTA dopaminergic activity 
Serotonergic projections to the VTA originate in the raphe nuclei and exert a tonic and phasic 
inhibitory effect on VTA dopaminergic neurones (reviewed by di Matteo et al. 2001). Thus 
studies have shown that whilst electrical stimulation of the dorsal raphe nucleus produces both 
excitatory and inhibitory effects on VTA DA cell firing, the inhibitory component of the response 
can be blocked by chemical lesion of dorsal raphe 5-HT neurones (Gervais and Rouillard, 
2000). Furthermore acute systemic administration of fluoxetine, which blocks the re-uptake of 
serotonin, inhibits the firing rate of VTA doparninergic cells, and this effect can be blocked by 
chemically lesioning raphe 5-HT neurones (Prisco and Esposito, 1995). 
Functional studies suggest that the inhibitory effect of serotonin on VTA dopaminergic cell 
firing is mediated by the 5-HT2c receptor. Thus intra-VTA application of the 5-HT2c receptor 
antagonists SB242084 and SB206553 increases the firing rate (and burst firing) of 
dopaminergic neurones and increases dopamine release in the nucleus accumbens and 
prefrontal cortex (di Mafteo et al. 1998; di Giovanni et al. 1999; Gobert et al. 2000). Furthermore 
the inhibitory effects of acute fluoxetine on VTA dopaminergic cell firing can be blocked by the 
55 
Chapter 1 
5-HT2B/2c antagonist mesulergine (Prisco and Esposito, 1995). An interesting finding in this 
study was that after administration of fluoxetine for 21 days, acute administration of fluoxetine 
did not cause any change in the firing rate of VTA DA cells compared to control animals. In 
addition, the ability of the 5-HT2B/2c agonist mCPP to reduce DA cell firing rate was abolished, 
suggesting a downregulation of serotonergic receptors in the VTA caused by overstimulation. 
mRNA for 5-HT2c receptors has been found in the VTA (Pompeiano et al. 1994; Abrarnowski 
et al. 1995; Eberle-Wang et al. 1997) and this is supported by recent work demonstrating that 
5-HT2C immunoreactivity is present in the VTA (Bubar and Cunningham, 2007). As the 5-HT2C 
receptor increases lP3/DAG via G-protein signalling and as a result is excitatory (see Feldman 
et al. 1997) the inhibitory action of the 5-HT2c receptor on dopamine cell firing seems to be 
anomalous. This issue has been clarified by Bubar and Cunningham (2007) with the 
demonstration that this receptor is located on GABAergic interneurones. Thus it would appear 
that serotonin potentiates the release of GABA in the VTA via 5-HT2c receptors, which in turn 
inhibits dopaminergic cell firing. This theory is supported by the demonstration that systemic 
administration of MDMA to rats increases the release of GABA in the VTA, and moreover by the 
fact that this effect can be blocked by local perfusion of the 5-HT2B/2c receptor antagonist 
SB206553 (Bankson and Yamamoto, 2004). 
Functional studies also suggest a role for 5-HT2A receptors in the regulation of VTA 
dopaminergic neurones as systemic administration of M100907, a 5-HT2A antagonist, has been 
found to decrease burst firing VTA DA neurones (Minabe et al. 2001). It has been shown 
however that 5-HT2A receptors located on glutarnatergic afferents to the VTA originating in the 
prefrontal cortex are at least partially responsible for this effect. Prefrontocortical perfusion of 
M100907 attenuates the increase in prefrontocortical doparnine, and blocks the increase in 
glutamate in the VTA, following systemic administration of DOI (Bortolozzi et al. 2005; Pehek et 
al. 2006). Furthermore the presence of the 5-HT2A receptor in the VTA is in question. 5-HT2A 
receptor mRNA has not been found in the VTA (Pompeiano et al. 1994), although 
immunocytochernical studies have shown that 5-HT2A immunoreactivity is present on 
cloparninergic neurones in this region (Ikernoto et al. 2000; Doherty and Pickel, 2000). 
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The literature suggests that serotonin is an important regulator of VTA doparninergic function, 
particularly in respect of its ability to alter the burst firing properties of these cells. Current data 
favours a role for the 5-HT2c receptor via an interaction with GABAergic interneuronal function, 
although there is the possibility that other receptor subtypes are involved. 
1.3.5. Dopamine autoreceptor function in mesocorticolimbic neurones 
The first evidence for autoreceptor control of VTA dopaminergic neurones was provided by 
Bunney et al. in 1973 who demonstrated that systemic application of antipsychotic drugs could 
increase the firing rate of these cells. This was interpreted as confirmation of a neuronal 
feedback hypothesis which stated that released dopamine inhibits the firing of DAergic 
neurones. Later work by Grace (1988) showed that application of the D2 agonist apomorphine to 
an in-vitro VTA slice preparation could inhibit neuronal firing, confirming the D2 receptor as 
responsible for these effects. The subsequent demonstration of somatodendritic release of 
doparnine in the VTA (Kalivas et al. 1989) and the observation that infusion of D2 antagonists 
into the VTA increases dopamine release in the PFC (Westerink et al. 1998; Chen and Pan, 
2000) and the nucleus accumbens (Westerink et al. 1996; Chen and Pan, 2000) provided 
support for an endogenous role for these autoreceptors in regulating doparninergic function. It is 
the case that the use of non-selective D2/D3 ligands raised the question of the role the D3 
receptor plays in somatodendritic autoreceptor function. Early in-situ hybridisation studies found 
little evidence for D3 transcript in the VTA (Bouthenet et al. 1991), although more recent 
immunocytochernical studies have demonstrated that doparninergic neurones in this region 
express both D2 and D3 receptors (Diaz et al. 2000). In functional studies the D2/D3 agonist 
quinpirole and the D3 preferring ligand 7-OH-DPAT have been shown to be equipotent at 
inhibiting VTA cell firing (Bowery et al. 1994) suggesting that both receptor subtypes may be 
involved in somatodendritic autoinhibition, however work of this type has been hampered by the 
lack of truly selective ligands for these receptors. More recent work using knockout mice has 
shown that autoinhibition of VTA doparninergic neuronal firing is dependent upon expression of 
the D2 receptor (Centonze et al. 2002) whilst another study found that G-protein coupled 
potassium channels are not activated by D2/D3 ligands in D2 knockout mice (Davila et al. 2003). 
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These studies therefore suggest that whilst D3 receptors may be expressed in VTA 
doparninergic neurones they are not functionally coupled to autoinhibitory effector mechanisms 
and may not play a significant role in the somatodendritic regulation of dopaminergic function. 
In addition to somatodendritic autoreceptors there is evidence for autoreceptors on 
doparninergic terminals which modulate synthesis (Hetey et al. 1985; Onali and Olianas, 1989) 
and release (Moghaddam and Bunney, 1990; Westerink et al. 1996; Kuroki et al. 1999), 
Although there is evidence that these receptors are present on mesolimbic terminals there is 
some controversy over the presence of these receptors at mesocortical terminals. Whilst in one 
study intra-PFC application of the D2 receptor antagonist sulpiride was found to increase local 
dopamine release (Bean and Roth, 1991) systemic administration of sulpiride has consistently 
been found to have no effect on dopamine release in this region (Moghaddam and Bunney, 
1990; Kuroki et al. 1999; Ago et al. 2005). Furthermore local infusion of another D2 antagonist, 
haloperidol, into the mPFC has been shown to have no effect on doparnine release (Gessa et 
al. 2000; Devoto et al. 2001). In the study of Moghaddam and Bunney (1990) equivalent doses 
of sulpiride were found to significantly increase DA outflow in the nucleus accumbens whilst 
studies in the lab at Newcastle have produced a similar result (L. Ferrie, doctoral thesis) 
suggesting that autoreceptor control differs between the two projection systems. It has been 
suggested that in the prefrontal cortex the D2 autoreceptor is located some distance from the 
synapse and therefore is only activated under conditions of elevated dopamine release 
(Cubeddu et al. 1990). This theory was supported by the observation that in prefrontocortical 
slices D2 antagonists can augment DA release following electrical stimulation but only when 
very high stimulation rates are used (Agneter et al. 1994). It was suggested that these high 
stimulation rates release dopamine in sufficient quantities for it to diffuse to extrasynaptic sites 
where the D2 receptor is located, and therefore under these conditions the receptor is active. A 
challenge to this theory comes from early work which found that systemic administration of the 
D2 agonist apornorphine has no effect on PFC doparnine release (Chiodo et al. 1984, White and 
Wang 1984) from which it was surmised that mesocortical neurones do not express 
autoreceptors. The inconsistencies between studies using systemic and local applications of 
ligands suggest that in the case of systemic administration drug interactions with other neuronal 
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systems may cloud the picture. It does appear to be the case, however, that the mesocortical 
and mesolimbic systems differ in their autoreceptor function. 
In terms of the mechanisms by which dopamine autoreceptors regulate neuronal function it is 
thought that somatodendritic receptors inhibit neuronal firing by activating K+ channels which 
hyperpolarise the cell membrane (Chiodo, 1992; Zahniser et al., 1992). This mechanism may 
also account for the modulation of release by terminal autoreceptors, however recent studies 
have demonstrated that D2 receptor activation may interfere with vesicular release via an 
interaction with the exocytotic machinery (Binda et al. 2005). In contrast, D2 receptor inhibition 
of doparnine synthesis is thought to occur as a result of a reduction in the phosphorylation state 
of tyrosine hydroxylase (due to a decrease in cAMP dependent protein kinase A activity) which 
inhibits enzyme function (Lindgren et al. 2001). These mechanisms allow for neuronal function 
to be modulated in response to extracellular dopamine levels and play an important role in 
regulating a variety of clopaminergic systems. 
1.3.6. Dopaminergic neurotransmission: physiological and psychological roles 
Dopamine release in terminal regions serves a wide variety of function. The mesostriatal 
system arising in the substantia nigra is intrinsically involved in the control of movement with the 
loss of striatal doparninergic afferents implicated in Parkinson's disease (Iversen and Iversen, 
2007). The tuberoinfundibular system (originating in the hypothalamus and arcuate nucleus) 
controls the secretion of prolactin from the pituitary, with dopamine released into the 
hypophyseal portal vein inhibiting the release of this hormone (Moore, 1987). The 
mesocorticolimbic dopamine systems are particularly associated with reward and cognitive 
functions in the terminal regions of the nucleus accumbens and prefrontal cortex respectively. 
The following section aims to provide a brief overview of the vast literature concerning some of 
the most important aspects of mesocorticolimbic doparninergic function. 
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1.3.6.1. Dopamine in the mesolimbic system. 
The mesolimbic dopamine neurons originate in the ventral tegmental area and project to 
regions such as the nucleus accumbens, hippocampus an amygdala. This system is involved in 
emotional regulation and has been associated, in particular, with brain reward processes. 
Brain reward has been the subject of intense study over the last twenty years with much 
evidence that dopamine plays a regulatory role. The ability of rewarding stimuli such as 
intracranial self stimulation, drugs of abuse, food, sex, and social interactions (reviewed by 
Salamone and Correa 2002) to increase doparnine release in the nucleus accumbens 
implicated both this brain region and the mesolimbic system in reward functions. A simplistic 
interpretation of these findings would be that dopamine release mediates the rewarding 
properties of these stimuli, however there is evidence to suggest that this is incorrect. Rather it 
has been suggested that doparnine is involved in anticipatory and "wanting" aspects of reward 
rather than the rewarding properties of the stimuli per se (Salamone and Correa, 2002). 
Evidence for this is provided by studies showing that dopamine depletion or administration of 
dopamine antagonists in the NAcc reduces the amount animals are willing to work for a 
rewarding stimulus but does not impair the appetite for that stimulus (Aberman et al. 1999; 
Nowend et al. 2001; Correa et al. 2002; Salamone et al. 2002b). This field is however 
controversial and others have stated that dopamine release is involved in learning and adaptive 
responses to reward stimuli (reviewed by Naranjo et al. 2001; di Chiara et al. 2007). This theory 
arose from the finding that whilst drugs of abuse increase dopamine release in the nucleus 
accumbens shell, natural reinforcers such as food only increase release in this region upon 
novel presentation (reviewed by di Chiara et al. 2007). As a consequence dopamine may be 
involved in learning processes involved in adaptation to novel rewarding stimuli. Overall whilst it 
is currently unclear what role dopamine actually plays in reward processes the ability of 
rewarding stimuli to alter mesolimbic dopaminergic function offers strong evidence for an 
involvement of this system in the brain reward circuit. 
60 
Chapter 1 
1.3.6.2. Dopamine in the mesocortical system 
As the name suggests, mesocortical dopaminergic neurons from the VTA innervate a range of 
cortical regions including the prefrontal, cingulate, and peri-/suprarhinal cortices. The prefrontal 
cortex is the region of the brain associated with executive functions such as working memory, 
decision making, action-outcome contingency detection and visual aftentional selectivity (Dailey 
et al. 2004). There is evidence that mesocortical release of doparnine in this region has a 
modulatory influence on these functions with studies showing that modest augmentation of 
dopaminergic activity with D, receptor agonists improves working memory, whilst supranormal 
doparninergic activity impairs working memory (Arnsten, 1997; Robbins, 2005). This suggests a 
biphasic effect of dopamine on working memory, further support for which is provided by the fact 
that adrenalectomy induced depletions of dopamine release in this region impair working 
memory (Mizoguchi et al. 2004). Further involvement of dopamine in executive functions has 
been demonstrated by the ability of dopaminergic manipulations to alter behavioural flexibility 
via both D, and D2 receptor mediated mechanisms (reviewed by Floresco and Magyar, 2006) 
and also to alter decision making processes associated with impulsivity and delayed reward 
(Floresco and Magyar, 2006). 
Prefrontocortical cognitive functions have also been implicated in top-down regulation of 
emotion via sub-cortical afferents. For example lesions of the prefrontal cortex impair the ability 
of humans to cope emotionally with changing situations (see Davidson and Irwin, 1999; Bandler 
et al. 2000) and a number of imaging studies have shown that the prefrontal cortex modulates 
amygdala activity during conscious suppression of emotion (Beauregard et al. 2001; Levesque 
et al. 2003; Ochsner et al. 2004; Ohira et al. 2006; Urry et al. 2006). In rats afferents from the 
prefrontal cortex to the amygdala have been demonstrated (Gaboft et al. 2005), whilst lesions of 
the prefrontal cortex have been found to impair the extinction of conditioned responses to 
aversive stimuli (Morgan et al. 2003). The involvement of dopamine in these processes is 
shown by selectively lesioning dopaminergic neurons in the PFC which delays the extinction of 
fear conditioning in rats (Morrow et al. 1999; Fernandez Espejo, 2003) consistent with the effect 
of gross lesions as demonstrated by Morgan et al. (2003). Thus clopaminergic innervation of the 
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mPFC appears to play an important role in emotional regulation as a result of its ability to 
modulate cognitive aspects of emotional processing in the PFC. 
The involvement of dopamine in reward, cognition, and emotion suggests that corticosteroid 
modulation of dopaminergic neurotransmission may alter these brain functions and this may 
play a role in the symptomology of bipolar disorder. A fuller discussion regarding these functions 
in relation to the results of the present study and the relevance to the symptoms of bipolar 
disorder can be found in chapter 5. 
1.3.7. Corticosteroids and mesocorticolimbic dopamine function 
It is established that corticosteroids regulate mesocorticolimbic dopaminergic function, 
however much of the evidence comes from studies in adrenalectomised animals. This data 
therefore has limited utility for predicting the effects of corticosteroid dysrhythmia and 
hypersecretion modeled in the present study, however it gives clues as to the aspects of 
doparnine function which might be sensitive to corticosteroids. 
Early studies showed that stereotyped behaviours in rats were increased in response to D2 
agonists such as apornorphine and LY-171555 following adrenalectorny (ADX) (Faunt and 
Crocker, 1988; 1989). Further evidence for alterations in doparnine receptor function was 
subsequently provided when it was shown that ADX decreases D, and D2 receptor binding in 
the substantia nigra and caudate putamen (Biron et al. 1992). This decrease in D2 receptor 
binding may account for an earlier observation that the apomorphine induced decrease in 
cloparnine release in the rat striaturn is attenuated following ADX (Tanganelli et al. 1990). 
Following on from this early work investigations began into the role of corticosteroids in the 
regulation of systems involved in drug abuse. Thus in the nucleus accumbens ADX was shown 
to decrease basal doparnine release, and attenuate the increase in dopamine levels produced 
by administration of drugs of abuse, including nicotine, morphine and cocaine (Piazza et al. 
1996; Shoaib and Shippenberg; 1996; Barrot et al. 2000). In the prefrontal cortex ADX has been 
found to reduce basal dopamine release in a similar manner to that seen in the nucleus 
accumbens and to induce impairments in working memory consistent with a doparninergic role 
in this aspect of prefrontocortical function (Mizoguchi et al. 2004). It is interesting to note that in 
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contrast to the observed effect in the nucleus accumbens, ADX has been shown to increase the 
release of doparnine in the striaturn in response to cocaine but had no effect on the response to 
morphine (Barrot et al. 2001). This suggests some heterogeneity in corticosteroid effects on the 
different doparninergic projections. 
The ADX induced attenuation of dopamine release in terminal regions innervated by the VTA 
may in part be explained by the ability of ADX to decrease the firing rate of VTA dopaminergic 
neurons (Overton et al. 1996), its ability to decrease the self-stimulation induced increase in 
doparnine synthesis in the nucleus accumbens (Nakahara et al. 2000), or by the evidence that 
dopamine metabolism is increased by ADX (although this has only been shown in the striatum; 
Lindley et al. 1999). One effect of ADX which is not consistent with a downregulation of 
doparninergic neurotransmission, however, is the downregulation of DAT binding in the nucleus 
accumbens found by Sarnyai et al. (1998) although this may explain the attenuation of cocaine 
induced dopamine release discussed earlier (Barrot et al. 2000). 
Whilst there is much evidence that adrenalectomy decreases doparninergic neuronal function 
in the nucleus accumbens, with some evidence that a similar effect occurs in the prefrontal 
cortex, relatively few studies have looked at the effects of chronic supranormal corticosteroid 
levels which are more relevant to this thesis. One study by Czyrak et al. (2003) found that 
chronic high corticosterone increases tyrosine hydroxylase mRNA in the ventral tegmental area, 
and TH protein levels in the nucleus accumbens (but not the VTA). This suggests an 
upregulation of dopamine synthesis in the NAcc in response to corticosterone and furthermore 
that protein trafficking is modulated by corticosteroids. Earlier work by Pacak et al. (2002) 
however showed that chronic administration of cortisol reduces DOPA accumulation in the 
nucleus accumbens following DOPA decarboxylase inhibition, a result which indicates 
decreased dopamine synthesis in this region. It may be the case that tyrosine hydroxylase 
protein is increased in the nucleus accumbens as a result of hypercortisolaernia, but that 
inhibition of enzyme activity results in a decrease in dopamine synthesis. 
In other dopaminergic terminal regions there is evidence that chronic administration of 
corticosteroids increases dopaminergic transmission. One study found an increase in striatal 
levels of the dopamine metabolite HVA following chronic administration of corticosterone 
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(Wolkowitz, 1994), whilst another found that chronic administration of corticosterone significantly 
increases HVA levels in the prefrontal cortex, with a concurrent non-significant increase in 
doparnine release in this region (Inoue and Koyama, 1996). One caveat, however, of using 
cloparnine, metabolites as a marker of dopaminergic neurotransmission is whether a change in 
levels represents an increase in release or an increase in metabolism. 
Further evidence that chronically elevated corticosteroids can modulate dopaminergic 
neurotransmission was shown in the study of Czyrak et aL (2003) which demonstrated an 
increase in D, receptor mRNA in the striaturn and nucleus accumbens, and an increase in VTA 
D, receptor binding. These are, however, post-synaptic receptors and consequently this effect 
does not suggest a direct modulation of doparninergic neuronal function. 
The use of blunt manipulations such as adrenalectomy and chronically elevated corticosteroid 
levels makes it difficult to predict the consequences of the more subtle corticosteroid 
dysrhythmia studied in this thesis. Nevertheless there is much evidence that corticosteroids 
modulate doparninergic activity in mesolimbic and mesocortical systems. This in turn supports 
the view that corticosteroid dysregulation might alter dopaminergic neuronal function in bipolar 
disorder and thus may play a role in the aetiology of the disease. 
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1.4. Summary 
To reiterate, the central hypothesis around which this thesis is based states that an underlying 
deficit in the hypothalamic-pituitary adrenal axis in bipolar disorder (characterized by 
dysregulation of the circadian pattern of secretion) produces a hypercortisolaernic state which in 
turn alters central mesocorticolimbic dopaminergic function. This introduction has aimed to 
provide an overview of biological systems implicated in this hypothesis and to review the current 
evidence supporting this theory. 
In section 1 the evidence for altered doparninergic function in bipolar disorder was reviewed, 
with data presented demonstrating elevated levels of clopamine metabolites and dopamine 
receptors in studies of bipolar patients. Doparninergic hypotheses of bipolar disorder have 
suggested that a hyperdoparninergic state is present and this is supported by the demonstrated 
ability of dopamine releasing drugs to produce manic-like affective states. The ability of mood 
stabilizing drugs to both increase and decrease dopamine release in mesocorticolimbic terminal 
regions does not offer any support for a hyperdopaminergic hypothesis however it does suggest 
that these drugs may produce their therapeutic effects via interactions with this system. The 
large body of literature implicating the mesolimbic projection in reward functions offers further 
support for pathophysiological deficits in this system as these aspects of behaviour are altered 
during manic and depressive episodes. In summary it was concluded that there is considerable 
evidence for a mesocorticolimbic component in the pathophysiology of bipolar disorder making 
this system a valid candidate for study in trying to elucidate the underlying aetiology of the 
disorder. 
In section 2 the data implicating the hypothalamic-pituitary-adrenal axis in bipolar disorder 
was reviewed. It was shown that there is evidence that the circadian rhythm of corticosteroid 
secretion is altered in bipolar disorder, with elevated hormone levels during the daily nadir in 
secretion. Alterations have also been found in feedback regulation of the HPA axis with a large 
proportion of bipolar patients exhibiting non-suppression of cortisol release in response to 
dexamethasone. Further evidence for dysfunction is given by the enhanced cortisol response to 
waking in bipolar patients and alterations in CRH responsiveness at the level of the pituitary. 
These data and the ability of corticosteroids to circulate throughout the body regulating a large 
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number of systems suggest that HPA axis dysfunction may be a primary causal factor in the 
aetiology of bipolar disorder. It therefore follows that modeling these deficits and investigating 
their effects in the CNS could increase our understanding of the disease processes at work in 
bipolar disorder. 
In section 3 the current data regarding corticosteroid regulation of doparninergic 
neurotransmission was surnmarised. There is significant evidence that both high doses of 
corticosteroids and adrenalectomy can alter mesocorticolimbic function. These effects range 
from altered synthetic enzyme mRNA expression to changes in dopamine release in terminal 
regions and altered behavioural responses to cloparninergic drugs. These studies support the 
general hypothesis that doparninergic deficits may arise from HPA axis dysfunction however the 
fact that relatively blunt manipulations of corticosteroid function were used means that they do 
not accurately reflect the situation in bipolar disorder. This thesis reports on investigations which 
have been carried out to address these issues and to determine whether HPA axis dysfunction 
similar to that seen in bipolar disorder can alter mesocorticolimbic function. 
66 
Chapter 2 
Chapter 2. 
Methods 
67 
Chapter 2 
Chapter 2. Methods 
2.1. Animals 
2.1.1. Legal status 
All animal procedures were carried out in accordance with UK Home Office guidelines laid out 
in the Animals (Scientific Procedures) Act 1986. 
2.1.2. Animal supply and housing 
Experiments were carried out in male hooded Lister rats purchased from Charles River UK Ltd 
(Kent, UK). Male rats were used in preference to females to avoid interactions of the oestrous 
cycle with the DA system (Kazandjian et al. 1987; Mackenzie et al. 1988; Xiao and Becker, 
1994) Animals were housed four to a cage (RC1 cages, 56 x 38 x 20 cm) with ad libitum access 
to food and water. Following delivery, animals were acclimatised for one week prior to any 
experimental or treatment procedures to overcome transport induced stress. All animals were 
kept under controlled conditions with a light cycle consisting of 12h light, 12h dark, lights on at 
7am GMT; temperature 21 ± 2'C and humidity -40%. Disturbance to the animals was kept to a 
minimum with cage cleaning occurring twice a week and weighing of the animals once every 
two days during treatment procedures. 
2.2. Corticosterone treatment procedure 
Corticosterone (Sigma, UK) was dissolved in 5ml of absolute ethanol (BDH) and the resultant 
solution diluted in one litre of tap water to yield a final concentration of 50 pg/ml corticosterone 
in 0.5% ethanol solution. The vehicle solution used to treat control animals consisted of 0.5% 
ethanol in tap water. These stock solutions were poured into water bottles and placed in the 
normal position on the cage with animals having ad libitum access. Water bottles were weighed 
every two days to monitor the rate of consumption and refilled with solution. Stock solution was 
made fresh every four days. 
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Animals (weight at start of treatment - 190-230g) were housed in cages of four as described 
in section 2.1.2. Treatment with corticosterone or vehicle solution was carried out for a period of 
12-15 days during which animals were weighed and checked for signs of illness every two days. 
Adrenal glands were removed at sacrifice to confirm the effect of treatment. See chapters 4 and 
5 for details of water consumption, animal weight profiles, and final adrenal weights. 
The treatment procedure described above has been previously validated in experiments in our 
laboratory (G. Fairchild, doctoral thesis 2003). 24 hour sampling of plasma corticosterone was 
performed in animals treated with corticosterone and vehicle solutions for 14 days to compare 
the diurnal rhythm of corticosterone secretion (see figure 2.1. ). Diurnal rhythms in corticosterone 
secretion were detected in individual animals using a single cosinor model. This analysis 
demonstrated that 8/8 vehicle treated animals exhibited significant diurnal rhythmicity, but only 
4/7 corticosterone treated animals exhibited significant diurnal rhythmicity. Mean diurnal 
concentration and Area Under Curve (AUC) values were similar for both treatment groups, 
however there was a significant effect of treatment on the amplitude of the diurnal rhythm (F2,20 
= 4.68, p<0.05). When post hoc tests were performed, it was revealed that the amplitude of the 
diurnal rhythm was significantly reduced in the corticosterone treated group compared with the 
vehicle treated group (p<0.05). No significant difference between diurnal peak values was found 
between corticosterone and vehicle treated animals, however values at the diurnal nadir were 
significantly lower in the vehicle treated group compared to the corticosterone treated group. 
Consistent with these findings was the significantly higher ratio between peak and nadir levels in 
the vehicle group compared with the corticosterone group. Weight gain and water consumption 
in treated rats did not differ from controls during the treatment period. These results 
demonstrate that corticosterone administration via drinking water leads to a flattening of the 
diurnal rhythm in corticosterone secretion by elevating the diurnal nadir but leaving the diurnal 
peak intact 
In a separate experiment, animals treated for 25-31 days with corticosterone in their drinking 
water demonstrated a 58% decrease in adrenal weight compared to their vehicle treated 
counterparts. Thus, as described previously, in the present experiment adrenal weight was used 
as a physiological measure to confirm the effect of treatment. 
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Figure 2.1. Diurnal profile of plasma corticosterone measured at hourly intervals over a 24- 
hour period on day 14 of treatment in vehicle treated rats (n=8, grey diamonds) and 
corticosterone treated rats (n=7, black squares). Solid bar indicates the dark 
period. 
2.3. NSD1 015 treatment procedure and tissue collection 
Following the 14 day corticosterone treatment detailed in section 2.2., animals (8 vehicle 
treated, 8 corticosterone treated) were injected intraperitoneally with 100 mg/kg NSD1015 
(Molekula Ltd., UK) and returned to their home cage. Either 20 min or 2 hours later the animals 
were sacrificed with sodium pentobarbital i. p. (0.7 ml/kg, 20% w/v solution, Dolethal Vetoquinol, 
UK), and the brain quickly removed. Tissue blocks containing the medial prefrontal cortex and 
the nucleus accumbens (according to the brain atlas of Paxinos and Watson, 1998) were rapidly 
dissected out and placed in pre-weighed Eppendorf tubes containing 1ml of OAM perchloric 
acid in preparation for the tyrosine hydroxylase assay detailed in section 2.6. The remaining 
mid- and hindbrain portion was rapidly snap-frozen in isopentane cooled on dry ice prior to 
storage at -70 OC to be used in in situ hybridization histochemistry (see section 2.5). 
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2.4. Neuronal retrograde tracing 
2.4.1. Surgical procedure and tissue preparation 
1. Male hooded Lister rats (- 300g) (Charles River, UK) were anaesthetised with 
0.25mg/kg medotomidine (Domitor, Pfizer Animal Health UK) and 58 mg/kg ketamine 
(Ketaset, Wyeth UK) and placed in a stereotaxic frame (David Kopf Instruments, USA) 
with the incisor bar set to 3.3mm below the interaural plane (flat skull position). Body 
temperature was maintained at -36 OC using a thermostatically regulated heating 
blanket (Harvard Instruments Ltd., UK) connected to a rectal probe. 
2. A longitudinal incision was made in the scalp and a trephine hole drilled in the skull at 
the desired rostro-caudal and medio-lateral coordinates (see 3) relative to bregma 
leaving the dural membrane intact. The dural membrane was then gently perforated 
with a fine needle 
3. A glass pipette (Supracaps 709007) pulled to a fine tip (diameter -50 pm) and 
containing a 2% Fluorogold (hydroxystilbamidine, Biotium UK) solution was 
stereotaxically implanted into either the medial prefrontal cortex or nucleus accumbens 
and 0.5-1.0 pI of Fluorogold was ejected pneumatically using a picospritzer (Parker 
Corp., USA) 
Prefrontal cortex coordinates from bregma: 
Nucleus accumbens coordinates from bregma: 
rostro-caudal +3. Omm 
medio-lateral -0.3mm 
dorso-ventral -4. Omm 
rostro-caudal +1.2mm 
medio-lateral -1.9mm 
dorso-ventral -6.9mm 
4. Following surgery the medotomidine sedation was reversed with 1mg/kg atiparnezole 
(Antisedan, Pfizer Animal Health UK) and the animals allowed to recover from 
anaesthesia in a recovery room maintained at - 25 OC 
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5. Following a post-operative period of one week, animals were sacrificed by transcardial 
perfusion (see section 2.5.1.1 .) and the brains cryoprotected in sucrose. Fluorescence 
immunocytochemistry was used to visualise tyrosine hydroxylase immunoreactivity (see 
section 2.5.2.2. ). 
2.4.2. Visualisation and image capture 
Visualisation and image capture for all experiments was carried out using a fluorescence 
microscope (Leica, Germany) and Metamorph image capture software (MIDS Inc. USA). 
2.5. Immunocytochemistry 
2.5.1. Horseradish peroxidase immunocytochemistty 
2.5.1.1. Tissue preparation 
Adult male hooded Lister rats were injected intraperitoneally with a lethal dose (0.7 ml/kg) of 
sodium pentobarbital solution (Dolethal, Univet UK; 20% w/v). Once fully anesthetized a 
perfusion line was placed into the left cardiac ventricle and the left jugular vein was severed 
prior to infusion of isotonic phosphate buffered saline (PBS) at 40C via a peristaltic pump 
(Gilson, France). Once ex-sanguination was complete 200-300 ml of a 4% 
paraformaldehyde/PBS solution was perfused and the brain removed. Tissue was then post- 
fixed in 4% paraformalclehyde/PBS solution for a period of 24 hours before transfer to a 30% 
sucrose solution for cryoprotection. Cryoprotection was deemed to be complete when the tissue 
was no longer buoyant in solution. 
Following cryoprotection, 35 pm coronal sections of the midbrain containing the VTA 
(according to the brain atlas of Paxinos and Watson, 1998) were cut on a freezing microtome or 
a cryostat (HM 500 OM, Microm International Gmph, Germany) maintained at -22 'C with a 
tissue temperature of -18 OC. Serial sections were collected in PBS in a 24 well cell-culture plate 
(Corning, USA) and stored at 4 *C. 
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2.5-1.2. Experimental procedure 
TH Immunocytochemistry 
1. Sections were washed in PBS for 30 minutes (2xl5 min) prior to incubation with 3% 
H202 to quench endogenous peroxidase activity. Sections were then washed again in 
PBS (2xl5 min). 
2. Sections were incubated with 1% Triton x-100 solution for 30 min (2x15 min) to 
solubilise cell membranes then washed in PBS (2x15 min). 
3. Tissue was incubated with 5% horse serum (Vector Laboratories, UK) for 15 minutes to 
prevent non-specific secondary antibody binding and then washed in PBS (2xl5 min). 
4. Sections were incubated for 15 min with streptavidin solution (streptavidin blocking kit, 
Vector Laboratories, UK), briefly washed in PBS, incubated with biotin solution 
(streptavidin blocking kit, Vector Laboratories, UK) for fifteen minutes and then washed 
in PBS (2x5 min). This step was carried out to prevent non-specific binding of the 
biotinylated secondary antibody and the streptavidin conjugated tertiary reagent. 
5. Primary antibody (mouse anti-tyrosine hydroxylase, Sigma UK) was diluted in diluent 
consisting of 300mg bovine serum albumin (Sigma UK) and 180mg of lysine (BDH, UK) 
in 10 ml PBS. 
6. Primary antibody in diluent was incubated with tissue overnight at 40C then incubated at 
room temperature for two hours. Tissue was then washed in PBS (2xl 5 min). 
7. Secondary antibody (biotin conjugated horse anti-mouse, Vector Laboratories UK) was 
incubated with normal rat serum at room temperature for 1 hr then centrifuged at 13,000 
rpm for ten minutes. Supernatant solution was diluted 1 /100 in diluent. 
8. Tissue was incubated with secondary antibody in diluent for 2 hrs at room temperature 
and then washed in PBS (2xl5 min) 
9. Sections were incubated with horseradish peroxidase conjugated streptavidin diluted 
1 /100 in diluent for 30 min then washed in PBS (2xl 5 min) 
10. Vector Novared HRP substrate (Vector Laboratories, UK) was applied to sections for 
visualization of antigen and then washed off with PBS (2x15 minutes) 
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GRIMR Immunocytochemistry 
1. Following labeling for TH as described above tissue was incubated with 5% goat serum 
(Vector Laboratories, UK) for 15 minutes and then washed in PBS (2xl 5 min). 
2. Sections were incubated for 15 min with avidin solution (avidin blocking kit, Vector 
Laboratories, UK), briefly washed in PBS, incubated with biotin solution (avidin blocking 
kit, Vector Laboratories, UK) for fifteen minutes and then washed in PBS (2x5 min). 
3. Primary antibody (rabbit anti-GR primary antibody, Santa Cruz Biotechnology; or rabbit 
anti-MR antibody, Kawata group, Kyoto Prefectural University, see Ito et al. 2000) was 
diluted in diluent consisting of 300mg bovine serum albumin (Sigma UK) and 180mg of 
lysine (BDH, UK) in 10 ml PBS. 
4. Primary antibody in diluent was incubated with tissue overnight at 40C then incubated at 
room temperature for two hours. Tissue was then washed in PBS (2xl 5 min). 
5. Secondary antibody (biotin conjugated goat a-rabbit secondary antibody, Vector 
Laboratories, UK) was incubated with normal rat serum at room temperature for 1 hr 
then centrifuged at 13,000 rpm for ten minutes. Supernatant solution was diluted 1/100 
in diluent. 
6. Tissue was incubated with secondary antibody in diluent for 2 hrs at room temperature 
and then washed in PBS (2xl5 min) 
7. Sections were incubated with Vector horseradish peroxidase ABC reagent (Vector 
Laboratories, UK) then washed in PBS (2xl 5 min) 
8. Vector SG HRP substrate (Vector Laboratories, UK) was applied to sections for 
visualization of antigen and then washed off with PBS (2x15 minutes) 
9. Tissue sections were mounted on subbed microscope slides and dehydrated/defatted in 
solvent series (70% EtOH, 95% EtOH, Abs. EtOH, Histoclear solvent) before 
coverslipping using Histornount mounting medium (National Diagnostics, UK). 
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2.5.2. Fluorescence immunocytochemistry 
2.5.2.1. Tissue preparation 
Animals (adult male hooded Lister rat; Charles River UK) were sacrificed by guillotine and 
their brains quickly removed. The whole brains were placed in 4% paraformaldehyde solution 
for fixation for no longer than 24 hours, before being transferred to a 30% sucrose solution for 
cryoprotection. Tissue was left in sucrose solution until it was no longer buoyant. 
Following cryoprotection, 35 pm coronal sections of the midbrain containing the VTA 
(according to the brain atlas of Paxinos and Watson, 1998) were cut on a freezing microtome or 
a cryostat (HM 500 OM, Microm International Gmph, Germany) maintained at -22 ± 2'C with a 
tissue temperature of -18 ±2 OC. Serial sections were collected in PBS in a 24 well cell-culture 
plate (Corning, USA) and stored at 4 OC. 
2.5.2.2. Experimental procedure 
1. Sections were washed in PBS for 30 minutes (2xl5 min) prior to incubation with 1% 
Triton x-1 00 solution for 30 min (2xl 5 min) to solubilise cell membranes then washed in 
PBS (2xl5 min). 
2. Primary antibodies (mouse anti-tyrosine hydroxylase, Sigma UK and/or rabbit anti-GR 
primary antibody, Santa Cruz Biotechnology) were diluted in diluent consisting of 
300mg bovine serum albumin (Sigma UK) and 180mg of lysine (BDH, UK) in 10 ml 
PBS. 
3. Primary antibodies were incubated with tissue overnight at 40C then incubated at room 
temperature for two hours. Tissue was then washed in PBS (2xl 5 min). 
4. Secondary antibodies (FITC conjugated goat a-mouse, Dako UK and/or Rhodamine 
conjugated bovine anti-rabbit, Santa Cruz Biotechnology) were incubated separately 
with normal rat serum at room temperature for 1 hr then centrifuged at 13,000 rpm for 
ten minutes. Supernatant solutions were then diluted 1/100 in diluent. 
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5. Tissue was incubated with secondary antibodies in diluent for 2 hrs at room 
temperature and then washed in PBS (2xl5 min) 
6. Sections were mounted on microscope slides using Vectashield hard-set mounting 
medium with DAR for nuclear visualisation (Vector Laboratories, UK). 
2.5.3. Visualisation and image capture 
Visualisation and image capture for all experiments was carried out using a fluorescence 
microscope (Leica, Germany) and Metamorph image capture software (MIDS Inc. USA). 
2.6. In-situ hybridisation histochemistry 
2.6.1. Tissue collection 
Male hooded Lister rats (- 276 g) which had undergone the corticosterone treatment protocol 
detailed in section 2.2. and the NSD 1015 treatment protocol described in section 2.3. (eight 
vehicle treated, eight corticosterone treated) were sacrificed with an overdose of sodium 
pentobarbital (0.7 ml/kg 20% w/v solution; Dolethal, Vetoquinol, UK). The brain was removed 
and the mid- and hindbrain portion was dissected and rapidly snap-frozen in isopentane cooled 
on dry ice prior to storage at -70 'C. 
2.6.2. Slide preparation 
Microscope slides (72 x 26 mm; Ultima, UK) were boiled in 1% Decon 90 (Decon Laboratories 
Ltd, UK) for 10 minutes followed by three 1 hr washes in deionised water. Slides were then heat 
sterilized at 180 T for four hours and allowed to cool before immersion in a solution of 0.5% 
(w/v) gelatine and 0.05% (w/v) CrK(S04)2 (Sigma, UK). Immersion solutions were prepared in 
RNAse-free conditions using diethylpyrocarbonate (DEPC) treated water and avoiding skin 
contact with treated slides. Following treatment the slides were dried overnight at 370C then 
wrapped in aluminium foil for storage. 
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2.6.3. Tissue sectioning 
Tissue was removed from storage and allowed to warm to -22 ±2 *C in the main compartment 
of a cryostat (HM 500 OM, Microm International Gmph, Germany). A block of tissue containing 
the midbrain was mounted rostral face down on a cryostat chuck with cryo-embedding 
compound (Microm International GmPh, Germany) and the chuck affixed to the cryostat head- 
stage (temp. -18 ±2 OC). 
Excess tissue was trimmed until the region of the brain containing the VTA was visible. 
Identification of the VTA was made by comparison of the cut surface of the tissue with diagrams 
in the rat brain atlas of Paxinos and Watson (1997). Three 12 pm sections were then cut and 
thaw mounted on microscope slides such that there was 240 pm between adjacent sections on 
each slide. Slides were then stored at -70 OC prior to further treatment. 
N. B. All solutions from this point forward made using DEPC treated water unless otherwise 
indicated 
2.6.4. Tissue pre-treatment for storage at -20 "C 
For tissue fixation and to improve retention on slides, tissue was pre-treated as follows: 
1. Slides were immersed in 4% paraformalclehyde/PBS solution for 5 minutes and then 
washed in PBS twice. 
2. Tissue was acetylated by immersion in 0.25% acetic anhydride in 0.1 M triethanolamine 
buffer for 10 min to reduce non-specific oligonucleotide probe binding. 
3. Following acetylation sections were dehydrated in ethanol series as follows: 70% EtOH 
(1 min); 80% EtOH (1 min); 95% EtOH (2 min); 100% EtOH (1 min) and then 
delipidated in chloroform for 10 minutes. 
4. Tissue was then immersed in 100% EtOH (1 min) and 95% EtOH (1 min) following 
which slides were air dried and stored at -20 OC. 
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2.6.5. Design and synthesis of oligonucleotide probes 
Oligonucleotide probes were designed complementary to mRNA sequences available on the 
National Centre for Biotechnology Information (NCBI) server 
(hftp: //www. ncbi. nlm. nih. gov/sites/entrez/). Candidate sequences were tested for specificity 
using the BLAST search engine (http: //www. ncbi. nim. nih. gov/BLAST/). For full details of probe 
sequences and synthesis see Chapter 4. Probes (manufactured by MWG Biotech AG) were 
supplied freeze dried and dissolved in TE buffer (10mM Tris buffer [Sigma, UK]; 1mM EDTA 
[Sigma, UK]; pH 7.5) upon delivery to yield a concentration of 100 pmol/pI and stored at -20 OC. 
2.6.6. Ylabeling of oligonucleotide probes 
Oligonucleoticle probes were labeled with [35 S]-dATP (deoxyadenosine 5 9_[a_35S] triphosphate) 
at the 3' end using the terminal deoxynucleotidyl transferase (TdT) reaction. The reaction was 
carried out by incubating the following at 37 OC for 1 hr: 
05 pl molecular biology water (Sigma, UK) (Not DEPC treated) 
e4 pI 25 MMOI COC12 (Sigma, UK) solution 
04 pl 5x TdT forward buffer (consisting of 500 mM sodium cacodylate, 1 mM 
mercaptoethanol, 10 MM COC12) (Amersham Biosciences, UK) 
0 2pl (3 pmol/ul) oligonucleotide probe 
o 3pl (10nmol) [35S]-dATP (Perkin Elmer, UK) 
0 2pl of TdT enzyme (Amersharn Biosciences, UK) 
When incubation was complete the reaction was stopped by adding 400 pl of a solution 
containing 200pl 0.5M EDTA (Sigma, UK), 1.567g Tris HCI and 100 pl triethanolarnine in 100 ml 
DEPC water (Reagent A) and placing the mixture on ice. 
Radio-labelled oligonucleoticle was separated from unbound [35 S]-dATP by loading 400pl of 
the reaction mixture onto a chromatography column containing Sephadex G-50 resin (Sigma, 
UK) and collecting the eluate. Seven further elutions with 250 pl of Reagent A were performed 
and fractions collected in centrifuge tubes to give a total of eight eluted fractions. These were 
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placed on ice and 2 pi of each fraction pipetted into a scintillation vial containing 3 ml 
scintillation fluid. These were then analysed for radioactivity using a liquid scintillation counter 
(Beckman, UK). The vial containing fraction number 4 was generally found to contain the 
radiolabelled probe, with scintillation counts in the region of 7.5e 4 CpM/ýl (see Chapter 4 for 
further details of counts for individual probes). 
2.6.7. In-situ hybridisation procedure 
Hybridisation buffer solution was prepared as follows: 
0 5ml cleionised formarnicle (100% solution) 
0 2ml 20 x saline sodium citrate (SSC) 
0 0.5 ml 0.5 M phosphate buffer 
0.1 ml sodium pyrophosphate 
01 ml 50 x Denhardt's solution 
e 0.2 ml denatured salmon sperm DNA 
9 0.2 ml polyadenosine (5 mg/ml) 
0 10 pi heparin (120mg/mi) 
lg dextran sulphate 
[35SI-labelled probes were diluted in a solution consisting of 10% sodium pyrophosphate, 5% 
dithiothreitol and hybridisation buffer to yield a concentration of le 6 cpm/200 pl in a quantity 
sufficient to allow the application of 200 pl to each slide. Slides were coverslipped following 
application of hybridisation mixture and incubated overnight at -37 OC in humidified covered 
trays containing 50% (v/v) formamideA x SSC. On the following day coverslips were washed off 
the slides with 1x SSC following which slides were washed twice in 1x SSC at 55 'C for twenty 
minutes and then 1x SSC at room temperature for 1 hr. Slides were then air dried and placed 
on Biomax [35S] sensitive film together with a [14C] microscale calibration strip covering the 
range 1.46-1098 Bq/g tissue (Amersham, UK) in a sealed photographic cassette. Cassettes 
were stored flat at room temperature (for details of exposure periods see Chapter 4). 
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2.6.8. Image capture and data analysis 
Following an appropriate exposure period films were developed using an automated Agfa 
Curix Compact plUSTM processor (Agfa-Gevaert N. V., Belgium). Developed films were placed on 
a light box providing a constant light source and digital images captured using a monochrome 
digital camera (model XC-75E, Sony Corp., Japan) linked to a PC. Optical densitometry was 
performed on captured images using Scion Image for Windows (Scion Corp., USA). For further 
details see Chapter 4. 
2.7. Tissue homogenate tyrosine hydroxylase assay 
2.7.1. Tissue homogenization and sample preparation 
Following corticosterone treatment (see section 2.2. ) and NSD1015 treatment (see section 
2.3. ), rat brain tissue from the prefrontal cortex or nucleus accumbens was homogenised using 
a sonicator (SoniprepTM) with the Eppendorf containing the hornogenate suspended in an ice 
bath. Following complete homogenisation the solution was microfiltered in a centrifuge (Biofuge 
Pico, Heraeus Instruments GmRH) at a speed of 13,000 r. p. m. and the resultant supernatant 
was diluted by a factor of 1 in 10 (in the case of mPFC tissue homogenates) or 1 in 20 (in the 
case of nucleus accumbens homogenates) in 0.1 M perchloric acid. Samples were stored at 4'C 
until measurement of DOPA content was carried out using HPLC with electrochemical detection 
(see section 2.9). 
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2.8. In-vivo microdialysis 
2.8.1. Probe construction 
Microdialysis probes were of a single cannula concentric design with a 4.5mm dialysing 
window. These were constructed from stainless steel tubing (internal diameter 0.38 mm; 
external diameter 0.5 mm; Goodfellow, UK) according to the method of Sharp and Zefterstr6m 
(1992) (see figure 2.4). Two 40 mm lengths of silica glass tubing (SGE Ltd., UK) were inserted 
into a 20 mm length of steel tubing with two 10 mm lengths of steel tube placed over the top of 
each silica tube. One of the silica tubes was retracted - 10 mm into the body of the main steel 
cannula and the three steel tubes were fixed in a Y-shape with epoxy resin (Araldite, Silmid Ltd., 
UK). The silica tubing protruding from the main cannula was trimmed to 4 mm and a length of 
tubular dialysing membrane (polyacrylonitrile/sodium methalyl sulphonate co-polymer; 20 kDA 
aCSF 
Steel tubi 
lon 
E 
Figure 2.2. Diagram of probes used for microdialysis 
Dialysate 
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molecular weight cut-off; inner diameter 0.22mm, outer diameter 0.31mm; AN 69, Hospal, 
Bologna, Italy) was placed over it and gently pushed inside the body of the probe. The junction 
of the dialysing membrane and the steel cannula was sealed with a small quantity of epoxy 
resin (Araldite, Silmid Ltd., UK), following which the end of the dialysing membrane was sealed 
with a small quantity of epoxy resin to yield a dialysing window of - 4.5 mm. Probes were made 
weekly in batches of twelve and stored in dry conditions. 
2.8.2. Probe perfusion medium 
During the microdialysis procedure probes were perfused with artificial cerebrospinal fluid 
(aCSF) consisting of: 
* 140 mM NaCl 
o3 mM KCI 
01 MM M9C12 
& 1.2 mM NaHP04 
o 0.27 mM NaH2PO4 
e 7.2 mM Glucose 
e 2.4 mM CaC12 
0 30 pM Bupropion hydrochloride 
0 pH 7.4 
A stock solution lacking CaC12, glucose and bupropion was prepared at the start of the study, 
vacuum filtered using 0.22 pm filter discs (Whatman, UK) and stored at 4 *C. CaC12, glucose 
and bupropion were added on the day of each experiment. 
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2.8.3. Surgical procedure 
1. Male hooded Lister rats (- 300 g) (Charles River UK) treated according to the 
corticosterone treatment protocol detailed in section 2.2. (12 vehicle treated animals; 12 
corticosterone treated animals) were anaesthetised with 1500 mg/kg of a 0.5 g/ml 
solution of urethane injected intraperitoneally. Animals were placed in a stereotaxic 
frame (David Kopf Instruments, USA) with the incisor bar set to 3.3mm below the 
interaural plane (flat skull position). Body temperature was maintained at -36 *C using a 
thermostatically regulated heating blanket (Harvard Instruments Ltd., UK) connected to 
a rectal probe. 
2. A longitudinal incision was made in the scalp and a trephine hole drilled in the skull 
directly above the prefrontal cortex (Coordinates relative to bregma: rostro-caudal +3.0; 
medio-lateral -0.7mm) leaving the dural membrane intact. An additional hole was drilled 
in a caudal position and a small engineering screw (diameter 1.2 mm; length 2.6 mm; 
Hilco Ltd, UK) was fixed into the skull to stabilize the microdialysis probe. 
3. The microdialysis probe was attached to an infusion pump (Harvard Apparatus Ltd., 
UK) via portex tubing (1.09 mm OD, 0.38 mm ID, Sims Portex Ltd., UK. ) and perfused 
with aCSF at a flow rate of 2.3 ml/min. The dura membrane was then gently perforated 
with a fine needle and the probe inserted into the brain using a stereotaxic manipulator 
(David Kopf Instruments, USA) at the following co-ordinates: 
Prefrontal cortex coordinates from bregma: rostro-caudal +3. Omm 
medio-lateral -0.7mm 
dorso-ventral -5.5mm 
4. Following probe implantation, dental cement (Simplex Rapid; Kemdent, UK) was 
applied to the exposed skull surrounding both the probe and the fixing screw to secure 
the probe in position. 
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5. Following a period >1 hr to allow neurotransmitter levels to stabilize, dialysate samples 
were collected into inverted polythene tubes every 20 min and placed on ice for 
immediate analysis using HPLC with electrochemical detection (see section 2.9. ). 
2.8.4. Drug administration 
All drugs were administered locally via the dialysis probe by dilution in aCSF. AI mM stock of 
the dopamine reuptake inhibitor bupropion (Sigma, UK) was prepared daily and diluted in aCSF 
to yield a concentration of 30 pM. Bupropion was perfused throughout all experiments. 
Potassium stimulated release was performed by perfusion of a hyperkalaemic aCSF which 
contained, in contrast to that detailed in section 2.7.2., 100 mM KCI and 43 mM NaCl. This was 
prepared in a stock solution, filtered and stored under the same conditions as standard aCSF. 
Sulpiride was diluted in aCSF to a final concentration of 10 pM from a 1mM stock solution 
prepared daily. 
2.8.5. Location of implanted probes 
At the end of the experiment, animals were given an overdose of urethane i. p. and toluidine 
blue solution was perfused through the probe to allow the location of the probe to be 
determined. The forebrain was then sectioned on a cryostat (HM 500 OM, Microm International 
GmPh, Germany) and the location of the blue dye compared to the brain atlas of Paxinos and 
Watson (1998). For location of implanted probes see chapter 5. 
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2.9. High Performance Liquid Chromatography 
2.9.1. Tissue DOPA content measurement 
Homogenate samples were analysed for DOPA content using reverse phase high- 
performance liquid chromatography (HPLC) with electrochemical (EC) detection. The HPLC-EC 
system consisted of the following: 
HPLC pump 
Gilson 302 HPLC pump/manometric module (flow rate 1 ml/min) 
o Guard Cell 
ESA model 5020 
Injector 
Rheodyne model 7125, USA. Fitted with 50pl loop (Anachem Ltd, UK. ) 
Separation column 
4.6 x 100 mm Microsorb 100-3 C18 stainless steel column (Varian Analytical 
Instruments, USA) 
Analytical Cell 
ESA Model 5011 
0 Electrochemical Detector 
Coulochem 11 (ESA, Analytical Ltd, UK) 
Recorder/integrator 
Waters 746 data module 
Mobile phase consisted of: 
o 83 mM NaH2PO4 
0 0.84 mM ethylenediamine tetraacetic acid (EDTA) 
40 0.46 mM octanesulphonic acid 
0 15% methanol 
0 PH = 4.0 
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Mobile phase was prepared in deionised water and filtered under vacuum using 0.22pm filter 
discs (Whatman, UK). Following filtration the solution was degassed by sonication for 1 hour. 
Mobile phase was pumped through the HPLC system at a flow rate of 1 mi/min and oxidised on 
a guard cell (potential difference =+ 390 mV) to remove impurities. 
50 pl homogenate, samples were manually loaded onto the HPLC system and oxidised on a 
coulometric sensor comprising of two electrochemical cells. The first of these cells was set at 
+100 mV to partially oxidize the sample and improve the signal to noise ratio of measurements 
taken from the second cell set at +350 mV. Changes in current on the second cell were 
detected using a Coulochem 11 electrochemical detector and plotted on a Waters 746 
record er/i nteg rator. 
DOPA concentrations in homogenate samples were determined by measuring peak heights 
(se figure 2.3) compared to an external DOPA standard (10-9 M) (see figure 2.4) prepared daily 
from a 10mM stock solution (prepared weekly in OAM perchloric acid). The linear relationship 
between peak height and DOPA concentration was confirmed using a series of DOPA 
standards (concentrations 10-7 M, 10-8 M, 10-9 M). The limit of detection for this assay was 
estimated to be in the range of 10-20 W. 
2.9.2. Tissue DOPA data analysis 
Tissue DOPA concentrations were calculated by determining total tissue sample DOPA 
content and dividing it by the wet mass of the dissected tissue. 
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Figure 2.3. Example chromatogram showing DOPA content (indicated by arrow) in a sample 
of homogenized nucleus accumbens tissue. 
CHANNEL AI NJ IT T YO-0-7-04 2'3, c56: 48 
Figure 2.4. Example chromatogram showing the peak obtained for a 5e -8 M DOPA standard 
(indicated by arrow). 
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2.9.3 Measurement of dialysate sample dopamine content 
High performance liquid chromatography with electrochemical detection was used to measure 
the dopamine content of dialysate samples. This was performed as in section 2.9.1. using a 
modified mobile phase consisting of: 
o 83 mM NaH2PO4 
0 1.33 mM ethylenediamine tetraacetic acid (EDTA) 
0 4.14 mM octanesulphonic acid 
0 12.5% methanol 
0 pH = 3.9 
This was pumped through the HPLC system at a flow rate of 1 ml/min and oxidized on a guard 
cell set at +450 mV. Dialysate samples were oxidised in a two-cell coulometric sensor as 
detailed previously with the potential of the first cell set at -300 mV and the potential of the 
second cell set at +400 mV. Current fluctuations on the second cell were measured using a 
Coulochern III electrochemical detector (ESA Analytical, UK) and recorded on a Waters 746 
recorder/integrator. 
Dopamine concentrations in dialysate samples were determined by measuring peak heights 
(see figure 2.5) compared to external dopamine standards (10-9 M and 5e -8M) (see figure 2.6) 
prepared daily from a1 OmM stock solution (prepared weekly in 0.1 M perchloric acid). The linear 
relationship between peak height and dopamine concentration was confirmed using a series of 
dopamine standards (concentrations 10-7 M, 10 -8 M, 10-9 M). The limit of detection of this assay 
was estimated to be in the range 2-3 W. 
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Figure 2.5. Example chromatogram showing dopamine content (indicated by arrow) in a 
dialysate sample obtained from the mPFC. 
CHANNEL A 
Figure 2.6. Example chromatogram showing the peak obtained from a 10-9 M dopamine 
standard (indicated by arrow). 
89 
INJECT 91-09-104 00: 43: 30 
Chapter 3 
Chapter 3. 
Corticosteroid receptor expression in the 
mesocorticolimbic dopamine system 
evidence from histological studies. 
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Chapter 3. Corticosteroid receptor expression in the mesocorticolimbic 
dopamine system - evidence from histological studies 
3.1. Introduction 
Underlying this PhD thesis is the theory that alterations to the diurnal corticosteroid rhythm 
seen in bipolar disorder are responsible for changes in mesocorticolimbic dopaminergic 
neurotransmission that in turn produce the symptoms of the disorder. In order to understand the 
effects of glucocorticoids on dopaminergic neurotransmission it is necessary to consider (a) 
whether doparninergic neurones in the VTA contain corticosteroid receptors, (b) whether 
activation of these receptors produces changes in gene transcription that code for proteins 
involved in neuronal function and (c) if these changes have functional consequences in terms of 
dopamine release at the terminal. The first of these factors, namely whether glucocorticoid 
receptors are present in the neurones of interest is the subject of this chapter. 
As discussed in chapter one, glucocorticoids exert their cellular actions via two types of 
intracellular receptor, the glucocorticoid and mineralocorticoid receptors (GR and MR 
respectively). When agonists bind to these receptors, chaperone heat shock proteins dissociate 
and the DNA binding site is exposed. Following hyperphosphorylation of the receptor protein it 
forms a dimer and translocates to the nucleus where it binds to glucocorticoid response 
elements (GREs) present on specific genes. Depending on the presence or absence of specific 
co-factors corticosteroids can both positively and negatively regulate gene transcription (for 
reviews see Schoneveld et al. 2004; Buckingham 2006). 
Despite a plethora of published data showing that clopaminergic neurones originating in the 
VTA are sensitive to both GR and MR mediated functional alterations (see for example Overton 
et al. 1996; Piazza et al. 1996; Barrot et al. 2000; Mizoguchi et al. 2004) only two I 
immunocytochernical studies have examined whether these neurones actually contain 
corticosteroid receptors. The first of these studies reported that around 61% of 
catecholarninergic neurones in the A10 cell group (which includes the VTA) express the 
glucocorticoid receptor (Harfstrand et al. 1986). In contrast a more recent study reported that 
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catecholaminergic neurones in the VTA are not immunopositive for GR (Czyrak and Chocyk, 
2001). To date no studies have examined the phenotype of MR expressing cells in this region of 
the brain. Given the contradictory nature of the evidence regarding GR, and the lack of data on 
MR, it was necessary to carry out immunocytochernical studies to determine if these receptors 
are present in doparninergic cells of the VTA. Tyrosine hydroxylase immunoreactivity was used 
as a marker for dopaminergic cells and co-reactivity with GR or MR binding markers was 
examined. 
As the VTA constitutes a heterogenous group of doparninergic cells projecting to various 
regions of the brain, the spatial distribution within the VTA of GR/MR-tyrosine hydroxylase co- 
reactivity was examined. To complement this, retrograde tracing from terminal regions of the 
mesocortical and mesolimbic projections (namely the prefrontal cortex and the nucleus 
accumbens) was carried out to examine whether these projections originate in topographically 
distinct regions of the VTA. This was to determine if there was any evidence that the projections 
differ in their corticosteroid sensitivity. 
3.1.1. Aims 
The first aim of this study was to determine whether VTA doparninergic neurones express 
glucocorticoid and/or mineralocorticoid receptors and if so what proportion of neurones express 
the receptors. Having established the presence of the receptors in doparninergic neurones, any 
spatial differences in corticosteroid receptor expression were to be compared with the 
distribution of neurones projecting to the prefrontal cortex or nucleus accumbens. The second 
aim was therefore to examine whether any differences in corticosteroid receptor expression 
exist between the different projections which could confer differences in corticosteroid 
sensitivity. 
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3.2. Methods 
3.2.1 Tyrosine hydroxylase and corticosteroid receptor immunocytochemistry 
Fluorescent immunocytochemistry protocol 
Animals (adult male hooded Lister rat; Charles River UK) were sacrificed by guillotine and 
their brains quickly removed. The whole brains were placed in 4% paraformaldehyde solution 
for fixation for no longer than 24 hours, before being transferred to a 30% sucrose solution for 
cryoprotection. Tissue was left in sucrose solution until it was no longer buoyant (- 3 days). In 
some animals nuclear translocation of GR was induced by administration of corticosterone 
(50mg/kg) one hour prior to sacrifice by sodium pentobarbitone. Dissection, fixation and 
cryoprotection were carried out as before. 
Following fixation and cryoprotection a coronal section -4 mm thick containing the VTA was 
cut by hand and coronal sections 35pm thick were cut on a freezing microtome (Microm, UK) 
and collected in phosphate buffered saline solution (PBS). Following incubation with Triton x- 
100 (1%) free floating sections were incubated overnight at 80C with primary antibodies (Mouse 
cc-TH, Sigma UK; Rabbit (x-GR, Santa Cruz Biotechnology USA: Rabbit a-MR, Kawata group, 
Kyoto Prefectural University, see Ito et al. 2000) in PBS containing BSA and lysine. After 
incubating at room temperature for two hours primary antibodies were washed off. 
Secondary antibodies (for TH, FITC conjugated goat a-mouse, Dako UK; for GR and MR, 
Rhodamine conjugated bovine (x-rabbit, Santa Cruz Biotechnology USA) were incubated with 
normal rat serum for one hour and centrifuged to reduce non-specific binding. Tissue sections 
were then incubated with secondary antibodies diluted in BSA/lysine diluent at a concentration 
of 1 /100 for two hours at room temperature. 
Following secondary antibody incubation sections were rinsed with PBS and mounted on 
microscope slides using Vectashield hard-set mounting medium with DAR for nuclear 
visualisation (Vector Laboratories, UK). 
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Horseradish peroxidise immunocytochemistfy prOtOCOI 
Animals (adult male hooded Lister rat; Charles River UK) were transcardially perfused with 
0.9% saline solution at 40C then perfused with 200-300ml 4% paraformalclehyde in phosphate 
buffered saline solution. Following perfusion the brain was dissected and post-fixed in 4% 
paraformaldehyde for 24 hours before transfer to a 30% sucrose solution for cryoprotection. 
Following fixation and cryoprotection a coronal section -4 mm thick containing the VTA was 
cut by hand and from this, coronal sections 35pm thick were cut on a freezing microtome 
(Microm, UK). Sections were collected in PBS and peroxidase activity quenched with 3% H202 
before incubating with 1% Triton x-1 00 for 30 minutes. 
TH ICC: 
Sections were incubated with 5% horse serum (Vector Laboratories, UK) for twenty minutes, 
streptavidin solution for 15 minutes, and biotin solution for a further 15 minutes 
(streptavidin/biotin blocking kit, Vector Laboratories, UK). Mouse a-TH primary antibody (Sigma 
UK) in BSA/lysine diluent was applied and left overnight @ 80C then room temperature for two 
hours and washed off. Secondary antibody (biotinylated horse a-mouse, Vector Laboratories, 
UK) was incubated with normal rat serum for one hour, centrifuged @ 13,000 rpm for 10 
minutes and the supernatant diluted 1: 100 in BSA/lysine diluent. Sections were then incubated 
with secondary antibody at room temperature for two hours, before application of horseradish 
peroxidase streptavidin (Vector Laboratories, UK) diluted 1: 100 in PBS. For antigen 
visualisation Vector Novared HRP substrate (Vector Laboratories, UK) was applied for ten 
minutes and washed off. 
GR ICC: 
The above process was then repeated with a goat serum blocking step, either a rabbit a-GR 
primary antibody (Santa Cruz Biotechnology, USA) or rabbit a-MR primary antibody (Kawata 
group, Kyoto Prefectural University, see Ito et al. 2000), biotinylated goat a-rabbit secondary 
antibody (Vector Laboratories, UK), horseradish peroxidase avidin biotin complex (ABC, Vector 
Laboratories, UK) and Vector SG HRP substrate. 
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Following labelling for both TH and GR or MR sections were mounted on microscope slides 
and dehydrated/defatted in solvent series (70% EtOH, 95% EtOH, Abs. EtOH, Histoclear 
solvent) before coverslipping using Histomount mounting medium (National Diagnostics, UK). 
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3.2.2. Fluorescence immunocytochemistry work-uP 
N. B. In all immuncytochemistry experiments, labelling specificity was confirmed by omitting the primary antibody 
incubation step from some tissue sections and ensuring no subsequent labelling occurred. All antibodies were 
validated in tissue from a number of animals. In the case of the TH and GR antibodies this was in excess of 15 
animals for each. Tissue from more than five animals was used to work-up the MR antibody. 
TH single-labelling 
Single label fluorescence for TH was carried out using established primary antibody 
concentrations of 1: 5,000 (mouse a-TH, Sigma UK) and secondary antibody concentrations of 
1: 100 (FITC conjugated goat a-mouse). To establish the optimum fixation period 24 hour and 72 
hour fixation times were tested and labelling was compared. At the longer fixation time 
immunoreactive labelling for TH was of a much lower intensity (see figure 3.1. ), thus a fixation 
period of no longer than 24 hours was deemed to be optimal for successful labelling 
TH + GR double-labelling 
Combining the TH labelling with GR labelling required optimisation of the GR primary antibody 
concentration. Concentrations of 1: 100,1: 200,1: 400 and 1: 700 rabbit a-GR (Santa Cruz 
Biotechnology USA) were tested in dual'label experiments using a rhodamine conjugated 
secondary antibody (1: 100 bovine a-rabbit, Santa Cruz Biotechnology USA). A concentration of 
1: 400 was found to give optimal signal strength with the lowest background signal however 
problems with visualisation remained. 
Autofluorescence of doparninergic cells was found to be a problem in these dual label 
experiments, probably due to the formation of aldehyde catecholamine conjugates during the 
fixation process. Attempts were made to reduce this by treatment of tissue with 0.1% NaBH4 for 
fifteen minutes (see Clancy and Cauller, 1998) but this was ineffective. Photobleaching of 
fluorescent conjugates with a mercury lamp for time periods of 30 and 60 minutes (see 
Neumann and Gabel, 2002) was also attempted, but again this was ineffective. At this point it 
was decided to try and improve the GR labelling to increase the signal to noise ratio rather than 
eradicate the autofluorescence. 
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Figure 3.1. Photomicrograph of TH (FITC labelled; green) in the VTA (x1O magnification). (A) 
24-hours paraformaldehyde tissue fixation. (B) 3 days paraformaldehyde tissue 
fixation. 
Figure 3.2. Photomicrograph (x40 magnification) of (A) TH (1/5,000 primary antibody conc.; 
FITC labelled; green) and (B) GR (1/400 primary antibody conc.; rhodamine 
labelled; red) immunoreactivity in the same VTA section. (1) TH +/ GR + cell; (2) 
TH +/ GR - cell; (3) TH -/ GR + cell. 
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Figure 3.3. Photomicrograph (x40 magnification) of GR (HRP DAB labelled) immunoreactivity 
in the VTA (primary antibody concentration 1/400). 
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Figure 3.4. Photomicrograph of TH (x40 magnification) (HRP Vector Novared labelled; brown) 
and GR (HRP Vector SG labelled; blue) immunoreactivity in the VTA. TH primary 
antibody concentration 1/5,000; GR primary antibody concentration 1/400. 
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The concentration of Triton x-100 was increased from 0.1% to 1% to improve solubilisation of 
cell membranes and improve antibody penetration. This produced more consistent GR labelling 
and improved signal strength resulting in the first successful double-labelling of TH and GR (see 
figure 3.2. ). Further attempts were made to improve the signal of labelled GR by using an 
amplification step in the form of biotin conjugated secondary antibodies (1: 100 biotinylated goat 
a-rabbit, Vector Laboratories UK) and fluorescent conjugated streptavidin. Cy3 conjugated 
streptavidin (1: 100 Extravidin Cy-3, Sigma UK) was found to give a strong GR signal but with 
high non-specific labelling. Texas red labelled avidin (1: 100, Vector Laboratories UK) was also 
used as a tertiary reagent and again gave a strong signal with some non-specific background 
labelling, however the improvement over fluorescent conjugated secondary antibodies was 
minimal. 
At this point an experiment had been carried out to label GR using horseradish peroxidise 
labelled streptavidin (1: 100 Vector Laboratories UK) with a DAB chromagen. This gave very 
clear labelling of GR which was a great improvement over attempts to label GR with 
fluorescence (see figure 3.3. ). Attempts to combine fluorescent labelling of TH with HRP-DAB 
labelling of GR were carried out but were unsuccessful. Whilst HRP labelling of GR was a 
success no fluorescent labelling of TH was observed. At this point it was decided to use HRP 
labelling for both TH and GR in future experiments. 
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3.2.3. HRP immunocytochemistry work-UP 
THIGR double labelling 
To reduce non-specific labelling all HRP-ICC was carried out on tissue from rats transcardially 
perfused with 0.9% saline and 4% PFA. This was to remove enclogenous HRP present in blood 
and to provide more reliable fixation. In addition any remaining endogenous HRP activity was 
quenched by application of 3% hydrogen peroxide prior to the labelling procedure. 
The work up on the HRP immunocytochernistry was primarily concerned with optimising the 
relative signal strengths between the TH and GR labelling. Initially the GR primary antibody was 
used at a concentration of 1: 400 (visualised with Vector SG HRP chromagen, Vector 
Laboratories UK), and TH antibody concentrations of 1: 5,000 and 1: 10,000 (visualised with 
Vector Novared HRP chromagen, Vector Laboratories UK). Further to this Vector HRP-ABC 
was initially employed as a tertiary reagent which offers greater signal amplification compared to 
standard HRP conjugated streptavidin. At these concentrations and with this visualisation 
method the TH labelling was far too intense for GR immunoreactivity to be visible (see figure 
3.4. ). To reduce the TH label intensity the ABC reagent was replaced with HRP conjugated 
streptavidin and the primary antibody concentration was reduced to 1: 50,000 and 1: 100,000. 
Double labelling was evident with a TH primary antibody concentration of 1: 100,000 and a GR 
primary antibody concentration of 1: 400 (see figure 3.5. ). 
In some experiments cross-labelling was observed where Vector SG (for labelling GR) 
appeared to be reacting with TH bound HRP. This was suggested by the presence of Vector SG 
in the cytoplasm of labelled cells, in contrast to the distribution seen in single labelling 
experiments. To prevent this from occurring a different enzyme conjugated tertiary reagent 
(alkaline phosphatase conjugated streptavidin, Vector Laboratories UK) was used to label TH. 
Some cross-labelling was still seen in some experiments, and furthermore the labelling 
produced by AP was considered too diffuse for use in double labelling (see figure 3.6. ). 
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Figure 3.5. Photomicrograph of TH (x40 magnification) (HRP Vector Novared labelled; brown) 
and GR (HRP Vector SG labelled; blue) immunoreactivity in the VTA. (A) TH 
primary antibody concentration = 1/50000; GR primary antibody concentration - 
1/400. (B) TH primary antibody concentration =1 /100,000; GR primary antibody 
concentration 1/400. 
Figure 3.6. Photomicrograph (x40 magnification) of TH immunoreactivity in the VTA labelled 
with (A) alkaline phosphatase and Vector Red substrate (primary antibody conc. 
1 /100,000) (B) horseradish peroxiclase and Vector Novared substrate (primary 
antibody conc. 1/500,000) 
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Figure 3.7. Photomicrograph (x40 magnification) of GR (HRP Vector SG labelled) 
immunoreactivity in the VTA. Primary antibody concentrations were (A) 1/100; (B) 
1/200; (C) 1/400 
102 
Chapter 3 
It was hypothesised that the cross reactivity was caused not by the use of the same enzyme to 
label both proteins but by cross reaction between secondary and tertiary labels such that the 
HRP-ABC tertiary reagent used to label GR was in fact reacting with unused binding sites on 
the TH bound biotinylated secondary antibodies. To prevent this, blocking steps were 
incorporated into the protocol via the application of streptavidin and biotin solutions (streptavidin 
blocking kit, Vector Laboratories UK) to the tissue following the TH labelling to block any 
remaining binding sites. After the incorporation of this step no further cross reactivity was 
observed with the cellular distribution of labelling for both antigens corresponding to that see in 
single labelling experiments. Consequently HRP labelling was used for both TH and GR from 
this point onwards. 
Further optimisations of primary antibody concentrations were subsequently carried out to 
improve labelling. The TH antibody concentration was reduced to 1: 500,000 (see figure 3.6. B), 
and a dilution series performed for the GR antibody at concentrations of 1: 100,1: 200 and 1: 400 
(see figure 3.7. ). The optimal GR antibody concentration was found to be 1: 200 and in 
combination with TH antibody at a concentration of 1: 500,000 successful double labelling was 
achieved. 
THIMR double labelling 
Using the TH primary antibody concentration (and Vector Novared HRP chromagen) from the 
GR/TH double labelling experiments, initial attempts to label MR were performed with an 
antibody concentration of 1: 100 (rabbit a-MR, Kawata group, Kyoto Prefectural University, see 
Ito et al. 2000) and Vector SG chromagen. This resulted in a very intense MR label which 
obscured the TH label. MR primary antibody concentrations of 1: 1000,1: 5,000,1: 10,000 and 
1: 50000 were tested in conjunction with TH labelling and a concentration of 1: 1,000 was found 
to be optimal (this can be seen in figure 3.11. ). At lower concentrations MR immunoreactivity 
was barely visible. Using an MR primary antibody concentration of 1/1,000 and a TH primary 
antibody concentration of 1/500,000 successful double labelling of TH and MR was achieved. 
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3.2.4. Fluorogold retrograde tracing of mesocorticolimbic neurones 
Adult male hooded Lister rats (Charles River, UK) were anaesthetised with a mixture of 
0.25mg/kg medotomidine (Domitor, Pfizer Animal Health UK) and 58 mg/kg ketamine (Ketaset, 
Wyeth UK) and placed in a stereotaxic frame. A glass pipette pulled to a fine tip of diameter 50 
pm and containing a 2% Fluorogold (hydroxystilbamidine, Biotium UK) solution (in PBS) was 
stereotaxically implanted into either the medial prefrontal cortex or nucleus accumbens and a 
small volume of Fluorogold was ejected by means of a pressure ejection device (Picospritzer, 
Parker Corp. USA) and the pipette left in place for five minutes. Following withdrawal of the 
pipette and wound closure the medotomidine sedation was reversed with 1mg/kg atiparnezole 
(Antisedan, Pfizer Animal Health UK) and the animals were allowed to recover from 
anaesthesia. Following a post-operative period of one week, animals were sacrificed by 
transcardial perfusion (see previous protocol) and the brains cryoprotected in sucrose. 
Fluorescence immunocytochernistry was used to visualise tyrosine hydroxylase 
immunoreactivity in sections containing the VTA (see previously) to determine co-localisation 
with fluorogold. Coronal sections containing the PFC and nucleus accumbens were cut, 
mounted on microscope slides and examined to determine the fluorogold injection site. 
3.2.5. Visualisation and image capture 
Visualisation and image capture for all experiments was carried out using a fluorescence 
microscope (Leica, Germany) and Metamorph image capture software (MIDS Inc. USA). 
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3.3. Results 
3.3.1. TH immunoreactivity 
The antibody against TH labelled a large number of cells in the midbrain- These were confined 
to specific nuclei comprising the A8 (retrorubral nucleus), A9 (substantia nigra) and A10 (ventral 
tegmental area, nucleus interfasicularis, nucleus linearis caudalis and nucleus linearis rostralis) 
cell groups (see figure 3.8. for TH labelling in the VTA). Some TH labelled cells were seen in the 
rostral parts of the median and dorsal raphe nuclei (137 and B8 cell groups). At the caudal extent 
of the VTA TH positive cells of the A9 and Al 0 groups were found to be separated by the 
medial lemniscus, whilst more rostrally the A9 (substantia nigra) and A10 (VTA) groups were 
contiguous. At the rostral extent of the VTA the A9 and A10 nuclei again become separated this 
time by the medial terminal nucleus of the accessory optic tract. The VTA was at all times 
contiguous with the nucleus interfasicularis, nucleus linearis caudalis and nucleus linearis 
rostralis. 
In the VTA TH labelled cells were large with extensive dendrites. DAR staining revealed that 
the nuclei of these cells were also large (see figure 3.9. ). TH labelling was present in the 
somatic cytoplasm but absent from cell nuclei, and was found extensively in dendrites. 
Cytoplasmic labelling was most dense close to the cell membrane. This paftern of labelling was 
found with both fluorescence and HRP immunocytochernistry (see figure 3.2 [A] and figure 3.6 
[B]). 
3.3.2. GR immunoreactivity 
The GR antibody labelled a very large number of cells throughout the midbrain. GR staining 
was evident in all monoarninergic areas present (A8, A9, A10, B7 and B8 cell groups) and 
throughout the dorsal midbrain. Fluorescence immunohistochernistry in conjunction with the 
nuclear stain DAR revealed that GR immunoreactivity was punctate and confined to the nuclei 
of labelled cells whilst absent from cytoplasmic and dendritic regions. HRP labelled GR was 
similarly punctate with a similar sized area of labelling compared to fluorescent labelled protein 
(see figures 3.10. and 3.11 . ). 
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Figure 3.8. Photomicrograph of TH immunoreactivity (10x magnification) in the ventral 
midbrain. (A) FITC labelled; (B) HRP labelled Vector Novared 
Figure 3.9. Photomicrograph (40x magnification) of FITC labelled TH immunoreactivity (A) 
and DAR nuclear staining (B) in the ventral midbrain. 
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Figure 3.10. Photomicrograph of GR immunoreactivity (40x magnification) in the ventral 
midbrain. (A) Rhodamine labelled (examples circled); (B) HRP labelled Vector 
SG. 
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Figure 3.11. Photom icrographs (1 00x m agn if ication) of (A) GR (H RP labelled Vector SG); (B) 
MR (HRP labelled Vector SG); (C) TH (HRIP labelled Vector Novared). 
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Labelling for GR was found to be highly dependent on the solubilisation of cell membranes 
during the ICC procedure. Initially at a variety of primary antibody concentrations no GR signal 
was found in the VTA or adjacent monoaminergic regions, however a higher concentration of 
triton-XlOO detergent revealed extensive labelling. 
Although fluorescence immunocytochernistry successfully labelled GR, HRP 
immunocytochernistry was much better suited to labelling this protein as it produced a stronger 
signal and lower background labelling. To improve labelling specificity a number of blocking 
steps were incorporated into the HRP ICC protocol including the use of bovine serum albumin in 
the diluent (as for fluorescent ICC), preincubation of the secondary antibody with rat serum (as 
for fluorescent ICC), incubation of the tissue with serum from the host species in which the 
secondary antibody was raised, and (strept)avidin/biotin blocking. Furthermore signal 
amplification was incorporated with the use of HRP conjugated Vector ABC reagent in the 
tertiary labelling step. This provided much greater resolution of the specific labelling compared 
to background. 
3.3.3. MR immunoreactivity 
MR antibody labelling was evident in many cells throughout the midbrain. In a similar fashion 
to GR labelling, MR was present in all monoarninergic areas present. Due to the 
aforementioned problems with fluorescence ICC for GR, only HRP ICC was used to label MR in 
the VTA. At a subcellular level MR staining was most dense in the cytoplasm with lighter 
staining in the nucleus. No stain was apparent in dendrites (see figure 3.11 B). 
3.3.4. GRITH colocalisation 
Simultaneous labelling of TH and GR protein in the VTA using fluorescence ICC established 
that with respect to these proteins there are three cell types present in the VTA. These are the 
TH expressing neurones which express GR, the TH expressing neurones which do not express 
GR, and the non-TH expressing cells which express GR (see figure 3.2. ). This established that 
some dopaminergic cells within the VTA express the glucocorticoid receptor. More 
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Figure3.12. Photomicrograph (100x magnification) of GR (HRP labelled Vector SG; blue) and 
TH (HRP labelled Vector Novared; red/brown) in the VTA. Three types of cell are 
visible (1)TH+/GR-; (2)TH+/GR+; (3)TH-/GR+. 
Figure 3.13. Photomicrograph (100x magnification) of MR (HRIP labelled Vector SG; 
blue/purple) and TH (HRP labelled Vector Novared; red/brown) in the VTA. Two 
types of cell are visible (1) TH -/ MR +; (2) TH +/ MR +. 
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detailed analysis was hampered by the consistently poor signal to background noise ratio of the 
GR signal. As a result of this it was decided to switch to a more sensitive immunolabelling 
method allowing for signal amplification steps to be incorporated into the procedure and utilising 
bright-field microscopy - namely horseradish peroxidase immunocytochemistry. 
Initially when dual labelling was attempted for GR and TH using HRP ICC the experiments 
failed principally because the TH label was too intense. This prevented the visualisation of the 
GR label (see figure 3.4. ). This problem was solved by reducing the TH primary antibody 
concentration by a factor of 100, and replacing the Vector ABC tertiary reagent used for the TH 
label with streptavidin conjugated HRP. This reduced the signal amplification, so through a 
combination of reducing the intensity of TH labelling and amplifying the GR labelling, successful 
visualisation of both antigens was achieved (see figure 3.12. ). The results of the previous 
fluorescent immunocytochemistry experiments were confirmed, as three cell types were 
demonstrated, namely TH labelled cells expressing GR, TH labelled cells not expressing GR, 
and non-TH labelled cells expressing GR. 
3.3.5. Analysis of GRITH colocalisation 
For analysis the VTA was divided into anatomical subdivisions according to the rat brain atlas 
of Paxinos and Watson (1988) (see figure 3.14. ). Five representative sections of the rostral- 
caudal axis were selected for analysis also corresponding to the brain atlas of Paxinos and 
Watson (plates 39-43). Visible TH positive cells were counted in each sub-region and co- 
labelling for GR was recorded (see tables 3.1. and 3.2. ). X2 analysis was performed on the data 
to establish whether any differences in the percentage of GR labelled TH positive cells existed 
either along the rostro-caudal axis or between regional subdivisions within the VTA. In both 
cases no significant differences were demonstrated (p>0.05). As a result of this it was 
concluded that within the VTA approximately 46% of TH expressing cells express GR with no 
significant regional variations in expression. 
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Figure 3.14. Subregions of the VTA as used for analysis of TH/GR colocalisation. PBP = 
parabrachial nucleus; PN= paranigral nucleus; VTA = ventral tegmental area. 
ill 
Chapter 3 
VTA sub-region 
Paranigral nucleus Parabrachial nucleus VTA 
Proportion GR +ve 70/134 176/377 110/269 
% GR +ve 52 47 41 
Table 3.1. The proportion of GR expressing TH positive cells relative to the total number of 
DA cells in subregions of the VTA. Cells counted in sections used for analysis in 
table 3.1. and totals calculated for each VTA subregion. Data from one animal. 
Distance Caudal Rostral 
from 
bregma 
(MM) -6.30 -6.04 -5.80 -5.60 -5.30 
Proportion 9/23 74/156 105/218 98/204 70/179 
GR +ve 
% GR +ve 39 47 48 48 39 
Table 3.2. The proportion of GR expressing TH positive cells relative to the total number of DA 
cells in midbrain sections taken along the rostro-caudal axis of the VTA in one 
animal. 
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3.3.6. MRITH colocalisation 
The GR/TH co-labelling protocol was adapted with very little alteration to examine MR/TH 
colocalisation. Upon examination it was observed that MR was found in all cells expressing 
tyrosine hydroxylase within the VTA. In addition a large number of non-catecholaminergic cells 
within the VTA were found to express MR (see figure 3.13. ). 
3.3.7. Fluorogold retrograde tracing of mesocorticolimbic neurones 
The aim of the Fluorogold retrograde tracing was to determine whether projections to the 
prefrontal cortex and nucleus accumbens originate in distinct regions of the VTA and whether 
these cells express corticosteroid receptors. The results obtained from these experiments were 
somewhat disappointing due to a number of problems. Due to the poor signal obtained from 
fluorescent labelled GR it was not possible to carry out TH and GR fluorescence 
immunocytochemistry on fluorogold treated rats. When HRP immunocytochemistry was 
attempted on fluorogold treated brains the labelling procedure resulted in loss of the TH label. 
Thus it was not possible to establish which terminal region GR containing catecholaminergic 
cells projected to. 
Using single labelling for TH, an attempt was made to simply map where projections to the 
PFC and NAcc originate in the VTA. Fluorogold injection sites in the PFC and NAcc can be 
seen in figures 3.15. and 3.16. This method was again hampered by poor reliabil. ity of labelling 
related to tissue quality. In light of these problems the amount of tissue available for analysis 
was extremely limited. Furthermore the interpretation of the results was hampered by doubts 
regarding the accuracy of fluorogold deposits in the terminal regions. Deposits of fluorogold 
occurred down the track of the pipette during implantation. Furthermore, at the injection site 
fluorogold was observed in adjacent regions to the PFC and NAcc. 
When tissue was examined to determine the distribution of cells it was found that cells labelled 
at their terminals in both the prefrontal cortex and nucleus accumbens were distributed 
throughout the VTA with no evident pattern of distribution (see figure 3.17. for FG distribution in 
the VTA following NAcc injection). In the case of the prefrontal cortex manual cell counting 
found similar numbers of cells in all four quadrants of the VTA (see table 3.3. ). In the case of the 
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nucleus accumbens manual counting was not possible due to the large number of cells however 
cells were observed distributed throughout the VTA (see figure 3.17-VTA NAcc). 
Lateral VTA Medial VTA Total 
Dorsal VTA 62 79 141 
Ventral VTA 59 64 123 
Total 121 143 264 
Table 3.3. Distribution of fluorogold labelled cells in the VTA following injection into the PFC 
(data from one animal). 
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Figure 3.15. Photomicrograph (xlO magnification) of Fluorogold injection site in the mPFC. 
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Figure 3.16. Photomicrograph (xlO magnification) of Fluorogold injection site in the NAcc. 
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Figure 3.17. Photomicrograph (100x magnification) of cells in the VTA retrogradely labelled 
with fluorogold from the nucleus accumbens. Blue = FG; Green = TH (FITC 
labelled) 
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3.4. Discussion 
The aims for this study were twofold: (i) to determine if corticosteroid receptors are present in 
catecholaminergic neurones of the VTA and if there is any pattern in the distribution of these 
corticosteroid receptor expressing cells, and (ii) to determine if, where a pattern of distribution is 
evident, whether this correlates with the projection targets of the cells in question. The results of 
the study demonstrated that both mineralocorticoid receptors and glucocorticoid receptors are 
present in cells expressing TH in the VTA. In the case of the glucocorticoid receptor, 46% of TH 
expressing cells co-expressed this receptor whilst all TH positive cells expressed MR. No 
significant pattern was seen in the distribution of the GR positive cells. It was not possible to 
carry out retrograde labelling in conjunction with immunocytochernistry for both TH and GR. 
However the lack of a discernible pattern in the GR/TH co-labelling and the fact that all TH 
positive cells expressed MR indicated that mesocortical and mesolimbic neurones are unlikely 
to differ in their expression of corticosteroid receptors. 
3.4.1. Tyrosine hydroxylase expression in the midbrain 
Tyrosine hydroxylase is the rate limiting enzyme in catecholamine synthesis (Nagatsu et al. 
1964) and is present in catecholaminergic neurones in the CNS. Here an antibody raised 
against TH was used to label dopaminergic cells in the midbrain at the level of the VTA. TH 
immunoreactivity was seen in the A8 (retrorubral nucleus), A9 (substantia nigra) and A10 
(ventral tegmental area, nucleus fasicularis, nucleus linearis) cell groups (see Dahlstrom and 
Fuxe, 1964; Paxinos and Watson, 1986). This is consistent with known doparninergic regions of 
the midbrain. Furthermore some TH immunoreactivity was observed in the predominantly 
serotonergic medial and dorsal raphe nuclei. This is in agreement with reports of dopaminergic 
cell bodies in this region (Trulson et al. 1985; Decavel et al. 1987; Stratford and Wirtschafter, 
1990; Datiche and Caftarelli, 1996; Hasue and Sharnmah-Lagnado, 2002). No TH 
immunoreactivity was seen outside of the aforementioned regions. For the purposes of this 
study all tyrosine hydroxylase expressing neurones in the VTA were considered to be 
doparninergic. Evidence to support this is provided by both fluorescence histochemistry 
(Dahlstrom and Fuxe, 1964) and immunocytochemistry experiments demonstrating that 
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neurones in the VTA contain dopamine (Onteniente et al. 1984; Decavel et al. 1987; Hasue and 
Shammah-Lagnado, 2002) (dopamine is not present in detectable amounts in noradrenergic 
fibres, see Kitahama et al. 2000). In addition immunoreactivity against dopamine-p-hydroxylase 
(the enzyme responsible for the synthesis of noradrenaline from clopamine) is reportedly absent 
from the VTA (Swanson and Hartman, 1975). 
At the subcellular level TH immunoreactivity was present in the cytosolic compartment with the 
highest density proximal to the cell membrane. Immunoreactivity was seen additionally 'in 
dendrites, but was not present in cell nuclei. Similar patterns of labelling have been observed in 
other immunocytochernical studies (see Harfstrand et al. 1986; Ford et al. 2006). This is in 
agreement with reports that TH exists in both cytoplasmic and membrane-bound forms 
(Kuczenski et al. 1972). 
3.4.2. GR and MR expression in the midbrain 
Widespread GR immunoreactivity has previously been reported in the brain and has been 
particularly well characterised in regions such as the hippocampus, cortex, hypothalamus, 
thalamus septum and midbrain (Ahima and Harlan, 1990; Cintra et al. 1994; Fuxe et al. 1985, 
1987; Morimoto et al. 1996). The current study demonstrated that a large number of cells 
throughout the midbrain express GR including the doparninergic cell groups of the VTA (and 
associated midline A10 nuclei) and substantia nigra, as well as in rostral portions of the 
serotonergic dorsal and medial raphe nuclei. Previous reports have shown similar pafterns of 
immunoreactivity in these monoarninergic regions (Ahima and Harlan 1990; Czyrak and 
Chocyk, 2001; Harfstrand et al. 1986; Morimoto et al. 1996). 
MR immunoreactivity in the CNS is less well characterised outside of specific regions such as 
the hippocampus and hypothalamus (Van Eekelen and De Kloet 1992; Agarwal et al. 1993; Ito 
et al. 2000; Han et al. 2005). Although one study reported that MR immunoreactivity is absent 
from the midbrain (Agarwal et al. 1993), an earlier study had found "low to moderate" levels of 
MR immunoreactivity in the substantia nigra and VTA and high levels in the dorsal raphe nuclei 
(Ahima et al. 1991). MR expression in the dorsal raphe nucleus has also been demonstrated by 
Gartside et al. (submitted, 2007). The present study supports these findings having 
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demonstrated MR immunoreactivity in a number of regions throughout the midbrain including 
the VTA, substantia nigra, and rostral portions of the dorsal and median raphe nuclei. 
Subcellular distribution of labelled corticosteroid receptors 
As discussed in chapter one, both MR and GR translocate to the nucleus upon binding of 
ligand. Given that under basal (non-stressful) conditions it has been proposed that the MR 
receptor is close to maximally occupied whilst the GR is mostly unbound (Reul and de Kloet, 
1985) one might expect MR to be present in the nucleus, with GR predominantly in the 
cytoplasm. The results of this study in fact showed the reverse, with GR predominantly located 
in cell nuclei with MR present in both nuclei and cytoplasm. 
A number of immunocytochernical studies have shown that GR is present in cell nuclei and in 
the majority of these studies GR was predominantly found in the nucleus compared to the 
cytoplasm (Gasc et al. 1989, Sanchez et al. 1990, Brink et al. 1992). Furthermore the study by 
Harfstrand et al. (1986) looking at GR expression in VTA catecholaminergic neurones showed a 
nuclear localisation of GR. It has been suggested that nuclear translocation of GR in 
immunocytochernical studies is in fact an artefact of the fixation and membrane solubilisation 
process which is carried out to allow antibodies access to GR (Nishi et al. 1999). Studies carried 
out in living cells using GFP conjugated glucocorticoid receptor have shown that GR is 
predominantly located in the cytoplasm until application of ligand (Nishi et al. 1999). An 
important factor to take into consideration is that in tissue taken from animals, stress and/or 
anaesthesia at the time of sacrifice may cause an elevation of corticosteroid levels which 
induces the translocation of GR i. e. the nuclear GR is in fact ligand bound. 
Ito et al. (2000), who developed the MR antibody used in this study, have shown that MR is 
present in both the nucleus and cytoplasm of fixed rat hippocampal cells, however incubation 
with an MR agonist induces nuclear translocation. This result has also been shown in live 
cultured cells (Fejes-Toth et al. 1998) and in experiments utilising GFP-conjugated MR in COS- 
and cultured hippocampal cells (Nishi et al. 2001). The data of Ito et al. (2000) suggest that 
MR is not maximally occupied under basal conditions given it's presence in the cytoplasm and 
the ability of ligand to induce translocation. This is a possible interpretation of the results 
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obtained in the present study, as MR labelling was most dense in the cytoplasm with a much 
lower density in the nucleus. Another possibility is that the observed cytoplasmic MR is an 
artefact of the ICC method and that leakage of protein out of the nucleus occurred following the 
membrane solubilisation step. Poor compartmentalisation of the stain used is unlikely to account 
for labelling in the cytoplasm as the same method was used to label MR as was used to label 
GR. GR immunoreactivity was confined to the nucleus suggesting that the stain is localised to 
immunolabelled proteins and does not leach to adjacent subcellular regions. 
In summary the nuclear compartmentalisation of GR was consistent with a stress induced 
activation of the receptor at the time of sacrifice. If this is the case, however, one would have 
expected the high affinity MR to be similarly translocated to the nucleus. Whilst the relative 
distributions of MR and GR between the nucleus and cytoplasm in the present study are 
consistent with similar studies in the literature, it is difficult to account for the presence of MR in 
the cytoplasm 
3.4.3. Corticosteroid receptor expression in dopaminergic cells of the VTA 
The results of this study clearly demonstrate that catecholaminergic cells in the VTA express 
corticosteroid receptors. In the case of the mineralocorticoid receptor this is an entirely novel 
finding, whilst with respect to the glucocorticoid receptor, this clarifies the confusion in the 
literature which arose from two contradicting papers. The earliest of these (Harfstrand et al. 
1986) demonstrated that around 61 % of dopaminergic cells in the VTA express the 
glucocorticoid receptor. A later study conducted in 2001 (Czyrak and Chocyk) reported that 
whilst glucocorticoid receptor was present in the VTA, it was not co-localised with TH. The 
results of the present study support the data published by Harfstrand et al. and offer further 
evidence that the glucocorticoid receptor is indeed present in catecholaminergic cells in the 
VTA. 
In the present study GR immunoreactivity in the VTA was consistently demonstrated using 
both fluorescence and HRP single-label immunocytochernistry. Results were consistent 
between the two methods from the subcellular level right up to the distribution within the VTA, 
and this consistency was maintained in dual-label experiments. It is likely that there is a 
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methodological explanation for the failure of Czyrak and Chocyk (2001) to demonstrate the 
colocalisation of GR and TH in the VTA. This may result from the lack of a membrane 
solubilisation step in their ICC protocol. In the present study an unusually high concentration of 
Triton x-100 was required for successful staining of GR in the VTA, whilst it appears that no 
tissue solubilisation step was used in Czyrak and Chocyk's work. Although Harfstrand et al. 
(1986) doesn't clearly state the methodology used, they based their double staining ICC 
protocol on one from a group who routinely used Triton x-100 in their immunocytochernical 
procedures (see Oertel et al. 1982). 
It is worth noting that whilst the study of Harfstrand et al. (1986) showed similar results to the 
present study, a slightly higher level of GR/TH co-localisation was found. In the Harfstrand study 
the entire A10 cell group was included in the analysis, and it is noted in the paper that the 
nucleus interfasicularis (IF) and nucleus linearis caudalis (CLi) showed particularly high TH/GR 
co-immunoreactivity. As the IF and CLi are distinct from the VTA, they were not included in the 
present study and this may account for the lower mean level of co-expression described here. 
The presence of GR in only around half of the dopaminergic neurones in the VTA is interesting 
as it contrasts with GR expression in other monoaminergic cell groups. GR has been shown in 
all serotonergic raphe nucleus neurones (Harfstrand et al. 1986; Gartside et al. submifted, 2007) 
and in the vast majority of noradrenergic neurones in the locus coeruleus and nucleus tractus 
solitarius (Harfstrand et al. 1986; Czyrak and Chocyk, 2001). The presence of two populations 
of doparninergic cells within the VTA differentiated by their expression of GR may reflect 
different projection targets for these neurones. Although no significant difference was found in 
the proportion of GR expressing dopaminergic cells across subregions of the VTA, it remains a 
possibility that GR expression differs between, for example mesolimbic and mesocortical 
dopamine neurones. 
The demonstration of MR in all dopaminergic neurones suggests that all dopaminergic cells in 
the mesolimbic and mesocortical systems will be sensitive to MR regulation and moreover 
sensitivity to MR mediated regulation does not differ between projection targets. 
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3.4.4. Corticosteroid receptors in non-dopaminergic cells of the VTA 
In the VTA large numbers of both glucocorticoid and mineralocorticoid receptors were found in 
cells not expressing tyrosine hydroxylase. The phenotype of these cells is unknown as no 
studies have as yet been carried out. It is known that the VTA contains both GABAergic (Van 
Bockstaele and Pickel, 1995; Carr and Sesack, 2000; Bubar and Cunningham, 2007) and 
glutarnatergic cells (Kawano et al. 2006; Yamaguchi et al. 2007) and it is possible that these 
cells express corticosteroid receptors. Additionally glial cells in other regions of the brain are 
known to express glucocorticoid receptors (Vielkind et al. 1990; Hwang et al. 2006), and this 
may also be the case in the VTA. 
3.4.5. Retrograde tracing of mesocorticolimbic neurones 
The results of the retrograde tracing experiments were somewhat disappointing. It had 
originally been envisaged that a combination of fluorescence immunocytochernistry and 
fluorogold retrograde tracing might be used to determine where individual GR/MR containing 
catecholaminergic cells project to. The poor results with fluorescent labelling of GR meant that 
this was not possible. When HRP immunocytochemistry was attempted with fluorogold tracing 
the TH stain in the VTA was lost. The reason for this is unknown, - although previous studies 
have successfully produced HRP reaction products from DAB in FG labelled neurones (Lee et 
al. 2005a; Lee et al. 2005b), other studies have failed to combine FG and HRP retrograde 
labelling (Shinder et al. 2001). It should be noted that the successful combination of HRP and 
FG labelling as carried out by Lee et al. (2005a; 2005b) was with an HRP retrograde tracer and 
not an HRP-conjugated immunolabel. There is the possibility that a specific incompatibility 
exists between HRP-ICC and FG retrograde tracing. 
As single-label fluorescence immunocytochernistry could be successfully combined with FG 
labelling it was decided to try and map the distribution of catecholaminergic cells projecting to 
the medial prefrontal cortex and the nucleus accumbens, the objective being to correlate this 
with the distribution of GR-TH and MR-TH co-labelled cells. There is some evidence to suggest 
that in primates, prefrontocortical neurones originate mainly in the dorsal tier of the VTA, with 
the ventral PFC mapping to the clorsomedial VTA and the dorsal PFC mapping to the 
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clorsolateral VTA (Williams and Goldman-Rakic, 1998). Furthermore it has been shown that 
doparninergic projections to the piriform cortex a preferentially located in the dorsal VTA 
(Datiche and Cattarelli, 1996). In contrast there is some evidence that neurones projecting to 
the nucleus accumbens originate in the ventral tier of the VTA along the whole medio-lateral 
axis (Fallon and Moore, 1978; Albanese and Minciacchi, 1983; Brog et al. 1993). It should be 
noted however that these studies did not show a ventral distribution of NAcc projections in all 
cases, my own interpretation of the data is that more localised injections of tracer in the nucleus 
accumbens led to better topographical resolution in the VTA. The results of the present study 
failed to find evidence for a distinct topography, with cells retrogradely labelled in the PFC and 
NAcc found throughout the VTA. A similar overlap in PFC and NAcc projections at the level of 
the VTA has been shown in previous studies (Carr and Sesack, 2000; Margolis et al. 2006). 
Whilst it is possible that the two projections do not arise in different regions of the VTA some 
methodological considerations must be taken into account when considering the present results. 
Inspection of tissue sections taken at the site of injection revealed some leaching to 
neighbouring tissue -a fact which could be significant given the proximity of the ventromedial 
prefrontal cortex and the nucleus accumbens. In addition, in reaching these ventral injection 
sites some fluorogold was found to be deposited along the pipette track through the overlying 
tissue. Inaccuracies in the fluorogold injection may therefore explain the lack of topographical 
differences. 
The principal aim of the retrograde tracing experiments was to determine whether 
mesocortical and mesolimbic projection neurones differ in their expression of corticosteroid 
receptors. As far as the mineralocorticoid receptor is concerned all doparninergic neurones 
appear to express this receptor and so both projection systems are likely to be equally sensitive 
to MR mediated signalling. As no significant subregional distribution of GR/TH colocalisation 
was found, and it was not possible to look at individual neurones, it is unclear whether 
mesocortical and mesolimbic projection neurones differ in their GR expression. 
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3.4.6. Functional implications of GR and MR expression in dopaminergic cells 
The presence of corticosteroid receptors in doparninergic neurones allows for direct 
modulation of dopaminergic function by elevated gluococorticoid levels. This in turn provides 
evidence for a direct link between endocrine abnormalities in bipolar disorder and doparninergic 
functional alterations which are characteristic of this disease. The functional consequences of 
elevated corticosteroid levels on doparninergic cells are investigated and discussed in the 
following chapters. 
The finding that MR is expressed in all doparninergic neurones suggests that circulating 
corticosteroids perform a homeostatic role in regulating neuronal function. The high occupancy 
of these receptors by physiologically normal levels of circulating corticosteroids (Reul and de 
Kloet, 1985) suggests that MR mediated effects are significant when corticosteroid levels fall. 
Indeed adrenalectomy has been shown to markedly reduce dopaminergic neurotransmission in 
the nucleus accumbens (Piazza et al. 1996; Shoaib and Shippenberg, 1996; Barrot et al. 2000) 
and the prefrontal cortex (Mizoguchi et al. 2004), and this effect may be attributable to removal 
of tonic MR activity. 
Based on the prevailing view that the MR is close to maximally occupied under basal 
conditions (as first proposed by Reul and de Kloet, 1985), disturbances to the corticosteroid 
rhythm which elevate circulating hormone levels would be expected to cause only minimal 
changes in the occupancy of MR. It has been suggested however that Reul and de Kloet 
overestimated the degree of MR binding particularly during the circadian nadir (Pace and 
Spencer, 2007). Consequently both MR and GR may be involved in the pathological 
consequences of elevated corticosteroid levels. Furthermore, the ability of GR and MR to form 
heterodimers demonstrated by Trapp et al. (1994) means that the presence of MR could be 
functionally important. MR/GR heterodimers can act both synergistically (Trapp et al. 1994) and 
antagonistically (Liu et al. 1995) with GR homodimer mediated transcriptional activity in cultured 
cells. MR/GR heterodimers have been shown to be more efficient than homodimeric receptors 
at mediating the corticosteroid induced transcriptional repression of the 5-HT1A gene in cultured 
cells (Ou et al. 2001). 
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Recent studies have demonstrated that changes in ligand concentration affect heterodimer 
formation with the degree of heterodimer formation in cultured cells increasing in response to 
elevated corticosteroid concentrations (Nishi et al. 2007). Consequently, corticosteroid 
dysrhythmia may alter the nature of corticosteroid signalling by promoting the formation of 
heterodimers during the elevated diurnal nadir. It may therefore be the case that these 
heterodimers play an important role in the pathological consequences of disturbances to 
circadian rhythmicity. 
The finding that GR wafs present in approximately half of the dopaminergic cells in the VTA 
may have important functional consequences. As discussed above it is likely that only those 
cells expressing GR receptor will be sensitive to elevated circulating corticosteroid levels. Given 
that all GR positive cells were also MR positive, these effects could be mediated by both GR 
homodimers and GR/MR heterodimers but it is the presence of GR that is critical. There 
remains the possibility that GR expression differs between the mesolimbic or mesocortical 
projection systems, and as a consequence elevated corticosteroid levels could affect these 
systems to different degrees. This could lead to a functional "imbalance" between the two 
systems following disturbances to the corticosteroid rhythm. It is also possible that in both 
projection systems there are dopamine neurones which express GR and those that do not. This 
would serve to somewhat "dilute" corticosteroid effects in each system and as such could be a 
means of maintaining a level of cloparninergic tone in the terminal regions in spite of elevated 
corticosteroid levels. It is also possible that sub-regions of either the prefrontal cortex or nucleus 
accumbens receive specific inputs from GR expressing doparninergic cells, however no data is 
available to support this theory. 
3.4.7. Functional implications of GR and MR expression in non-dopaminergic cells 
In addition to the presence of GR and MR in doparninergic cells, large numbers of non- 
dopaminergic cells in the VTA were found to express these receptors. These may be 
GABAergic or glutamatergic neurones or glial cells, functional alterations of which could lead to 
secondary changes in dopaminergic function. As GABA and glutamate are important regulators 
of doparninergic neuronal function in the VTA and glia are responsible for the uptake of a variety 
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of amino acid transmitters (Ganong, 2001) any changes in the function of these cells will have 
implications for doparninergic neurotransmission. 
As yet no one has shown whether non-dopaminergic neurones in the VTA are corticosteroid 
sensitive, however glial cell function has been shown to be altered by corticosteroids. In 
particular, glial glutamine synthetase (which is responsible for the catabolism of glutamate) is 
inducible by corticosteroids (reviewed by Vardimon et al. 1999). Furthermore glial glutamate 
transporter expression is regulated by corticosteroids, though no evidence for this has been 
found in the midbrain (Zschocke et al. 2005). Changes to glutamate availability would have 
consequences for doparninergic transmission as DA neurones are tonically regulated by 
glutamate which promotes neuronal firing. Glia are also involved in glucose transport, and it has 
been shown that hippocampal astrocytic glucose transport is decreased by corticosteroids 
(Virgin et al. 1991). If this were to occur in the VTA doparninergic function may well be altered 
due to changes in energy availability. Thus, there are a variety of mechanisms by which 
changes in glial function could affect dopaminergic neurotransmission. A link between 
glucocorticoid induced glial abnormalities, altered doparninergic function and mood disorders is 
supported by data showing changes in glial function in a variety of psychiatric disorders 
including bipolar disorder (reviewed by Cotter et al. 2001). Overall these factors could be as 
important as direct corticosteroid effects in the regulation of doparninergic neurotransmission. 
3.5. Conclusion 
The data presented in this chapter demonstrate that a variety of cells within the VTA contain 
corticosteroid receptors. Dysregulation of the circadian corticosteroid rhythm could therefore 
produce changes in VTA doparninergic function via direct and indirect effects on doparninergic 
cells. The presence of MR in VTA DAergic cells is a novel finding, whilst the clear demonstration 
of GR in these cells offers some clarification of the confusion which existed in the literature. 
Overall the findings offer a firm basis on which a hypothesis integrating endocrine and 
doparninergic abnormalities observed in bipolar disorder can be constructed, a hypothesis 
which is examined in the rest of this thesis. 
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Chapter 4. Effect of corticosterone administration on mRNA levels in the VTA 
4.1. Introduction 
As discussed in chapter 1, glucocorticoid receptors act as regulators of DNA transcription to 
produce alterations in cell function. When corticosteroids bind to GR/MR receptors chaperone 
heat shock proteins dissociate and the DNA binding site is exposed. Following 
hyperphosphorylation of the receptor protein it forms a dimer and translocates to the nucleus 
(Buckingham 2006; Schoneveld et al. 2004). Corticosteroid effects on a particular gene may be 
through direct transcriptional control (which can be positive or negative), or via transcriptional 
regulation of genes for transcription factors and co-activators which in turn regulate the 
expression of the gene in question. Furthermore the presence or absence of essential cofactors 
means that corticosteroid effects on a given gene can be tissue specific, varying between 
different cell types (for reviews see Buckingham 2006; Schoneveld et al. 2004). 
Given the presence of GR and MR receptors in dopaminergic cells of the VTA as shown in 
Chapter 3, the ability of corticosteroids to modulate dopaminergic function (see Chapter 1), and 
the corticosteroid dysrhythmia in bipolar disorder, the question arises - do alterations in 
corticosteroid secretion affect dopaminergic transmission by modulating gene transcription 
within the VTA and could such changes underlie the symptoms of bipolar disorder? 
A number of proteins intrinsic to doparninergic neurones could be considered to be 
candidates for modulation by corticosteroids. These proteins, which include enzymes, 
neurotransmitter transporters and neurotransmitter receptors are described in more detail 
below. 
Tyrosine Hydroxylase 
0 The rate limiting enzyme in dopamine synthesis (Nagatsu et al. 1964) and therefore a 
critical determinant of the amount of dopamine available for uptake into synaptic 
vesicles. 
129 
Chapter 4 
Vesicular Monoamine Transporter 2 (VMAT2) 
0 Responsible for the uptake of cytoplasmic dopamine into synaptic vesicles in 
preparation for release (Peter et al. 1995; Nirenberg et al. 1996; Hoffmann et al. 1998). 
VMAT2 activity determines vesicular content (Colliver et al. 2000), which in turn governs 
the quantal size of cloparnine release following depolarisation (Pothos et al. 2000). 
Dopamine Transporter (DAT) 
Following neurotransmitter release the clopamine transporter is responsible for uptake 
of dopamine from perisynaptic sites (see reviews by Hoffman et al. 1998; Chen & Reith 
2000). Alterations in the function of this protein affect synaptic concentrations of 
dopamine and the time course of removal of dopamine from the synapse, as well as the 
amount of diffusion from the synapse to extrasynaptic sites (Cragg & Rice 2004). 
Monoamine Oxidase A (MAO-A) 
0 Responsible for the oxidative metabolism of dopamine within clopaminergic terminals 
and the principle metabolic pathway for dopamine where efficient dopamine re-uptake 
occurs (Gesi et al. 2001; Shih 2004). More importantly MAO-A activity is a determinant 
of cytoplasmic dopamine content and is therefore likely to affect dopamine availability 
for uptake into synaptic vesicles. 
D? Recepto 
0 The D2 receptor is the inhibitory autoreceptor on dopamine neurones. It is present at 
somatodendritic sites where it inhibits impulse activity and at the terminal where it 
modulates synthesis and release of dopamine (O'Hara et al. 1996; White 1996; 
Centonze et al. 2002; Lindgren et al. 2003) and as such is a key determinant of 
dopaminergic neuronal activity. 
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NMDAR1 
0 NMDA receptors mediate excitatory input to dopaminergic neurones in the midbrain and 
control the switch from tonic pacemaker to phasic burst firing (Charlety et al. 1991; 
Chergui et al. 1993). Burst firing results in greater cloparnine release, on average, per 
depolarisation event than the tonic pacemaker mode (Johnson et al. 1992; Chergui et 
al. 1994; Meltzer et al. 1997; Gonon, 1998; Adell and Artigas, 2004). 
0 The NMDA receptor subunit 1 (NMDAR1) is the essential subunit in NMDA receptor 
formation as it contains both the glutamate and glycine binding sites. Functional NMDA 
receptors are tetramers consisting of two NMDAR1 subunits with either two NMDAR2 
subunits or an NMDAR2 and an NMDAR3 subunit (for review see Kew and Kemp, 
2005). 
GluRl 
0 AMPA receptors are excitatory on mesolimbic dopaminergic neurones, producing an 
increase in firing rate via increased intracellular Na+ (Meltzer et al. 1997; Adell and 
Artigas, 2004). Furthermore there is evidence that mesocortical dopaminergic neurones 
are under tonic excitatory stimulation by this receptor subtype (Westerink et al. 1998; 
Takahat and Moghaddarn, 2000). 
Glutamate receptor subunit 1 (GluRl) is one of four subunits which can form the 
tetrameric AMPA receptor. Wild-type receptors are thought to be heteromeric and the 
GluRl subunit is thought to favour the formation of a Ca 2+ permeable receptor channel 
(for reviews see Carlezon and Nestler, 2002; Kew and Kemp, 2005) 
5-HT2c Recepto 
0 The 5-HT2c receptor is an excitatory serotonin receptor with a signal transduction 
pathway producing IP3/DAG as a second messenger (Rang et al. 1999). It has been 
shown that serotonin potentiates the dopamine induced inhibition of VTA neurones via 
5-HT2 receptors (Brodie and Bunney, 1996). Further work with selective antagonists 
has shown a tonic inhibition of mesocorticolimbic doparninergic neurotransmission via 
131 
Chapter 4 
5-HT2c receptors (DiMafteo et al. 1999; DiMatteo et al. 2002; Gobert et al. 2000). These 
receptors are found on both dopaminergic neurones and GABAergic interneurones 
(Bubar and Cunningham, 2007), and it would appear that the inhibitory effect of 5-HT2C 
agonists arises from a stimulation of GABAergic signalling which inhibits dopamine 
nerve cell firing. 
In this chapter the abnormal diurnal Gorticosterone rhythm seen in bipolar disorder was 
modelled by administering a low dose of cortiGOsterone to male hooded Lister rats in their 
drinking water for two weeks. To examine the effect of this on gene transcription in the VTA in 
situ hybridisation histochemistry was performed on brain slices containing the VTA using a 
number of probes complementary to mRNA coding for the proteins discussed above. 
4.1.1. Subregions of the VTA 
A number of retrograde tracing experiments have provided evidence that doparninergic 
neurones projecting to different brain structures may arise in distinct subregions of the VTA. 
Thus there is evidence that in primates, mesocortical prefrontocortical efferents arise in the 
dorsal VTA (Williams and Goldman-Rakic, 1998). Similarly in the rat, tracing studies have 
shown that mesocortical dopaminergic innervation of the piriform cortex arises in dorsal regions 
of the VTA (Datiche and Cattarelli, 1996). In terms of mesolimbic efferents to the nucleus 
accumbens there is some data to suggest that these arise in the ventral portion of the VTA 
(Fallon and Moore, 1978; Albanese and Minciacchi, 1983; Brog et al. 1983), however the data is 
unclear. In chapter 3 retrograde tracing with fluorogold did not show a distinct topography of 
prefrontal cortex and nucleus accumbens projections, however methodological problems may 
account for this result. 
For the analysis of the present data the VTA was divided into four regions corresponding to 
those shown in figure 4.1. Thus it was hoped to relate any subregional differences in 
corticosteroid effects on mRNA transcription in the VTA to potential functional consequences in 
mesocortical and mesolimbic neurones projecting to the prefrontal cortex and the nucleus 
accumbens respectively. 
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Figure 4.1. Subdivisions of the VTA used for in situ hybridisation histochemistry data analysis 
(figures from Paxinos and Watson, 1996). DL= clorsolateral; DM = clorsomedial; 
VL = ventrolateral; VM = ventromedial. 
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4.1.2. Aims 
The principal hypothesis of this thesis is that the abnormalities in the diurnal corticosteroid 
rhythm seen in bipolar disorder modulate central doparninergic neurotransmission, and that this 
is responsible for some of the symptoms observed in these disorders. In this chapter the aim 
was to examine how an artificially induced abnormal corticosteroid rhythm affects the 
expression of mRNAs coding for protein determinants of presynaptic dopaminergic neuronal 
activity. To this end in-situ hybridisation histochernistry was employed to compare mRNA levels 
in the VTA of corticosteroid and vehicle treated animals. Analysis of mRNA levels in subregions 
of the VTA was carried out to determine whether flattening the corticosteroid rhythm might 
produce different effects in subpopulations of dopaminergic neurones projecting from this brain 
region. 
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4.2. Methods 
4.2.1. Animals & corticosterone Treatment 
The two-week corticosteroid treatment protocol has been described in Chapter 2. Briefly, male 
Lister hooded rats (Charles River, UK) housed in group of four were treated for 15 days with 
drinking water supplemented with corticosterone (50mg/1) and 0.5% EtOH (n=8). Control 
animals received drinking water containing 0.5% EtOH over the same period (n=8). Animal 
weights and water consumption were recorded during this period. In addition, upon sacrifice, 
adrenal glands were removed for comparison. 
Note: All animals were injected with NSDIO15 (100 mglkg i. p. ) 20 minutes prior to sacrifice. This 
was so forebrain tissue could be assayed for tyrosine hydroxylase activity (see chapter 5). 
4.2.2. Tissue collection 
After sacrifice by overdose of sodium pentobarbital (0.7 ml/kg i. p., 20% w/v solution, Dolethal, 
Vetoquinol UK), the brain was removed and the portion containing the midbrain was snap 
frozen in isopentane on dry ice. Tissue was stored at -80'C prior to cutting and in-situ 
hybridisation treatment (see Chapter 2 for full ISH tissue preparation method). 
4.2.3. Oligonucleotide probes 
Oligonucleotide probes synthesised from the following nucleotide sequences were used for in- 
situ hybridisation histochemistry: 
Tyrosine Hydroxylase (TH): 36 base probe sequence complimentary to bases 1380 to 1415 
(inclusive) of the rat TH gene (1-22651 Anton et al. 1994): 5' GGG AGA ACT GGG CAA ATG 
TGC GGT CAG CCA ACA TGG 3'. 
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Vesicular Monoarnine Transporter 2 (VMAT2): 48 base probe sequence complimentary to 
bases 271 to 318 of the rat vesicular monoamine transporter gene (NM 013031 Schwartz et al. 
2003): 5'ATG CCT TTA GGT CTG GTG GTC TGG TCT CGA GCA CCA GAG GTG GAG GCT 
3, 
Dopamine Transpotler (DAT): 43 base probe sequence complimentary to bases 1015 to 1057 
of the rat DA transporter gene (M80233 Kilty et al., 1991): 5' GAG AAG GCA ATC AGC ACT 
CCA AAC CCA ACG CCG AGG GAG AAG C 3'. 
Monoamine Oxidase A (MAO-A): 36 base probe sequence complimentary to bases 1591 to 
1626 of the monoamine oxidase A gene (XM 001058993): 5'AAG ATA CGC AAA TTC CCG 
AGC AGT TTT TGT CCA ACA 3' 
D2 receptor 36 base probe sequence complimentary to bases 787 to 820 of the rat dopamine 
D2 receptor (X1 7458 Monsma et al. 1989): 5' GTG TTG ACC CGC TTC CGG CAC TTC CGG 
AGG ACG AGT 3' 
NMDA receptor subunit I (NMDARI): 39 base probe sequence complimentary to bases 558 to 
596 of the NMDAR1 subunit of the NMDA receptor (U1 1418 Sullivan et al. 1994): 5' CGG TGC 
CGC CCT ACT CCC ACC AGT CCA GCG TCT GGT TTG AGA 3' 
AMPA receptor subunit GluRI: 39 base probe sequence complimentary to bases 1899 to 1937 
of the GluRl subunit of the AMPA receptor (X17184 Hartley et al. 1998): 5'GTC ACT GGT TGT 
CTG GTC TCG TCC CTC TTC AAA CTC TTC 3' 
5-HT2c receptor: 36 base probe sequence complimentary to bases 697 to 732 of the serotonin 
2C receptor (NM 012765 Julius et al. 1988): SACG GCG CAG GAC GTA GAT CGT TAA GAA 
GTA GGT GAT 3' 
136 
Chapter 4 
4.2-4. In-situ hybridisation procedure 
Oligonucleoticle probes were labelled with 35 S-dATP at the T-tail end using terminal 
deoxynucleotidyl transferase (TDT) enzyme. Radiolabelled probe and unbound 35S were 
separated using Sephadex columns and the radioactivity in column fractions was measured 
with a scintillation counter. The radioactivity counts for the labelled oligonucleotides are shown 
in table 4.1. 
Oligonucleotide Probe Radioactivity (cpm/pl) Exposure Period 
Tyrosine Hydroxylase 9.2e 4 2 weeks 
Vesicular Monoamine 1e4 7 4 weeks Transporter 2 . 
Doparnine Transporter 9.9e 
4 
2 weeks 
Monoamine Oxidase A 8.5e 4 4 weeks 
D2 receptor 7.4e 
4 4 weeks 
NMDA receptor subunit 1 8.7e 
4 6 weeks 
AMPA receptor subunit GluRl 35.9e 
4 
2 weeks 
5-HT2c receptor 10.6e 
4 4 weeks 
Table 4.1. Radioactivity counts and exposure periods for 35S labelled 
oligonucleotide probes. 
Tissue sections on microscope slides (one slide from each animal, 3 sections per slide) were 
incubated with radiolabelled probe overnight, washed and dried, then exposed to MR Biomax 
film (Amersham Biosciences, UK). A slide containing a 14 C microscale standard was included 
for the purpose of calibration. After an appropriate period of time films were developed using an 
automatic developer (Agfa Curix Daylight Processor) and analysed. Exposure periods for each 
probe can be seen in table 4.1. 
137 
Chapter 4 
4.2.5. Data analysis 
Optical densitometry was used to measure mRNA expression in the VTA. The same 
rostrocaudal level of the VTA from each animal was used for each probe, this being determined 
using the tyrosine hydroxylase signal to "align" the sections between animals. In total 16 slides 
were incubated with each probe - one slide each from eight control animals and eight 
corticosterone treated animals. Separate measurements were made in the clorsolateral, 
ventrolateral, dorsomedial, and ventromedial regions of the VTA and optical density for each 
subregion was averaged between the left and right sides of the brain. Optical density was also 
measured across the whole VTA and averaged between the left and dght sides of the brain. 
Optical densitometry readings from a 14C standard microscale included in each experiment 
were plotted to obtain a calibration graph. Optical densitometry values measured in the VTA 
were then converted to values expressed in nCi/g of brain tissue from this standard curve. 
Statistical analysis was carried out using 2-way repeated measures ANOVA to look for effects 
of treatment and VTA region. Where an interaction of treatment and region was found Student's 
unpaired Mest was performed on data from each VTA region to determine in which regions 
significant effects occurred. Comparison of expression levels across the whole VTA was 
performed using Student's unpaired Mest. 
138 
Chapter 4 
4.3. Results 
4.3.1. Corticosterone treatment 
Animals were treated with vehicle or corticosterone for 15 days. Animals gained weight 
steadily throughout the experiment (see figure 4.2. ). At 15 days animal weights did not differ 
significantly between treatment groups (vehicle treated 294 ±4g, n=8; corticosterone treated 
293 ±4g, n=8; p>0.05). At 15 days water consumption per cage did not differ significantly 
between treatment groups (vehicle treated 245 ± 11 ml/cage/2 days, n=2; corticosterone treated 
271 ± 25 ml/cage/2 days, n=2; p>0.05) (see figure 4.3. ). 
Adrenals were removed from four animals in each treatment group following sacrifice. Adrenal 
weight was significantly lower in corticosterone treated animals than vehicle treated animals 
(corticosterone treated 14.5 ± 2.2 mg, n=4; vehicle treated 28.8 ± 0.9 mg, n=4; p<0.01) (see 
figure 4.4. ) consistent with the known effects of this method of corticosterone administration 
(see chapter 2). 
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Figure 4.2. Animal weights during vehicle (n=8) and corticosterone (n=8) treatment. 
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Figure 4.3.2 day water consumption per cage of four rats treated with vehicle (n=2 cages) or 
corticosterone (n=2 cages). 
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Figure 4.4. Adrenal weights at 15 days in vehicle (n=4) and corticosterone treated (n=4) 
animals (* p<0.01). 
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4.3.2. Tyrosine hydroxylase mRNA expression 
Tyrosine Hydroxylase mRNA was seen expressed abundantly in the VTA, and adjacent 
doparninergic cells groups such as the substantia nigra. No expression was seen outside these 
regions (see figure 4.5. ). Figure 4.6. shows the sub-regional expression levels within the VTA in 
vehicle and corticosterone treated animals. 
Figure 4.5. Tyrosine hydroxylase mRNA in the ventral midbrain. DL= dorsolateral; DM = 
dorsomedial; VL = ventrolateral; VM = ventromedial. 
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Figure 4.6. Tyrosine hydroxylase mRNA signal in subregions of the VTA in vehicle (n=8) and 
corticosterone (n=8) treated animals. 
Lateral Medial 
Vehicle Cort Vehicle Cort 
Dorsal 155 ±3 nCi/g 170 3 nCi/g 101 ± 3. nCi/g 116 ±4 nCi/g 
Ventral 157 ±6 nCi/g 182 6 nCi/g 199 ±6 nCi/g 222 ±5 nCi/g 
Main effect of treatment F[i 14]= 29.0 P<0.001 
Main effect of VTA sub-region F[3,42] = 179.1 P<0.001 
Treatment x sub-region interaction F[3,42] =0.3 n. s. 
Table 4.2. Two-way repeated measures ANOVA of tyrosine hydroxylase mRNA signal in sub- 
regions of the VTA. 
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A 14% increase in TH mRNA expression was seen in corticosterone treated animals across 
the VTA as a whole (vehicle: 147 ±3 nCi/g; cort treated: 168 ±5 nCi/g; p<0.01). Two-way 
repeated measures ANOVA revealed that the effect of corticosterone treatment was consistent 
across sub-regions of the VTA (see table 4.2. ). 
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4.3.3. Vesicular monoamine transporter 2 mRNA expression 
VMAT2 mRNA was seen expressed abundantly in the VTA and adjacent substantia nigra. A 
high level of expression was also seen in the medial mamillary nucleus (see figure 4.7. ). Figure 
4.8. shows the subregional expression levels within the VTA. 
Figure 4.7. VMAT2 mRNA in the ventral midbrain. DL= dorsolateral; DM = dorsomedial; VL = 
ventrolateral; VM = ventromedial. 
144 
Chapter 4 
280 
260 
240 
220 
200 
180 
160 
140 
120 
_0 
U) 100 Ln 
m 
80 
60 
40 
20 
0 
ý Vehicle treated 
E= Cort treated 
Dorsolateral Ventrolateral Dorsomedial Ventromedial 
Figure 4.8. VMAT2 mRNA signal in subregions of the VTA in vehicle (n=8) and corticosterone 
(n=8) treated animals. 
Lateral Medial 
Vehicle Cort Vehicle Cort 
Dorsal 204 ±9 nCi/g 242 ±8 nCi/g 99 ±2 nCi/g 109 ±3 nCi/g 
Ventral 180 ±7 nCi/g 213 ±5 nCi/g 153 ±7 nCi/g 172 ±5 nCi/g 
Main effect of treatment F[I 14]= 26.0 P<0.001 
Main effect of VTA sub-region F[3,42]= 200.1 P<0.001 
Treatment x sub-region interaction F[3,421 =1 -0 n. s. 
Table 4.3. Two-way repeated measures ANOVA of VMAT2 mRNA signal in sub-regions of the 
VTA. 
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There was a 13% increase in VMAT2 expression across the whole VTA following 
corticosterone treatment (vehicle: 158 ±4 nCi/g, cort: 175 ±5 nCi/g; p<0.01). Two-way repeated 
measures ANOVA revealed that the effect of corticosterone treatment was consistent across 
sub-regions of the VTA (see table 4.3. ). 
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4.3.4. Dopamine transporter mRNA expression 
Doparnine transporter mRNA showed strong expression and was found exclusively in the 
doparninergic cell groups of the substantia nigra and VTA (see figure 4-9). Regional expression 
within the VTA can be seen in figure 4.10. 
No significant effect of corticosterone treatment was found across the VTA as a whole 
(vehicle: 105 ±4 nCi/g, cort: 104 ±3 nCi/g; p>0.05). Two-way repeated measures ANOVA 
confirmed the lack of effect across sub-regions of the VTA (see table 4.4. ). 
Figure 4.9. DAT mRNA in the ventral midbrain. DL= dorsolateral; DM = dorsomedial; VL = 
ventrolateral; VM = ventromedial. 
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Figure4.10. DAT m RNA signal in subregions of the VTA in vehicle (n=8) and corticosterone 
(n=8) treated animals. 
Lateral Medial 
Vehicle Cort Vehicle Cort 
Dorsal 138 ±7 nCi/g 128 ±6 nCi/g 74 ±4 nCi/g 71 ±3 nCi/g 
Ventral 135 ±7 nCi/g 134 ±6 nCi/g 91 ±2 nCi/g 95.4 ±2 nCi/g 
Main effect of treatment F[j 0 , 14] ' -1 n. s. 
Main effect of VTA sub-region F[3,42] ": 103.3 P<0.001 
Treatment x sub-region interaction F[3,42] =0-9 n. s. 
Table 4.4. Two-way repeated measures ANOVA of DAT mRNA signal in sub-regions of the 
VTA. 
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4.3.5. Monoamine oxidase A mRNA expression 
Low to moderate expression of monoamine oxidase A mRNA was observed in the VTA as 
well as the substantia nigra. Expression was also seen in the CA1, CA2 and CA3 regions of the 
hippocampus, medial mamillary nucleus, and the amygdala (see figure 4.11. ) The signal 
intensities across VTA subregions can be seen in figure 4.12. 
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Figure 4.11. MAO-A mRNA in the ventral midbrain. DL= clorsolateral; DM = dorsomedial, VL = 
ventrolateral; VM = ventromedial. 
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Figure 4.12. MAO-A mRNA signal in subregions of the VTA in vehicle (n=8) and corticosterone 
(n=8) treated animals. 
Lateral Medial 
Vehicle Cort Vehicle Cort 
Dorsal 23.2 ± 15.6 nCi/g 23.7 ± 1.3 nCi/g 21.9 ± 1.0 nCi/g 24.6 ± 1.6 nCi/g 
Ventral 24.0 ± 0.7 nCi/g 25.8 ± 1.9 nCi/g 26.9 ± 1.0 nCi/g 28.5 ± 2.0 nCi/g 
Main effect of treatment F[1,13] 0.7 n. s. 
Main effect of VTA sub-region F[3,391 9.2 P<0.001 
Treatment x sub-region interaction F[3,391 0.5 n. s. 
Table 4.5. Two-way repeated measures ANOVA of MAO-A mRNA signal in sub-regions of the 
VTA. 
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No significant effect of treatment was found across the VTA as a whole (vehicle: 24.5 ± 0.8 
nCi/g, cort: 26.5 ± 1.4 nCi/g; p>0.05). Two-way repeated measures ANOVA confirmed no 
significant effect of corticosterone treatment on signal intensity across sub-regions of the VTA 
(see table 4.5. ). 
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4.3-6. D2 receptor mRNA expression 
D2 receptor mRNA expression was found to be of relatively low intensity compared to 
background signal in both the VTA and substantia nigra, however, signal was selectively found 
in these areas (see figure 4.13. ). The subregional signal intensities in the VTA can be seen in 
figure 4.14. 
a 
I -* 
a 
Figure 4.13. D2 mRNA in the ventral midbrain. DL= clorsolateral; DM = dorsomedial; VL 
ventrolateral; VM = ventromedial. 
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Figure 4.14. D2 mRNA signal in subregions of the VTA in vehicle (n=8) and corticosterone 
(n=8) treated animals. 
Lateral Medial 
Vehicle Cort Vehicle Cort 
Dorsal 29.1 ± 1.5 nCi/g 30.4 ± 0.9 nCi/g 20.9 ± 0.9 nCi/g 24.4 ± 1.1 nCi/g 
Ventral 27.8 ± 1.8 nCi/g 35.0 ± 1.5 nCi/g 20.7 ± 1.3 nCi/g 25.9 ± 1.1 nCi/g 
Main effect of treatment F[1,131 7.8 P<0.05 
Main effect of VTA sub-region F(3,391 42.8 P<0.001 
Treatment x sub-region interaction F[3,39] 2.5 p=0.07 
Table 4.6. Two-way repeated measures ANOVA of D2 mRNA signal in sub-regions of the 
VTA. 
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Across the VTA as a whole there was 19% increase in D2 mRNA in corticosterone treated 
animals (vehicle: 23.8 ± 1.2 nCi/g, cort treated: 28.4 ± 0.9 nCi/g; p<0.01). This was confirmed by 
two-way repeated measures ANOVA where a statistically significant main effect of treatment 
was found and a trend towards an interaction between the effect of treatment and region (see 
table 4.6. ). 
As there was a trend towards an interaction between effect of treatment and VTA sub-region 
analysis of sub-regional effects was carried out. Student's Mest revealed significant increases in 
D2 mRNA following corticosterone treatment in all regions except the dorsolateral VTA (see 
table 4.7. ). In addition increases in expression in the ventral portion of the VTA were relatively 
larger than that seen in the clorsomedial VTA. 
Lateral Medial 
Dorsal 5% increase 17% increase 
n. s. p<0.05 
Ventral 26% increase 25% increase 
P<0.01 P<0.01 
Table 4.7. Regional differences in the effect of corticosterone treatment on D2 mRNA 
expression in the VTA. 
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4.3.7. NMDA receptor subunit I mRNA expression 
Expression of NMDAR1 subunit mRNA in the midbrain was widespread, with high expression 
in the CA1, CA2 and CA3 regions of the hippocampus and the amygdala, and lesser expression 
in the periaqueductal grey region and the cortex. Expression in the VTA was found to be 
relatively low compared to these regions (see figure 4.15). Signal intensities in the VTA can be 
seen in figure 4.16. 
" 
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Figure 4.15. NMDAR1 mRNA in the ventral midbrain. DL= clorsolateral; DM = dorsomedial-, 
VL = ventrolateral; VM = ventromedial. 
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Figure 4.16. NMDAR1 mRNA signal in subregions of the VTA in vehicle (n=8) and 
corticosterone (n=8) treated animals. 
Lateral Medial 
Vehicle Cort Vehicle Cort 
Dorsal 29.98± 1.9 nCi/g 29.3 ± 1.5 nCi/g 29.7 ± 1.6 nCi/g 28.5 ± 1.6 nCi/g 
Ventral 29.4 ± 1.5 nCi/g 30.8 ± 1.5 nCi/g 30.2 ± 1.6 nCi/g 31.8 ± 1.8 nCi/g 
Main effect of treatment F[i 14) 0.02 n. s. 
Main effect of VTA sub-region F[3,42) 1 -0 n. s. 
Treatment x sub-region interaction F[3,42] 0.7 n. s. 
Table 4.8. Two-way repeated measures ANOVA of NMDAR1 mRNA signal in sub-regions of 
the VTA. 
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There was no effect of treatment on mRNA across the VTA as a whole (vehicle: 30.9 ± 1.4 
nCi/g, cort: 30.7 ± 1.1 nCi/g; p>0.05). Two-way repeated measures ANOVA revealed no 
significant main effect of treatment on mRNA expression across sub-regions of the VTA (see 
table 4.8. ). 
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4.3.8. AMPA receptor GluRl subunit mRNA expression 
Similar to the pattern of expression seen with NMDAR1, GluRl expression was widespread 
and particularly intense in the hippocampal CA1, CA2 and CA3 regions and the amygdala. 
Lesser expression was seen in the periaqueductal grey region, the cortex, and interpeduncular 
nucleus, whilst in the VTA expression was of a relatively low intensity (see figure 4.17. ). 
VTA 
Figure 4.17. GluRl mRNA in the ventral midbrain. DL= dorsolateral; DM = clorsomedial; VL 
ventrolateral; VM = ventromedial. 
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Figure 4.18. GluRl mRNA signal in subregions of the VTA in vehicle (n=8) and corticosterone 
treated (n=8) animals. 
Lateral Medial 
Vehicle Cort Vehicle Cort 
Dorsal 12.8 ± 0.6 nCi/g 9.0 ± 0.5 nCi/g 8.4 ± 0.4 nCi/g 6.9 ± 0.4 nCi/g 
Ventral 17.3 ± 0.7 nCi/g 15.0 ± 0.5 nCi/g 9.3 ± 0.5 nCi/g 7.6 ± 0.2 nCi/g 
Main effect of treatment F11,13] = 23.1 P<0.001 
Main effect of VTA sub-region F[3,39] = 120.9 P<0.001 
Treatment x sub-region interaction F(3,391 = 3.4 P<0.05 
Table 4.9. Two-way repeated measures ANOVA of GluRl mRNA signal in sub-regions of the 
VTA. 
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Across the whole VTA there was a 15% decrease in GluRl mRNA transcription following 
corticosterone treatment (vehicle: 10.6 ± 0.2 nCi/g, cort treated: 9.0 ± 0.2 nCi/g; p<0.001). Two- 
way repeated measures ANOVA confirmed the main effect of treatment and demonstrated a 
significant interaction between VTA sub-region and the effect of treatment (see table 4.9. ). 
Sub-regional differences in the effect of corticosterone were analysed with Student's Mest 
which revealed significant decreases in expression in all regions, with a relatively larger 
decrease in the dorsolateral region compared to other areas (see table 4.10). 
Lateral Medial 
Dorsal 29% decrease 18% decrease 
P<0.001 P<0.05 
14% decrease 19% decrease Ventral 
p<0.05 P<0.05 
Table 4.10. Regional differences in the effect of corticosterone on GluRl mRNA expression in 
the VTA. 
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4.3.9.5-HT2c receptor mRNA expression 
Expression of mRNA for the 5-HT2c receptor was widespread and particularly intense in the 
choroid plexus and in the substantia nigra pars compacta. Lesser expression was seen in the 
periaqueductal grey region and in the dorsomedial geniculate nucleus. In contrast to these 
regions expression in the VTA was of relatively low intensity (see figure 4.19. ), 
.1 
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Figure 4.19.5-HT2C mRNA in the ventral midbrain. DL= clorsolateral; DM = dorsomedial; VL 
ventrolateral; VM = ventromedial. 
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Figure 4.20.5-HT2C mRNA signal in subregions of the VTA in vehicle (n=8) and corticosterone 
(n=8) treated animals. 
Lateral Medial 
Vehicle Cort Vehicle Cort 
Dorsal 13.3 ± 9.8 nCi/g 9.5 ± 2.5 nCi/g 10.6 ± 4.5 nCi/g 8.3 ± 4.4 nCi/g 
Ventral 17.6 ± 1.4 nCi/g 13.0 ± 0.8 nCi/g 7.9 ± 0.4 nCi/g 7.7 ± 0.6 nCi/g 
Main effect of treatment F[i 9.4 , 131 P<0.01 
Main effect of VTA sub-region F[3,391 50.2 P<0.001 
Treatment x sub-region interaction F[3,391 3.2 p<0.05 
Table 4.11. Two-way repeated measures ANOVA of 5-HT2C mRNA signal in sub-regions of 
the VTA. 
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Due to the low level of expression in the VTA measurements were made of background signal 
present on the photographic film. On average, background signal adjacent to tissue sections 
was 2 nCi/g (n=8). This was significantly lower (p<0.01) than the mean signal in the 
dorsomedial VTA - the region with the weakest signal. The measured signal in tissue sections 
is therefore representative of mRNA binding in the VTA. 
Across the whole VTA there was 23% decrease in 5-HT2C signal following corticosterone 
treatment (vehicle: 10.9 ± 0.4 nCi/g, cort treated: 8.4 ± 0.4 nCi/g; p<0.05). Two-way repeated 
measures ANOVA showed a significant main effect of corticosterone treatment and an 
interaction between treatment and VTA sub-region (see table 4.11. ). 
Sub-regional effects of corticosterone were tested using Student's Mest. This demonstrated a 
consistent effect in all regions except for the ventromedial region where there was no effect of 
corticosterone treatment (see table 4.12). 
Lateral Medial 
Dorsal 29% decrease 21 % decrease 
P<0.01 p<0.05 
Ventral 26% decrease 2% decrease 
p<0.05 n. s. 
Table 4.12. Regional differences in the effect of corticosterone on 5-HT2C mRNA expression 
in the VTA. 
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4.4. Discussion 
4.4.1. Principal Findings 
This chapter describes the effects of a subtle modulation of corticosteroid secretion, designed 
to mimic endocrine abnormalities seen in bipolar disorder, on the transcription of mRNA for key 
proteins involved in doparninergic neurone function in the VTA. In-situ hybridisation 
histochernistry usin g 35S labelled oligonucleotide probes and optical densitometry of exposed 
films was used to measure this effect. It was found that corticosteroid treated animals had 
significantly increased levels of mRNA for the dopamine synthetic enzyme tyrosine hydroxylase, 
the vesicular monoamine transporter (VMAT2) responsible for dopamine uptake into synaptic 
vesicles, and the dopamine D2 autoreceptor. In addition corticosterone treated animals 
demonstrated lower mRNA expression for the GluRl subunit of the excitatory AMPA receptor, 
and the inhibitory 5-HT2c receptor (see table 4.13. ). 
Probe Effect of cort on mRNA transcription 
TH 14% 
VMAT2 13% 
DA T 
MAO-A - 
D2 19% 
NMDAR1 - 
GluRl 15% 
5-HT2C 23%j 
Table 4.13. The effect of corticosterone on mRNA transcription in the VTA as a whole. 
To confirm the specificity of the probes used, the patterns of expression were compared to 
those seen in other studies in the literature. In all cases mRNA distributions were consistent 
with previous reports (see table 4.14. for references). 
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mRNA Probe 
TH Nicot et al. 1995 
Lucas et al. 1998 
Palkovits et al. 1999 
Dietz et al. 2005 
Shepard et al. 2005 
VMA T2 Hoffmann et al. 1998 
Cordeiro et al. 2002 
Schwartz et al. 2003 
DAT Letchworth et al. 1999 
Romero-Ramos et al., 2000 
Lipska et al. 2003 
Dietz et al. 2005 
Shepard et al. 2005 
MAO-A Luque et al. 1995 
D2 Aubert et al. 1997 
Stefanski et al. 2007 
NMDARI Laurie and Seeburg, 1994 
Fitzgerald et al. 1995 
Paquet et al. 1997 
Rafiki et al. 1998 
Lu et al. 1999 
Guilarte et al. 2000; 
G1uRI Brene et al. 1998 
Grignaschi et al. 2004 
5-HT2C Holmes et al. 1995 
Eberle-Wang et al. 1997 
Huang et al. 2006 
Table 4.14. Literature references for comparison of mRNA distributions. 
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It is interesting to note that whilst for the most part mRNA coding for proteins intrinsically 
involved in doparninergic neurotransmission (specifically TH, VMAT2, DAT, and the D2 receptor) 
was restricted to the doparninergic nuclei of the VTA and substantia nigra, intense VMAT2 
expression was also observed in the mamillary nucleus. This may reflect the presence of 
histaminergic neurones in this region (see Erickson et al. 1995) which employ VMAT2 for 
vesicular uptake (Erickson et al. 1995; Hofmann et al. 1998). 
In contrast to the above probes, mRNA coding for the glutamate receptor subunits NMDAR1 
and GluRl, and the 5-HT2c receptor demonstrated a much wider distribution within the brain 
sections. Particularly intense expression was seen with all three probes in the hippocampus, 
with expression in most other regions throughout the midbrain. In the case of the NMDAR1 and 
GluRl mRNAs this may be explained by the ubiquity of glutarnatergic signalling throughout the 
brain. The widespread distribution of 5-HT2c receptor mRNA also suggests that serotonergic 
signalling is present in a wide variety of regions at this level of the midbrain. 
Differences in mRNA expression between sub-regions of the VTA were found with all probes 
except the NMDA receptor subunit 1. These differences in expression levels show a general 
pattern towards a lateral-medial gradient with higher expression in the ventrolateral VTA and 
lower levels in the dorsomedial VTA for most probes. An interesting exception to this was the 
tyrosine hydroxylase probe whose binding was highest in the ventromedial region, in contrast to 
all other probes. There is little evidence from this study that other characteristic doparninergic 
cell components (such as VMAT2, DAT and D2 receptor) follow a similar pattern of expression 
to TH in the VTA. This suggests that regional variations do not relate to dopaminergic cell 
density as this would have led to similar patterns of expression. 
One possible explanation is that mRNA expression differs between doparninergic cells 
projecting to different regions of the brain. For example, D2 mRNA levels were lowest in the 
clorsomedial VTA and highest in the lateral VTA (dorsal and ventral regions). As there is 
evidence to suggest that projections to the nucleus accumbens arise in the ventrolateral VTA, 
whilst ventral prefrontocortical projections have been suggested to arise in the dorsomedial (but 
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not the ventrolateral) VTA, the differences in mRNA expression may relate to differences in D2 
autoreceptor function between these projections (see chapter 1 section 3.5. ). 
For both GluRl and 5-HT2C mRNA's there was a tendency for higher expression in lateral 
regions of the VTA. it is possible that for these probes in particular the differences reflect a 
higher density of innervation by glutamatergic and serotonergic afferents (respectively) in the 
lateral portion of the VTA. Alternatively, the fact that these receptors may be present on other 
cell types in the VTA suggests that the results could reflect cell density or expression levels in 
non-dopaminergic cells. 
Overall the differences in mRNA expression between subregions are not discussed in detail 
principally because this chapter is concerned with the effect of corticosteroids on mRNA 
expression. Whilst it is interesting that basal levels of expression differ. it is beyond the scope of 
this study to explain why these differences occur or to determine the functional consequences 
of such differences. 
For some of the probes (D2, GluR1 and 5-HT2C) sub-regional differences in the magnitude of 
the corticosteroid effect were found (see table 4.15. ). These are discussed in greater detail in 
the following sections, however it is important to note that whilst the magnitude of the effect 
varied, an increase in one subregion and a decrease in another were never observed. Thus 
transcriptional regulation does not fundamentally differ between VTA subregions. 
Probe Dorsolateral VTA 
Ventrolateral 
VTA 
Dorsomedial 
VTA 
Ventromedial 
VTA 
D2 5% 26% 17% T 25% T* 
GluRl 29% 14% 18% 1 19%j- 
5-HT2c 29% 26% 21% 1 2%j 
Table 4.15. Subregional effects of corticosterone administration on mRNA expression in the 
VTA. (* p<0.05; ** P<0.01; *** P<0.001). 
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4.4.2. Effect of corticosterone administration on hyrosine hydroxylase mRNA expression 
Tyrosine hydroxylase is the rate limiting enzyme in catecholamine synthesis and a major 
determinant of intracellular clopamine availability. The results of this study show that flattening of 
the corticosteroid rhythm with exogenous corticosterone elevates the expression of mRNA for 
tyrosine hydroxylase by 14% in the VTA. 
The fact that TH mRNA transcription can be modulated by corticosteroids is supported by a 
number of studies in the literature. Czyrak et al (2003) claimed to find an increase in TH mRNA 
in the rat VTA with chronic corticosterone treatment (although as yet the original data has not 
been published). Perhaps more convincingly, increases in TH transcription have been 
demonstrated in the rat adrenal medulla and in pheochromocytorna cell lines following 
administration of corticosteroids (Baetge et al. 1981; Tank et al. 1986; Kumai et al. 2000). This 
upregulation of TH transcription by corticosteroids is consistent with a large body of work 
looking at the interaction between stress and TH transcription. Such studies may be taken as 
indirect evidence for corticosteroid regulation of transcriPtion on the basis that corticosteroid 
secretion is increased by stress. The majority of this work has been carried out in peripheral 
adrenergic and central noradrenergic systems where a variety of different stressors have been 
shown to increase transcription of tyrosine hydroxylase in the adrenal medulla and sympathetic 
ganglia (reviewed by Sabban and Kvetnansky, 2001; Stachoviak et al. 1986) and in the rat 
locus coeruleus (the major noradrenergic nucleus in the brain) (Mamalaki et al. 1992; Wang et 
al. 1998; Serova et al. 1999; Chang et al. 2000; Sabban and Kvetnansky, 2001). Only one study 
has looked at stressor effects on TH transcription in midbrain doparninergic areas. Similar to the 
studies discussed above, it was shown that acute and chronic immobilisation stress produces 
an increase in TH mRNA compared to controls in the rat VTA (Serova et al. 1999). 
Although the present study did not investigate the mechanism by which corticosteroids induce 
TH transcription, Hagerty et al. (2001 a and 2001b) have demonstrated the presence of a GRE 
in the promoter region of the mouse tyrosine hydroxylase gene. This GRE has been shown to 
be sufficient to confer maximal positive transcriptional regulation by glucocorticoids. As the 
mouse TH gene (1-22651) and the rat TH gene (NM_009377) are homologous (BLAST search 
www. ncbi. nlm. nih. gov/BLAST/) this GRE is likely to be present in the rat TH gene also. This 
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suggests that the corticosteroid effect on TH transcription is produced directly via binding of GR 
to the gene. 
Whilst previous studies have established the principle that TH is regulated by corticosteroids, 
and identified a potential mechanism, the present studies provide the first evidence that a subtle 
manipulation of corticosteroid levels modelling the flattened circadian rhythm seen in bipolar 
disorder can also alter TH mRNA transcription in the VTA. 
4.4.3. Effect of corticosterone administration on VMA T2 mRNA expression 
VMAT2 is the vesicular transporter responsible for the uptake of dopamine into synaptic 
vesicles and plays a role in determining the magnitude of dopamine release at the synapse. 
This study showed that elevating the nadir in the diurnal corticosteroid rhythm produced a 13% 
increase in VMAT2 mRNA levels in the VTA. 
Although the effect of corticosteroids on VMAT2 mRNA expression has not previously been 
examined, one study looking at the effects of long-term repeated immobilisation stress and 
novel stressors showed an increase in VMAT2 mRNA in the medullary noradrenergic cell 
groups Al and A2 (Rusnak et al. 2001). This provides indirect evidence that corticosteroids can 
increase VMAT2 mRNA and so may influence vesicular uptake. Interestingly, chronic 
administration of dexamethasone has been shown to increase the catecholamine content of 
synaptic vesicles in the carotid body (Hellstrom and Koslow, 1975), and it is possible that this 
increase in catecholamine storage is a result of corticosteroid induced VMAT2 transcription. 
Whilst the above studies, and the present data, suggest that elevated corticosteroid levels 
facilitate VMAT2 transcription and function, this is put into question by published data showing a 
reduction in VMAT2 binding in the mesolimbic terminal regions of the nucleus accumbens and 
striaturn following repeated restraint stress (Zucker et al. 2005). It is important to note however 
that stress paradigms provide only indirect evidence for corticosteroid mediated effects. 
Furthermore it is possible that this decrease in binding is due to a post-transcriptional effect i. e. 
a reduction in protein synthesis, a change in post-translational modification, or a reduction in 
transporter binding induced by protein phosphorylation. The discrepancy between changes in 
mRNA levels and levels of protein (see Gygi et al. 1999) is a problem when trying to extrapolate 
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functional consequences from in-situ hybridisation data. In the case of corticosteroids, as it is 
likely that their effects are mediated by changes in gene transcription, it is of value to know that 
changes in mRNA levels occur. 
The present data suggest that, as a consequence of flattening the corticosteroid rhythm, there 
is the potential for VMAT2 protein levels and VMAT2 function to be increased in doparninergic 
neurones. It is the case however that further studies are needed to see whether the increase in 
mRNA transcription is mirrored by an increase in protein levels and transporter function (see 
chapter 5. ). 
Whilst the effects on VMAT2 gene transcription seen in this study may result from a direct 
effect of corticosterone, it is possible that the induction of VMAT2 transcription was secondary 
to increased tyrosine hydroxylase transcription and increased dopamine synthesis. It would be 
unsurprising to find that vesicular uptake capacity increases with synthetic capacity to allow the 
surplus dopamine to be utilised. Conversely increased VMAT2 activity (resulting from increased 
transcription) may have induced the transcription of TH. Close coupling of tyrosine hydroxylase 
and vesicular uptake has been demonstrated by Chen et al. (2003), who showed that disrupting 
the proton gradient of synaptic vesicles (required for VMAT2 activity) abolishes the ability of 
ATP to increase TH activity. Increased VIVIAT2 activity might also be expected to decrease 
cytoplasmic dopamine concentrations, which in turn could reduce end product inhibition of TH 
activity. it is possible that functional interactions between these proteins might affect 
transcription of their respective genes. 
When the increase in VMAT2 throughout the whole VTA is compared with the effect on TH 
expression it can be seen that they parallel one another, with a 14% increase in TH expression 
and a 13% increase in VMAT2. It is therefore tempting to suggest that VMAT2 transcription is in 
some way linked to TH mRNA levels. It is the case, however, that in vehicle treated animals the 
pattern of TH expression across VTA subregions did not parallel that of VMAT2. For example, 
the highest subregional expression of TH occurred in the ventromedial VTA, whilst for VMAT2 
the highest expression was seen in the dorsolateral VTA. Whilst this is a significant caveat, it is 
also true that the effect of corticosteroid treatment did not differ across VTA subregions for 
170 
Chapter 4 
either probe. Thus the effect of corticosteroid treatment on TH and VMAT2 transcription was 
parallel in all VTA subregions. 
Concomitant changes in TH and VMAT2 protein levels in the mouse striatum have been 
observed following prenatal heptachlor treatment (which increased protein levels; Caudle et al. 
2005) and in iron regulatory protein knockout mice (which decreased protein levels in the 
ventral striaturn only; Salvatore et al. 2005). It is possible however that the decreases observed 
by Salvatore et al. (2005) were the result of doparninergic cell loss rather than 
transcriptional/translational regulation. Long term immobilisation stress has been shown to 
increase TH and VMAT2 mRNA in the Al and A2 noradrenergic cell groups (Rusnak et al. 
2001). It is significant however that in the locus coeruleus an increase was found in TH mRNA 
but not VMAT2 mRNA (Rusnak et al. 2001). Similarly Bergzon et al. (1999) found that kainic 
acid seizures transiently increase TH mRNA in the locus coeruleus but not VMAT2 mRNA. The 
relevance of this last study may be limited however by the fact that the transient increase 
occurred 48 hours after treatment and had normalised to basal levels after two weeks. It may be 
the case that VMAT2 transcriptional induction requires a long term change in TH mRNA levels 
and thus wasn't seen by Bergzon et al. (1999). To summarise there is not currently enough 
evidence in the present study, or the literature to support the theory that the changes in TH and 
VMAT2 mRNA are directly linked. Thus whilst it is an interesting observation, further work is 
required to determine the degree of transcriptional and functional coupling between TH and 
VMAT2. 
4.4.4. Effect of corticosterone administration on dopamine transporter mRNA expression 
The dopamine transporter is an important regulator of cloparninergic neurotransmission, the 
activity of which determines the time course of dopamine removal from the synapse and its 
ability to diffuse to postsynaptic sites. No change in doparnine transporter mRNA expression as 
a consequence of corticosterone administration was seen in this study. In the literature, the 
effect of corticosteroids and stress on DAT mRNA expression and function appear to be 
complex and vary by brain region. Although one study found an increase in midbrain (no 
distinction made between A8, A9 and A10 cell groups) DAT mRNA in response to repeated 
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restraint stress (Copeland et al. 2005), GR antisense partial knockout in rats has been shown to 
be without effect on DAT mRNA in the substantia nigra (Cyr et al. 2001) 
Of some relevance to the present study are the findings of Filipenko et al. (2001) who have 
shown a positive correlation between increases in TH mRNA and DAT mRNA levels in the rat 
VTA in winners of repeated social victory experiments, suggesting that their expression is in 
some way linked. The present data showing an increase in TH mRNA following corticosteroid 
administration but no effect on DAT mRNA, suggests that the effect on DAT mRNA seen by 
Filipenko et al. was not corticosteroid mediated - indeed it might be expected that circulating 
corticosteroid levels would be higher in the losers of social victory experiments due to the 
stressful nature of the defeat, and therefore Filipenko's data may not be directly comparable 
with the results of the present study. Studies looking at DAT protein levels in the mouse striaturn 
have found that TH, VMAT2 and DAT increase in animals prenatally exposed to heptachlor 
(Caudle et al. 2005) whilst iron regulatory protein knockout mice have decreased levels of these 
proteins in the ventral striatum (Salvatore et al. 2005). This provides further evidence that the 
expression of these proteins is linked, however the present data suggests no interaction at the 
transcriptional level between these proteins. Furthermore as discussed in section 4.4.3. the data 
obtained by Salvatore et al. (2005) may reflect a loss of nigrostriatal DA neurones rather than a 
co-regulatory mechanism. Thus there is little evidence to suggest that TH transcription affects 
DAT transcription as a secondary effect of corticosterone treatment. 
No evidence for a genomic modulation of VTA DAT expression was found in the present 
study following flattening of the corticosteroid rhythm. Furthermore the literature provides scant 
evidence for a corticosteroid mediated effect on DAT protein expression given that the effect 
differs by stress paradigm. 
4.4.5 Effect of corticosterone administration on MAO-A mRNA expression 
MAO-A is present within clopaminergic terminals and is the first enzyme in the intraneuronal 
metabolic pathway for dopamine. The majority of dopamine metabolism occurs by this 
intraneuronal route (see chapter 1) and as a consequence MAO-A activity critically affects 
cytoplasmic dopamine availability and turnover. No effect of corticosteroid administration on 
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MAO-A mRNA transcription was seen in this study. This is surprising as a glucocorticoid 
response element (GRE) has been identified in the promoter region of the human MAO-A gene 
which upon GR binding promotes MAO-A catalytic activity in human neuroblastoma and 
glioblastorna cell lines (Ou et al. 2006). Furthermore, glucocorticoid receptors promote MAO-A 
transcription indirectly via an interaction with R1/SP1 transcription factor binding at SP1 binding 
sites in neuroblastorna and UW228 cell lines (Ou et al. 2006). It is possible that the subtle 
corticosteroid manipulation used in the present study was insufficient to replicate these effects. 
There is some evidence to suggest that glucocorticoid regulation of MAO-A transcription is 
tissue specific. Thus one study has shown that MAO-A transcription is increased in human 
skeletal muscle cells following dexamethasone treatment (Manoli et al. 2005). In contrast, work 
carried out by Lindley et al. (2005) in the rat brain has shown that neither adrenalectomy nor 
adrenalectomy followed by sustained corticosteroid administration has any effect on MAO-A 
expression in the medial prefrontal cortex or striatum. As MAO-A expression in the prefrontal 
cortex is at least partially dependent on MAO-A gene transcription in the VTA (via the 
mesocortical projection), with the rest likely to come from raphe serotonergic and locus 
coeruleus noradrenergic neurones which also contain corticosteroid receptors, the results of this 
work are in concordance with the results of the present study. The interaction of the 
glucocorticoid receptor with other transcriptional factors demonstrated by Ou et al. (2006) may 
offer an explanation as to how this tissue specificity could arise, as these necessary 
transcription factors may be absent in mesocorticolimbic doparninergic cells. 
4.4.6. Effect of corticosterone administration on D2 receptor mRNA expression 
D2 mRNA in the VTA codes for the dopamine D2 receptor which is localised to doparninergic 
cell bodies in the VTA and terminals in forebrain areas, where it acts as an autoreceptor. D2 
mRNA is also expressed by non-dopaminergic cells in forebrain areas where it codes for post- 
synaptic receptors. Corticosteroid administration was found to increase the expression of D2 
mRNA in the VTA by 19% on average. This effect was greater in the ventral VTA than the 
dorsal VTA, and no effect was seen in the dorsolateral VTA. 
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There is some evidence in the literature to support a role for glucocorticoids in transcriptional 
regulation of D2rnRNA. One study in which high levels of corticosterone were administered to 
rats via pellets (resulting in a >600% increase in plasma corticosterone levels compared to 
sham treated rats) found that D2 mRNA transcription decreased in the striatum but not in the 
nucleus accumbens shell or core (Lammers et al. 1999). The relevance of the mRNA data in 
this study is limited by the fact that D2 mRNA in terminal regions is not located in dopaminergic 
cells, however it does offer evidence that D2 transcription can be regulated by corticosteroids. 
Indirect evidence for corticosteroid regulation of D2 transcription in the VTA is provided by 
Dziedzicka-Wasylewska et al. (1997) who showed a selective decrease in D2 mRNA in the 
lateral VTA following chronic stress. That the effect of chronic stress was opposite to the effect 
seen with administration of corticosteroids in the present study may reflect the fact that chronic 
stress effects are unlikely to be mediated solely by corticosteroids. 
In support of the present data a GRE has been found in the proximal part of the promoter 
region of the D2 gene however it appears to be under complex regulatory control (Lammers et 
al. 1999). The D2 gene expressing the full endogenous promoter is not induced by 
dexamethasone in cultured neuroblastorna cells (Lammers et al. 1999) or primary striatal 
cultures (Valdenaire et al. 1998), although a truncated form of the promoter region did show an 
upregulation of transcriptional activity with dexamethasone in the study by Lammers et al. 
(1999). This truncated form of the gene did not include the GRE, however, suggesting that the 
effect of dexamethasone was indirect. It is possible that in the endogenous gene co-regulatory 
factors are responsible for inhibiting dexamethasone induced transcription in both the 
neuroblastorna and striatal cells. Such factors may not be present in VTA DA cells which might 
explain the upregulation of transcription observed in the present study. 
An alternative explanation is that increases in D2 message in the VTA are indirectly modulated 
by corticosteroids. If doparnine release parallels the increases in TH and VMAT2 mRNA 
induced by corticosteroid administration, D2 transcription may increase as a result of elevated 
extracellular dopamine levels to provide compensatory feedback inhibition of dopaminergic 
neurotransmission. Such an increase in VTA D2 receptor transcription has been observed 
following chronic treatment with the NMDA receptor antagonist MK-801 (Healy and Meador- 
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Woodruff, 1996) which stimulates dopamine release in mesocorticolimbic terminal regions 
(reviewed by Svensson, 2000). 
In summary, flattening the diurnal rhythm of corticosteroid secretion resulted in an increase in 
D2 mRNA in the VTA. This effect was greater in the ventral VTA than the dorsal VTA, with no 
effect seen in the dorsolateral VTA. Relating this to the topography of doparninergic projections 
in the VTA (which is still unclear, see section 4.1.1. ) suggests that mesolimbic projections 
originating in the ventral VTA (such as those terminating in the nucleus accumbens) will see a 
greater increase in D2 transcription than mesocortical projections located in the dorsal VTA 
(such as those projecting to the prefrontal cortex). 
4.4.7. Effect of corticosterone administration on NMDARI expression 
The NMDA receptor is an important regulator of the firing rate of dopamine neurones in the 
VTA, and mediates the switch to burst firing which leads to increased efficiency of dopamine 
release in terminal regions (Charlety et al. 1991; Chergui et al. 1993). The NMDAR1 subunit of 
this receptor contains both the glutamate and glycine binding sites and is essential for the 
formation of functional receptors (Kew and Kemp, 2005). 
No effect of corticosteroid administration was found on NMDAR1 expression in any of the 
regions of the VTA. Although one study has shown that NMDAR1 mRNA expression is 
decreased in the paraventricular nucleus following corticosteroid administration (Lee et al. 
2003), the same study and others have shown no effect on NMDAR1 transcription in the 
hippocampus (Kamphuis et al. 2003; Lee et al. 2003; Weiland et al. 1997). This suggests that 
the effects of corticosteroids are regionally selective. As far as studies in the VTA go, it has 
been shown that voluntary wheel running, which induces increases in corticosteroid secretion, 
has no effect on NMDAR1 subunit expression (Makatsori et al. 2003). Thus the lack of effect on 
NMDAR1 transcription shown in the present study is consistent with previous data. 
In the context of this body of literature, the results of the present study show that NMIDAR1 
subunit protein expression in the VTA is unlikely to be affected by changes to the corticosteroid 
diurnal rhythm seen in affective disorders, however changes in other subunits might occur 
which alter receptor function. The NMDAR1 subunit was chosen as it contains the ligand 
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recognition and glycine binding sites for the receptor complex making the functional 
consequences of changes in transcription somewhat more predictable than with other subunits. 
NMDAR2 subunit expression has been shown to be increased in the hippocampus following 
corticosteroid treatment (Kamphuis et al. 2003; Lee et al. 2003; Weiland et al. 1997), however 
without an increase in NMDAR1 subunit expression the number of functional receptors would 
not be expected to increase. It is possible, however, that changes in ion channel permeability or 
kinetic properties occur as a result of increased NMDAR2 expression. The data from the 
present study does not preclude the possibility that this occurs in the VTA following changes to 
the corticosteroid diurnal rhythm seen in bipolar disorder. 
4.4.8. Effect of corticosterone administration on GluRl expression 
The GluRl protein is one of four subunits which can form the pentameric AMPA receptor and 
its presence favours the formation of a Ca 2+ permeable channel. AMPA receptors have been 
implicated in mediating tonic excitatory input to mesocortical dopaminergic neurones. The 
GluRl subunit is therefore an important regulator of AMPA receptor activity, and hence 
doparninergic: function. 
A 15% decrease in GluRl expression was found in the VTA as a result of corticosteroid 
administration. Subregional differences in the magnitude of the effect were found such that 
expression in the dorsolateral VTA was decreased by a significantly greater amount than other 
regions. The greater decrease in this region suggests that mesocortical efferents (such as those 
projecting to the prefrontal cortex; see section 4.1. ) may experience a greater decrease in 
expression of GluRl than those which project from other regions of the VTA, such as 
mesolimbic nucleus accumbens projection arising in the ventral VTA. 
The negative effect of corticosteroid administration on GluRl expression seen here broadly 
agrees with studies in the published literature. Thus the increase in corticosteroid secretion 
induced by voluntary wheel running has been shown to correlate with decreased GluR1 
expression in the VTA (Makatsori et al. 2003). Functional changes in AMPA receptor mediated 
signal transduction have also been demonstrated with corticosteroid agonists found to reduce 
the response to AMPA agonists and antagonists in the nucleus tractus solitarius, an effect 
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which was shown to be GR mediated (Shank and Scheuer, 2003). It is of note that MR 
mediated effects may be opposite to those mediated by GR as hippocampal GluRl expression 
is reduced by adrenalectomy and this can be reversed with the MR agonist aldosterone 
(Watanabe et al. 2003). This positive mineralocorticoid effect on gene transcription would not be 
seen in studies involving levels of corticosteroids similar, or greater than, those seen under 
normal physiological conditions, as the mineralocorticoid receptor is thought to be close to 
maximally occupied under these conditions (Reul & De Kloet, 1985). As such the 
mineralocorticoid receptor mediated effect does not contradict the data from the present study 
suggesting that GR may downregulate AMPA receptor expression under conditions of 
excessive corticosteroid secretion. Thus in pathological conditions involving a flattened 
corticosteroid diurnal rhythm GluRl expression may be clownregulated, with the potential to 
reduce AMPA receptor mediated signalling. 
4.4.9. Effect of corticosterone secretion on 5-HT2c receptor expression 
Corticosterone administration decreased 5-HT2c receptor expression by 23% in the whole 
VTA. Subregional analysis revealed that this effect was confined to dorsolateral, dorsomedial, 
and ventrolateral regions. It may be significant that the ventromedial region showed the lowest 
level of expression of this mRNA. Given that levels of expression throughout the VTA were low 
it may be the case that the lack of effect in this region was the result of the signal being at the 
limits of discrimination from background. This was shown not to be the case however as 
background signal was much lower than the average signal in the ventromedial VTA suggesting 
that the result in this region was valid. 
In the rat, studies have shown that adrenalectomy increases 5-HT2c receptor mRNA 
expression in the hippocampus and this can be reversed by corticosteroid replacement (Holmes 
et al. 1995). In light of this work it is perhaps unsurprising that in the present study, 
administering corticosterone in the drinking water with the specific aim of elevating the diurnal 
nadir in corticosterone levels resulted in a decrease in 5-HT2c receptor expression. Some work 
has been carried out looking at the functional effects of corticosteroids on 5-HT2c receptors and 
the results of these studies agree with the data discussed so far. Thus in two studies short term 
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administration of dexamethasone (Tozawa et al. 1999) and chronic high doses of corticosterone 
(Berendsen et al. 1996) have been shown to reduce behavioural and biosynthetic responses to 
5-HT2c receptor stimulation. These data suggest that transcriptional changes in response to 
corticosteroids appear to be mirrored in functional changes. 
As mentioned previously it appears that in the VTA the effect of corticosteroids on 5-HT2C 
receptor transcription demonstrates some heterogeneity, with all areas but the ventromedial 
region showing a decrease in expression. Retrograde tracing studies (see section 4.1. ) suggest 
that doparninergic neurones from this region project to the nucleus accumbens but not to the 
prefrontal cortex. Thus corticosteroid 5-HT2c transcriptional regulation may have less of an 
effect on this mesolimbic projection than, for example, prefrontocortically projecting mesocortical 
neurones originating in the dorsal VTA. Overall however the data indicate that flattening the 
corticosteroid rhythm decreases 5-HT2c receptor mRNA transcription in most areas of the VTA. 
4.4.9. Functionai consequences in VTA dopaminergic projections 
When predicting the consequences of alterations in mRNA transcription, as has already been 
mentioned, there is no linear relationship between changes in transcription and protein function 
(see Gygi et al. 1999). This means that any predictions are speculative and must allow for the 
possibility that post-transcriptional modifications and regulatory effects on protein function may 
occur downstream to modulate the effects of the changes in transcription. This can work to 
enhance the transcriptional effects so that a small increase in transcription results in a relatively 
greater change in protein function, or downstream events may counter the effect so that a 
relatively small or no change in protein function occurs. Notwithstanding this caveat, the 
following section discusses the possible functional implications of the mRNA results taken at 
face value. As discussed in section 4.1.1. an attempt has been made to relate any subregional 
differences in corticosteroid effects to functional consequences in mesocortical (prefrontal 
cortex) and mesolimbic (nucleus accumbens) projection systems. 
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Intrinsic Regulators 
This study looked at transcription of mRNA sequences coding for proteins which can be 
classified into two groups. There are the proteins intrinsically involved in dopaminergic neuronal 
function (TH, VMAT2, DAT, MAO-A, and the D2 receptor), and there are the proteins which 
mediate the modulation of doparninergic function by external signals (the NMDA receptor, the 
AMPA receptor, and the 5-HT2c receptor). In the first group, the effect of corticosteroid 
administration was an increase in tyrosine hydroxylase and VMAT2 transcription, with no effect 
on the dopamine transporter or MAO-A. Thus, if these transcriptional changes are mirrored by 
changes in protein levels the predicted result would be an increase in the intracellular doparnine 
concentration (as a result of increased TH activity), an increase in vesicular doparnine content 
(due to increased VMAT2 activity, see Pothos et al. 2000), and as a result, greater release of 
doparnine. In the absence of changes in DAT or MAO-A function this would lead to increased 
synaptic levels of doparnine. It is the case that no changes in doparnine transporter function or 
metabolic monoamine oxidase activity would be predicted from the present results. 
In addition to changes in TH and VMAT2 transcription, corticosteroid treatment increased the 
transcription of D2 mRNA. At the protein level such an increase would counter the hypothesised 
increase in dopamine release by upregulating somatodendritic and terminal autoinhibitory 
feedback mechanisms resulting in a decrease in neuronal firing rate and an inhibition of 
cloparnine synthesis and release. 
From the subregional pattern of corticosteroid effects on D2 transcription such an increase in 
autoinhibtion would be predicted to occur to a greater extent in those neurones projecting from 
the ventral VTA (which may be mesolimbic neurones projecting to the nucleus accumbens; see 
section 4.1. ) compared to those projecting from the dorsal VTA (which are suggested to be 
mesocortical neurones projecting to the prefrontal cortex). It is of particular note that no effect 
was seen in the dorsolateral VTA. This may "dilute" the effect of the increase in D2 m RNA in the 
dorsomedial VTA as far as overall dopamine synthesis and release in cortical regions is 
concerned. Thus in terms of doparninergic neurotransmission it is predicted that corticosteroid 
dysrhythmia increases D2 autoinhibition in mesolimbic neurones by a greater extent than in 
mesocortical neurones. 
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Of further relevance to the dichotomy of mesocortical and mesolimbic projections is the 
suggestion that terminal (but not somatodendritic; see Westerink et al. 1996; 1998) D2 
autoreceptor inhibition is less efficient in the mesocortical system than in the mesolimbic system 
and indeed may not play a role in regulating dopamine synthesis and release under normal 
physiological conditions (see chapter 1 section 1.3-5. ). There are therefore three possibilities 
regarding the effect of corticosteroid dysrhythmia on terminal autoreceptor function in these 
neurones: 
1. The terminal D2 receptor has no physiological role at mesocortical terminals. In this 
scenario doparnine synthesis and release will be restrained only by a reduced firing rate 
mediated by increased somatodendritic autoreceptor function in neurones originating in 
the dorsomedial VTA. 
2. Under normal physiological conditions the terminal D2 receptor does not function, but 
corticosteroid dysregulation increases D2 mRNA transcription in mesocortical neurones 
bringing the terminal receptor "online". In this case the predicted increase in dopamine 
synthesis and release would be restrained in cortical regions by the terminal 
autoreceptor in conjunction with increased somatodendritic autoinhibition. 
3. D2 receptors are present and functional on mesocortical dopamine terminals. As a 
consequence the increase in D2 mRNA transcription restrains the predicted increase in 
dopamine synthesis and release in mesocortical projection neurones via the terminal 
autoreceptor, and decreases the neuronal firing rate via the somatodendritic 
autoreceptor in a similar fashion to that predicted for the mesolimbic system. 
In summary, it is hypothesised that corticosteroid dysrhythmia will increase dopamine 
synthesis and vesicular uptake in all doparninergic neurones in the VTA. The tendency for these 
effects to increase doparnine release will be restrained by increased somatodendritic D2 
receptor inhibition of neuronal firing which will occur to a greater extent in the mesolimbic 
system than the mesocortical system. Furthermore the corticosteroid induced increase in 
terminal autoreceptor inhibition of synthesis and release is predicted to occur to a greater extent 
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in the mesolimbic system than in the mesocortical system, if indeed terminal autoreceptors are 
functional on mesocortical neurones. Thus, overall, any increase in dopamine release is likely to 
be greater in the prefrontal cortex than in the nucleus accumbens. Indeed it might be predicted 
that dopamine synthesis and release might decrease in the nucleus accumbens as a 
consequence of increased autoreceptor inhibition. 
Extrinsic Regulators 
The second group of mRNAs studied were those coding for proteins acting as receptors 
mediating afferent regulation of doparninergic function in the VTA. The effects of corticosteroid 
administration on the transcription of mRNA for these proteins showed much subregional 
heterogeneity and, again, predicting the functional effects is complex. 
The effect of corticosteroid administration on the GluRl subunit of the AMPA receptor 
demonstrated some regional variation, with a much greater effect in the dorsolateral VTA than 
in all other regions. As AMPA receptors are excitatory on dopaminergic neurones (see Meltzer 
et al. 1997; Adell and Artigas, 2004) the inhibition of transcription is likely to result in a decrease 
in the firing rate, with the potential for a greater decrease in dorsolateral VTA neurones than 
neurones present in other areas. Thus prefrontocortical neurones present in the dorsal VTA 
may experience a greater decrease in tonic stimulation than, for example, mesolimbic neurones 
projecting from other regions of the VTA to the nucleus accumbens. Leaving aside the 
subregional differences, it has been suggested that prefrontocortical neurones are under tonic 
stimulation by AMPA receptors in contrast to neurones projecting to the nucleus accumbens 
(Westerink et al. 1996; 1998; Adell and Artigas, 2004) and hence the decrease observed is 
likely to affect mesocortical neurones to a greater extent. 
The reduction in 5-HT2c receptor transcription also displayed regional differences, with no 
effect in the ventromedial VTA and a similar effect in the dorsal and lateral regions. As this 
excitatory receptor is postulated to be present on GABAergic interneurones where it is under 
tonic stimulation (DiMafteo et al. 1999; DiMatteo et al. 2002; Gobert et al. 2000), a reduction in 
its transcription could result in the disinhibition of VTA doparninergic neurones. Based on the 
suggestion that there may be topographical differences within the VTA regarding mesolimbic 
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and mesocortical DA projections, the effect of this may be to increase firing rate, and hence 
terminal release in the mesocortical projections arising from the dorsal tier of the VTA and the 
mesolimbic projections arising in the ventrolateral portion of the VTA. As the ventromedial 
region is populated by mesolimbic neurones projecting to the nucleus accumbens (see section 
4.1. ), it is likely that the decrease in firing rate would be "diluted" in mesoaccumbens neurones 
due to the lack of an effect in this region. 
Overall the data suggest that a relatively subtle alteration of the corticosteroid rhythm could 
have important effects on VTA doparninergic neurotransmission. Moreover topographical 
differences in transcriptional modulation suggest that on balance prefrontocortical projections 
are likely to experience a relatively greater increase in neurotransmission than mesolimbic 
projections. This has the potential to produce an imbalance in the mesocorticolimbic dopamine 
system which might have implications for pathophysiological states which exhibit flattened 
diurnal corticosteroid rhythmicity such as bipolar disorder. 
4.4.10. Pathophysiological correlates of corticosteroid effects 
The alterations in gene expression found in this study correlate well with a number of findings 
in mood disorders in which a flattening of the corticosteroid rhythm can be seen, principally 
bipolar disorder and major depression (particularly psychotic major depression) (see McQuade 
and Young, 2000; Rothschild, 2003). Regarding the observed increase in tyrosine hydroxylase 
expression, post-mortem analysis of brains from patients with major depression has shown 
elevations in tyrosine hydroxylase protein in the locus coeruleus consistent with the results of 
the present study (Zhu et al. 1999). 
VMAT2 binding has been found to be elevated in bipolar disorder in both the thalamus and 
ventral midbrain compared to controls (Zubieta et al. 2002). With regards to major depression, 
elevations in platelet VMAT2 density have been observed with no changes in binding affinity 
(Zucker et al. 2002). These findings are consistent with the elevations in VMAT2 expression 
found in the present study. 
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The increase in D2 receptor mRNA expression in the present study could be considered 
consistent with the therapeutic efficacy of antipsychotics as a component of combination 
therapies in the treatment of manic and depressive episodes (for reviews see Surja et al. 2006; 
Wijkastra et al. 2007). There is however little evidence that D2 receptor expression is altered in 
bipolar disorder, where PET studies have shown no alterations in striatal D2 binding in manic 
and euthymic bipolar subjects (Anand et al., 2000; Yatham et al. 2002). One PET study has 
shown increased D2 binding in the basal ganglia of subjects with psychotic mania but no 
difference was found in non-psychotic manic subjects (Pearlson et al. 1995). Whilst no change 
in striatal D2 binding has been found in bipolar subjects, binding in mesocorticolimbic terminal 
regions has not been examined. It therefore remains a possibility that receptor expression is 
altered in these regions in bipolar disorder. 
In terms of the AMPA receptor, and specifically the GIuR1 subunit, very little clinical work has 
been carried out. However in one study GluRl transcripts were shown to be reduced in post- 
mortern brains of bipolar disorder patients but not unipolar depressives or schizophrenics 
(Meador-Wood ruff et al. 2001). 
Currently no work has been carried out to assess 5-HT2c receptor binding in mood disorders 
however there is evidence for pre-mRNA editing of gene transcripts (via de-amination of 
adenosine residues) in the prefrontal cortex of depressed suicide patients (Gardiner and Du, 
2006). If this effect is a consequence of elevated corticosteroid levels then the decreased in-situ 
binding seen in the present study may result from a lack of binding to edited transcripts rather 
than a decrease in transcription. As mRNA editing was not examined in this study it is unknown 
whether this effect takes place in corticosteroid treated animals. 
Overall based on the clinical evidence the changes in mRNA transcription seen in the present 
study may also occur in bipolar and unipolar affective disorders. The present study offers strong 
evidence that the flattening of the corticosteroid rhythm seen in these affective disorders may 
underlie such changes. 
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4.5. Conclusion 
The results of this study show that corticosteroid administration to mimic the flattening of the 
corticosteroid rhythm seen in bipolar disorder can alter transcription of a number of different 
genes coding for proteins in the VTA which act as important regulators of doparninergic 
neurotransmission. Furthermore subregional differences in corticosteroid effects were found in 
the VTA which suggests there may be heterogeneous regulation of mesocortical and 
mesolimbic projection systems originating in the VTA. This has important implications in 
understanding the aetiology of mood disorders, and this is further supported by the fact that 
several of the observed changes in gene transcription are mirrored by altered protein function in 
those mood disorders which show characteristic alterations in HPA axis function, namely bipolar 
and unipolar depression. 
The following chapter investigates the hypotheses developed here looking at tyrosine 
hydroxylase function in the prefrontal cortex and nucleus accumbens, and doparnine, release in 
the prefrontal cortex following corticosterone treatment. 
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synthesis and release in mesocorticolimbic terminal regions 
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Chapter S. Effect of corticosterone administration on dopamine synthesis 
and release in mesocorticolimbic terminal regions 
5.1. Introduction 
The results presented in chapter 4 suggest that altering the diurnal cortisol rhythm alters the 
transcription of genes coding for proteins involved in dopamine synthesis and release, and 
receptors which modulate dopamine synthesis and release. Specifically, in the rat VTA, 
increases were found in the transcription of tyrosine hydroxylase (the rate limiting enzyme in 
doparnine synthesis; Nagatsu et al. 1964), VMAT2 (the transporter responsible for vesicular 
uptake of dopamine; Hoffmann et al. 1998; Nirenberg et al. 1996, Peter et al. 1995) and the D2 
receptor (the impulse, release and synthesis modulating autoreceptor at dopaminergic cell 
somatodendritic sites and terminals; Centonze et al. 2002; Lindgren et al. 2003; O'Hara et al. 
1996; White 1996). 
Based on this data it was hypothesised that corticosteroid treatment would produce an 
increase in dopamine synthesis, vesicular uptake and release in mesocortical neurones 
projecting to the prefrontal cortex. The increase in D2 receptor transcription was postulated to 
have limited impact on these functional effects due to its low efficacy in the prefrontal cortex and 
the lesser increase in D2 mRNA found in areas of the VTA which have been suggested to 
project to this region. In contrast it was hypothesised that increased D2 receptor transcription in 
mesolimbic neurones, induced by corticosteroid treatment, will augment autoinhibitory signalling 
such that the functional effects of increased TH and VMAT2 transcription on nucleus 
accumbens clopamine release would be aftenuated. 
To test these hypotheses a study was performed to investigate dopamine synthetic activity in 
the rat prefrontal cortex and compare it with that in the nucleus accumbens following two weeks 
of corticosterone administration. DOPA accumulation was measured in tissue homogenates of 
rats injected with a DOPA decarboxylase inhibitor prior to sacrifice to give a measure of tyrosine 
hydroxylase activity (see Lamensdorf et al. 1997; Lindley et al. 1999; Pacak et al. 2002; Pan et 
al. 2006). 
Subsequently an in vivo microdialysis study was carried out to measure the effect of 
corticosterone treatment on the bupropion and potassium evoked efflux of dopamine in the rat 
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medial prefrontal cortex. Furthermore terminal D2 receptor sensitivity was assessed by 
measuring bupropion and potassium evoked dopamine efflux in the presence of the D2 receptor 
antagonist sulpiride to investigate autoreceptor function following corticosteroid treatment 
Overall these experiments were designed to test the potential functional consequences on 
doparninergic neuronal activity of an altered corticosterone rhythm similar to that seen in 
patients with bipolar disorder (see chapter 1). 
5.1.1. Aims 
The aims of this study were as follows: 
1) To investigate whether the increase in tyrosine hydroxylase mRNA transcription 
produced by altering the diurnal corticosterone rhythm are reflected in changes in 
dopamine synthetic activity in the medial prefrontal cortex and nucleus accumbens. 
2) To investigate the effect of altering the diurnal corticosterone rhythm on dopamine 
release and D2 receptor sensitivity in the medial prefrontal cortex. 
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5.2. Methods 
5.2.1. Animals 
The 2-week corticosterone treatment protocol has been described in Chapter 2. Briefly, male 
Lister hooded rats (Charles River, UK) were treated for 14-16 days with drinking water 
supplemented with corticosterone (50mg/1) and 0.5% EtOH (n=8 for tyrosine hydroxylase assay, 
n=12 for in-vivo microdialysis). Control animals received drinking water containing 0.5% EtOH 
over the same period (n=8 tyrosine hydroxylase assay, n=12 for in-vivo microdialysis). Animal 
weights and water consumption were recorded during this period. In addition, upon sacrifice, 
adrenal glands were removed and weighed. 
5.2.2. Drugs and chemicals 
Tissue homogenate tyrosine hydroxylase assay 
A solution of NSD1015 (Molekula, UK; 100mg/ml) was made up on the day of sacrifice. 
Pentobarbital (Dolethal, Univet, UK) was pre-prepared as a standard solution. 
In vivo microdialysis 
Stock aCSF and high K+ aCSF were prepared at the start of the study with Ca 2+ and glucose 
added on the day of the experiment (see Chapter 2 for full details). 
A 10 mM DA (Sigma, UK) standard was prepared weekly in 0.1 M perchloric acid and stored 
at 40C. Using this standard, serial dilutions were prepared daily using aCSF to gain DA 
standards at concentrations of 10-8 and 10-9 M. Solutions of bupropion (Sigma, UK; 3 mM) and 
sulpiride (Sigma, UK; 10 mM) were prepared daily using aCSF. A 50% w/v solution of urethane 
was prepared daily by dissolving in water for injection. 
All drugs were administered via the perfused aCSF. Four types of aCSF were used during an 
experiment: (i) normal aCSF containing 30 pM bupropion (ii) high K+ aCSF containing 30 pM 
bupropion (iii) normal aCSF containing 30 pM bupropion and 10 pM sulpiride (iv) high K+ aCSF 
containing 30 pM bupropion and 10 pM sulpiride. 
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5.2.3. Tissue homogenate tyrosine hydroxylase assay 
Following 2-weeks of corticosterone treatment, animals were injected on the morning of the 
fifteenth day with 100 mg/kg NSD1015 i. p. and returned to their home cage. Either 20 min or 2 
hours later the animals were sacrificed with overdose of pentobarbital i. p., and the brain quickly 
removed. The medial prefrontal cortex and the nucleus accumbens were rapidly dissected out 
and placed in separate pre-weighed Eppendorf tubes containing 1ml of OAM perchloric acid. 
VTA tissue from the animals treated for 20 minutes with NSD1015 was used in the in situ 
hybridisation procedure detailed in chapter 2. 
Forebrain tissue was hornogenised using a sonicator (Soniprep, MSE UK) with the Eppendorf 
containing the homogenate suspended in an ice bath. Following complete homogenisation the 
solution was centrifuged and microfiltered. The resultant solution was diluted by a factor of 10 
(in the case of mPFC tissue homogenates) or 20 (in the case of nucleus accumbens 
homogenates) in 0.1 M perchloric acid. Samples were stored at 40C for no longer than 24 hours 
until measurement of DOPA content was carried out using HPLC with electrochemical detection 
(see Chapter 2). 
5.2.4. In vivo microdialysis 
Following the 14 day corticosterone treatment protocol animals were anaesthetised and 
surgically implanted with microdialysis probes in the prefrontal cortex (see figure 5.1. for probe 
location and chapter 2 for full details). Dialysate samples were collected every twenty minutes 
for measurement of dopamine content using HPLC with electrochemical detection (see chapter 
2 for full details). 
Two experiments were performed, the first of which was carried out on na'(ve animals (n=5) to 
assess the repeatability of depolarisation evoked release in the mPFC using high K+ aCSF. In 
this experiment, following attainment of steady dopamine levels with aCSF containing 30 pM 
buproprion, aCSF containing 100 mM K+ was perfused for twenty minutes before switching back 
to the original perfusion medium. Following a period of 120 minutes a second switch to aCSF 
containing 100 mM K+ was performed, again for twenty minutes, before returning to the original 
perfusion solution for the remainder of the experiment. 
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The second experiment was performed to investigate corticosterone modulation of dopamine 
release and autoreceptor function in the mPFC. Once a steady baseline was obtained with 
aCSF containing 30 pM bupropion, levels of dopamine were measured over a one hour period. 
Following this, depolarisation evoked release was induced by switching the perfusion to aCSF 
containing 100 mM K+ and 30 pM buproprion for a period of 20 minutes. This was then followed 
by a period of no less than one hour to allow for the return of a steady baseline with the original 
aCSF. The perfused aCSF was then switched to one containing 10 pM sulpiride and 30pM 
buproprion. This was perfused for one hour and twenty minutes and was then switched for 
aCSF containing 100 mM K+, 10 pM sulpiride and 30pM buproprion for a period of twenty 
minutes. Following this, normal aCSF containing sulpiride and buproprion was perfused for the 
remainder of the experiment. 
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Figure 5.1. Location of dialysis probes in the medial prefrontal cortex (diagram from Paxinos 
and Watson, 1998). Distance from bregma; rostro-caudal = +3.0 mm, medial-lateral 
= -0.7 mm, dorsal-ventral = -5.5 mm. 
Grey region indicates dialysing "window". 
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5.2.5. Data analysis 
Tissue homogenate tyrosine hydroxylase assay 
DOPA concentrations were averaged across each treatment group in the study and Student's 
Mest was used to determine the statistical difference between groups. Where a non-normal 
distribution was found a Mann-Whitney U-test was carried out. 
In-vivo microdialysis 
For the first experiment assessing the repeatability of potassium evoked release, data was 
expressed as peak DA concentration and compared by Student's paired Mest. 
To determine the effect of corticosterone on dopamine levels in the presence of bupropion 
data was averaged over a one hour period for each treatment group and between groups 
analysis performed by Student's unpaired Mest. 
The effect of sulpiride on doparnine levels in the presence of bupropion was analysed by 2- 
way ANOVA with repeated measures comparing data averaged over treatment groups during 
the one hour application period with baseline data averaged over a one hour period. 
The effect of sulpiride on potassium stimulated dopamine levels in the two treatment groups 
was analysed using 2-way ANOVA with repeated measures. Measures of potassium evoked 
release were peak DA concentration attained, % increase over baseline levels, and absolute 
increase in doparnine levels. 
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5.3. Results 
5.3.1. Tyrosine hydroxylase activity in mesocortical and mesolimbic terminal regions 
following corticosterone administration 
5.3.1.1. Gorticosterone treatment 
For details of animal weights and water consumption during corticosterone treatment and final 
adrenal weights see chapter 4 section 3.1. 
5.3.1.2. Tyrosine hydroxylase activity in the medial prefrontal cortex 
Tissue DOPA content in the medial prefrontal cortex was measured following both 20 minutes 
and 2 hours of NSD1015 treatment in vehicle and corticosterone-treated rats. DOPA 
concentrations 20 minutes after NSD1015 were undetectable by HPLC with electrochemical 
detection. When the experiment was repeated with 2 hours of NSD1015 treatment the mean 
DOPA accumulation was 93% greater in the corticosterone treated animals than control animals 
(1.1 ± 0.3 pmol/mg in vehicle treated animals, n=7; 2.1 ± 0.5 pmol/mg in corticosterone treated 
animals, n=7; see Figure 5.2. ). A trend towards statistical significance was found with both 
Student's t-test (p=0.07) and Mann-Whitney U-test (p=0.07). 
5.3.1.3. Tyrosine hydroxylase activity in the nucleus accumbens 
Tissue DOPA content in the nucleus accumbens was measured following both 20 minutes 
and 2 hours of NSD1015 treatment in na*(ve and corticosterone treated rats. In both 
experiments DOPA concentrations were much higher than those found in the mPFC. Following 
20 minutes of NSD1015, corticosterone treatment resulted in a 52% decrease in DOPA 
accumulation compared to control animals. Thus DOPA concentrations were 29 ± 5.3 pmol/mg 
in vehicle treated animals and 13.7 ± 2.6 pmol/mg in corticosterone treated animals (see Figure 
5.3. ). This difference was found to be statistically significant (p<0.05). 
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Figure5.2. DOPA concentration in the mPFC after NSD1015 treatment in vehicle (20 min, 
n=8; 2hr, n=8) and corticosterone treated (20 min, n=8; 2hr, n=8) animals. 
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Figure 5.3. DOPA concentration in the nucleus accumbens after NSD1015 treatment in vehicle 
(20 min, n=7; 2hr, n=8) and corticosterone treated (20 min, n=8; 2hr, n=8) animals 
(* p<0.05). 
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When the experiment was repeated with a2 hour post-NSD1015 survival period there was no 
statistically significant difference in nucleus accumbens tissue DOPA concentrations between 
vehicle and corticosterone treated animals. Vehicle treated animals had a tissue concentration 
of 13.9 ±2 pmol/mg DOPA whilst corticosterone treated animals had a concentration of 13.2 ±3 
pmol/mg (see Figure 5.3. ). In the vehicle treated group DOPA levels at 2 hours were 
significantly lower than at the 20 minute time-point (p<0.05 Student's Mest). 
5.3.2. Dopamine release in the medial prefrontal cortex 
5.3.2.1. Repeated potassium stimulated release 
The planned experiments for measuring clopamine release in the mPFC required the use of 
two potassium stimulations during the course of an experiment, the aim being to examine the 
effect of a D2 antagonist on stimulated dopamine release. To determine the validity of 
comparing these stimulations a preliminary study was carried out to determine if repeated 
stimulations are consistent. The time course of this experiment can be seen in figure 5.4. Note 
30 pM bupropion was present in perfused aCSF throughout the experiment. 
Infusion of 100 mM K+ aCSF down the microdialysis probe evoked a large increase in 
dialysate dopamine. A small decrease in baseline (with bupropion) extracellular dopamine (- 9± 
5.1 fmol per sample; 15% decrease) was found following the first potassium stimulation, 
however this was not statistically significant (before K+ stimulation 59.1 ± 5.6 fmol/sample; after 
K+ stimulation 50.1 ± 5.0 fmol/sample; p>O. 1 Student's t- test for paired samples). A second K+ 
stimulation also increased dialysate dopamine levels there was no statistically significant 
difference between the two responses, i. e. the potassium evoked release was no different in 
magnitude at K2 compared to Kl (mean difference 9.4 ± 16.6 fmol; Kl 166.4 ± 6.8 fmol/sample; 
K2 175.8 ± 13.3 fmol/sample; p>0.5 Student's Mest for paired samples; see figure 5.5. ). Thus it 
was concluded that potassium stimulated dopamine release remains consistent over two 
applications. 
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Figure 5.4. Repeated potassium stimulation of dopamine release in the medial prefrontal 
cortex (n=5). 
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Figure 5.5. Comparison of peak dopamine levels between consecutive potassium stimulations. 
K1 = first potassium stimulation, K2 = second potassium stimulation (n=5). 
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5.3.2.2. Corticosterone treatment 
Animals were treated with vehicle or corticosterone for between 14 and 16 days. Average 
length of treatment for vehicle treated animals was 15.25 ± 0.25 days (n=12) and for 
corticosterone treated animals 14.75 ± 0.22 days (n=12). Treatment lengths did not differ 
significantly (p>0.05 Student's t-test). 
Animals gained weight steadily throughout the experiment (see figure 5.6. ). At 13 days animal 
weights did not differ significantly between treatment groups (vehicle treated 300.5 ± 3.6 g, 
n=12; corticosterone treated 293.1 ± 3.3 g, n=12; p>0.05). At 13 days water consumption per 
cage did not differ significantly between treatment groups (vehicle treated 317 ± 20 mi/cage, 
n=3; corticosterone treated 263 ± 16 ml/cage, n=3; p>0.05) (see figure 5.7. ). 
Adrenals were removed from each animal following microdialysis. Adrenal weight was 
significantly lower in corticosterone treated animals than vehicle treated animals (corticosterone 
treated 20.75 ± 1.2 mg, n=12; vehicle treated 37.6 ± 1.5 mg, n=12; p<0.01) (see figure 5.8. ). 
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Figure5.6. Animal weights during vehicle (n=12) and corticosterone (n=12) treatment. 
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Figure 5.7. Water consumption per cage of four rats per two days treated with vehicle (n=3 
cages) or corticosterone (n=3 cages). 
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Figure 5.8. Adrenal weights in vehicle (n=1 2) and corticosterone treated (n=1 2) animals 
(* P<0.01). 
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5.3.2.3. Corticosterone effects on dopamine release in the medial prefrontal cortex 
To examine the effect of corticosterone treatment on extracellular DA in the PFC four different 
measures were employed, namely (i) dopamine release in the presence of bupropion, (ii) 
potassium stimulated dopamine release in the presence of bupropion, (iii) dopamine release in 
the presence of a D2 receptor antagonist and bupropion and (iv), potassium stimulated 
dopamine release in the presence of a D2 receptor antagonist and bupropion. The time course 
of this experiment can be seen in figure 5.9. Perfused aCSF contained 30 pM bupropion at all 
times. 
(i) Baseline bupropion stimulated dopamine release 
To examine baseline dopamine levels with bupropion the average of three samples taken 
over the course of one hour immediately prior to K+ stimulation of release was calculated. 
During this period corticosterone treated animals had significantly higher levels of dopamine 
than vehicle treated animals (vehicle 39.3 ± 5.5 fmol/sample, n=11; corticosterone 61.6 ± 5.1 
fmol/sample, n=12; p<0.01; see figure 5.10. ). 
(ii) Potassium stimulated release 
Perfusion of high K+ aCSF evoked an increase in dialysate doparnine. The peak DA 
concentration induced by high K+ aCSF stimulation was significantly greater in the 
corticosterone treated group than the vehicle treated group (vehicle 110.1 ± 15.8 fmol/sample, 
n=10; corticosterone 174.5 ± 18.6 fmol/sample, n=10; p<0.05; see figure 5.11. ). The absolute 
increase over baseline dopamine levels was also greater in corticosterone treated animals 
(vehicle 72.3 ± 12.0 fmol/sample, n=10; corticosterone 112.9 ± 6.1 fmol/sample, n=10) although 
this failed to reach statistical significance (p=0.058). No statistically significant difference in the 
percentage increase over baseline dopamine levels was found between the two treatment 
groups (see figure 5.12. ). 
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Figure 5.9. Dopamine release in the medial prefrontal cortex in vehicle and corticosterone 
treated animals. N. B. Data shown are only those from animals which survived the 
whole experiment (vehicle treatment n=6; corticosterone treatment n=7). K+ 
potassium stimulated release. 
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Figure 5.10. Mean baseline dopamine levels (with 30pM bupropion) in the medial prefrontal 
cortex in vehicle (n=1 1) and corticosterone treated (n=12) animals as measured 
by in-vivo microdialysis (* p<0.01). 
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Figure 5.11. Peak dopamine release in the mPFC following potassium stimulation in vehicle 
(n=10) and corticosterone treated (n=10) animals (* p<0.05). 
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Figure 5.12. % increase in mPFC dopamine levels compared to baseline levels following 
potassium stimulated release in vehicle (n=1 0) and corticosterone treated (n=1 0) 
animals. 
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(iii) Effect of corticosterone administration on the dopamine response to sulpiride 
Upon application of 10 pM sulpiride a decrease in dopamine levels occurred in both vehicle 
and corticosterone treated animals. (see figure 5.9. and 5.13. ). Two-way ANOVA with repeated 
measures showed a trend towards a significant effect of sulpiride (F[1,15]=3.9, p=0.07), a 
significant effect of corticosterone treatment (F[1,15]=6.7, p<0.05), but no interaction between 
the two. The percentage change between baseline levels during the hour prior to sulpiride 
application and levels during infusion of sulpiride was also calculated (Vehicle -10.5 ± 3.4% n=8; 
Cort treated -5.5 ± 7.6% n=9). Although the vehicle treated group had a greater average 
decrease in dopamine release compared to corticosterone treated animals there was no 
statistically significant difference between the two treatment groups (p > 0.05 Student's t-test) 
(see figure 5.14. ). 
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Figure 5.13. Comparison of mPFC dopamine release in vehicle (n=8) and corticosterone 
treated (n=9) animals under baseline conditions (with 30pM bupropion) and 
following intra-PFC infusion of 1OpM sulpiride. 
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Figure 5.14. Average % change in mPFC doparnine release in vehicle (n=8) and 
corticosterone treated (n=9) animals following 1OpM sulpiride administration 
compared to baseline levels (with 30pM bupropion). 
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(iv) D2 receptor effects on potassium stimulated dopamine release following corticosterone 
administration 
Table 5.1 shows data for potassium stimulated dopamine release in the absence and 
presence of sulpiride (1 Opm) in both vehicle and corticosterone treated groups of animals. 
Absolute 
Treatment n 
Peak DA level increase over 
% increase 
over baseline (fmol) baseline DA level 
(fmol) levels 
K+ 7 112.9 ± 18.5 71.2 ± 14.4 186.7 ± 39.1 
V hi l e c e 
K++ 
Sulpiride 7 115.7 ± 13.2 72.7 ± 11.7 207.6 ± 56.6 
K+ 6 177.8 ± 12.8 114.2 ± 9.0 195.7 ± 33.3 
Cortico- 
sterone K++ 6 187 4± 28 9 7 121 1± 25 179 6± 31 4 Sulpiride . . . . . . 
Table 5.1. Data ± s. e. m. for repeated potassium stimulations in the absence and presence of 
sulpiride (10pm). 
Two-way repeated measures ANOVA showed no effect of sulpiride on peak DA level 
P>0.05) (see figure 5.15), absolute increase in DA from baseline level (F[1,11]=0.1, 
p>0.05), or percentage increase in DA levels (F[1,11]=0.004, p>0.05) (see figure 5.16). 
Corticosterone treatment had a significant effect on peak DA level (F[1,11]=153.2, p<0.05) and 
absolute increase over baseline levels (F[1,11]=5.7, p<0.05), with no effect on the percentage 
increase over baseline levels (see figure 5.16). 
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Figure 5.15. Peak mPFC dopamine release in vehicle and corticosterone treated animals 
following potassium stimulation in the presence and absence of 1OpM sulpiride 
(Sulp) (see table 5.1 for animal numbers). 
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Figure 5.16. % increase in mPFC dopamine release in vehicle and corticosterone treated 
animals following potassium stimulation in the presence and absence of IlOpM 
sulpiride (Sulp) (see table 5.1 for animal numbers). 
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5.4. Discussion 
5.4.1. Principal findings 
The principal findings of this series of experiments are summarised in table 5.2. From this it 
can be seen that disruption of the corticosteroid rhythm (i) increased tyrosine hydroxylase 
activity in the prefrontal cortex (although this failed to reach statistical significance) (ii) increased 
baseline and stimulated dopamine release in the prefrontal cortex (in the presence of 30pM 
bupropion) and (iv) had no effect on D2 autoreceptor function in the prefrontal cortex. 
mPFC 
Tyrosine Hydroxylase , (93% ) (non-significant trend) 
activity 
Dopamine release 
T baseline (57%) and K+ 
stimulated (58%) efflux 
D2 receptor function No change 
Table 5.2. Summary of findings in animals treated with two weeks of corticosterone compared 
to vehicle treated animals. 
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5.4.2. Tyrosine hydroxylase function in corticosterone treated animals 
(i) Medial prefrontal cortex 
20 minutes of NSD1015 treatment prior to sacrifice failed to produce measurable levels of 
DOPA in mPFC tissue samples, however following 2 hours of NSD1015 pre-treatment DOPA 
levels were elevated such that measurement was possible. This revealed a trend towards an 
increase in DOPA levels in corticosterone treated animals over those found in vehicle treated 
animals. This result is consistent with the hypothesis that the increase in tyrosine hydroxylase 
gene transcription seen in the VTA (see chapter 4) results in an increase in tyrosine 
hydroxylase activity and therefore DOPA synthesis in this brain region. 
(ii) Nucleus accumbens 
The results of the two experiments looking at tyrosine hydroxylase activity in the nucleus 
accumbens are, at first glance, somewhat at odds with each other. In the first instance, with a 
20 minute post-NSD1015 survival time, DOPA levels were significantly lower in the 
corticosterone treated group compared to the vehicle treated group. Such a result is consistent 
with a study published by Pacak et al. (2002) in which seven days of corticosterone infusion 
was found to produce a similar effect. It is the case however that with a longer post-NSD1015 
survival time of 2 hours (which was carried out principally to elevate PFC DOPA levels to a 
measurable level), no effect of corticosterone was found and furthermore DOPA levels in the 
vehicle group were markedly lower than at the 20 minute timepoint. 
Intuitively, a longer survival time after dosing with a DOPA clecarboxylase inhibitor would be 
expected to increase rather than decrease tissue DOPA concentrations. One possible 
explanation comes from the finding that DOPA can not only inhibit tyrosine hydroxylase activity 
significantly (Nagatsu et al. 1964), but is itself a substrate for tyrosine hydroxylase (Haavik, 
1997). In the vehicle treated animals the high rate of tyrosine hydroxylation (as suggested at the 
twenty minute time point) may have depleted tyrosine levels and elevated DOPA levels. This 
would produce a situation in which DOPA oxidation was favoured explaining the decrease seen 
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at the two hour time point. In the corticosterone treated group the lower rate of TH activity 
possibly resulted in the maintenance of a larger pool of tyrosine, and thus DOPA oxidation may 
not have occurred to the same extent. As a result, at the two hour time-point DOPA oxidation in 
vehicle treated animals may have masked their higher rate of TH activity relative to the 
corticosterone treated group. Measurement of tyrosine levels would help to clarify this issue. 
If the theory regarding DOPA oxidation is accepted it appears to have had little impact on the 
DOPA synthesis in the PFC. It is of course possible that the results have indeed been distorted 
by DOPA oxidation and that the rate of synthesis is in fact much higher in corticosterone treated 
animals than the results would indicate. Alternatively, tyrosine availability relative to synthetic 
rate might be such that in mPFC dopaminergic cells DOPA oxidation is competitively inhibited. 
From the present data it is impossible to estimate the effect of DOPA oxidation on these results. 
There is no reason to suspect that in the mPFC DOPA oxidation would have occurred 
preferentially in the vehicle treated group, where the rate of synthesis was lower and therefore 
tyrosine availability was likely to be greater, and so the overall result is probably valid even if the 
measured levels do not give a true indication of the rate of DOPA synthesis. 
Overall, determination of TH activity revealed that the medial prefrontal cortex and nucleus 
accumbens are differentially regulated by HPA axis dysrhythmia. In the medial prefrontal cortex 
the corticosterone induced increase in transcription of tyrosine hydroxylase within the VTA 
appears to increase TH activity, whereas in the nucleus accumbens no increase was seen, and 
indeed there was some evidence of a decrease in TH activity in this region. Given that the 
results from the previous chapter suggest that tyrosine hydroxylase gene transcription is 
increased by hypercortisolaernia across the whole VTA, the lack of increase in TH activity in the 
nucleus accumbens suggests a post-translational modification of tyrosine hydroxylase function. 
One possible mechanism for such a post-translational modification is the increase in D2 receptor 
gene transcription seen in the VTA following corticosterone treatment (see Chapter 4) as this 
receptor can regulate tyrosine hydroxylase activity by altering the phosphorylation state of the 
enzyme at the terminal (Lindgren et al. 2003). Data from the microdialysis study (see later) 
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suggests that the D2 receptor is not functional in the mPFC, and furthermore in chapter 4 D2 
receptor gene transcription was upregulated to a greater extent in areas of the VTA thought to 
project to the nucleus accumbens than those areas thought to project to the mPFC. These 
findings may explain why such a post-translational effect on TH activity appears to have 
occurred selectively in the nucleus accumbens. 
As mentioned in the previous chapter, changes in dopamine synthesis can produce parallel 
changes in vesicular content and therefore doparnine release (Floor et al. 1995, Pothos et al. 
2000; Eisenhofer et al. 2004). The results presented here suggest that modulating the 
corticosteroid rhythm can result in an increase in dopamine synthesis in the mPFC but not in the 
nucleus accumbens. The effect of hypercortisolaernia therefore has the potential to produce an 
imbalance in mesocortical vs. mesolimbic dopamine release. 
5.4.3. Dopamine release in the medial prefrontal cortex in corticosterone treated animals 
In the second part of this chapter the consequences of corticosteroid dysrhythmia on 
extracellular DA levels in the mPFC were examined using microdialysis. Flattening the 
corticosterone rhythm increased baseline bupropion stimulated dopamine levels in the mPFC 
markedly. Furthermore corticosterone treatment also increased potassium stimulated dopamine 
release. 
The increase in bupropion stimulated baseline dopamine levels seen in the corticosterone 
treated group could be due to a number of factors. One possibility which can be discounted is a 
lower rate of clopamine transporter mediated dopamine uptake in the corticosterone treated 
animals. First the in situ study showed no effect of corticosterone treatment on DAT 
transcription. Secondly and crucially, perfusion of the DA uptake blocker bupropion at a 
concentration shown to maximally inhibit uptake in the nucleus accumbens (L. Ferrie, doctoral 
thesis) would have masked any effects of corticosterone treatment on DAT function. As a 
consequence of the DAT blockade changes in DAT activity are not responsible for the elevated 
clopamine levels, and furthermore dialysate clopamine levels reported here are indicative of 
actual quantities of dopamine released. 
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Another possible explanation for the increase in bupropion stimulated DA release is that an 
increase in the basal neuronal firing rate occurred following corticosterone treatment. However, 
the fact that corticosterone treated animals also exhibited elevated dopamine levels in the 
presence of a depolarising stimulus (high K+ aCSF) suggests this is unlikely to be the 
explanation. If an increase in firing rate was solely responsible for the increase in release, 
potassium stimulation would have produced a similar peak dopamine concentration in both 
treatment groups as the induction of dopamine release by this method is independent of the 
neuronal firing rate. 
A further potential mechanism is a corticosterone induced decrease in terminal D2 receptor 
function which would attenuate autoreceptor inhibition of doparnine synthesis and release. Such 
a mechanism is not thought to be likely in light of the in situ data showing an increase in D2 
receptor gene transcription in the VTA which would be expected to increase D2 receptor 
function. Furthermore in the present study the D2 receptor was not found to be tonically active in 
either vehicle or corticosterone treated rats (see section 5.4.4. ) 
The most credible theory based on the present data involves a corticosterone-induced 
upregulation of vesicular doparnine content. The trend towards an increase in tyrosine 
hydroxylase activity in the mPFC (see section 5.4.2. ) (reflecting the corticosterone induced 
upregulation of TH gene transcription seen in Chapter 4) suggests that there is an increase in 
dopamine synthesis following corticosterone treatment. This could result in greater vesicular 
doparnine content as a result of altering the concentration gradient between the interior of the 
vesicle and the cytoplasm, resulting in a lower rate of vesicular leakage and a corresponding 
increase in vesicular content. Furthermore, in the previous chapter it was shown that gene 
transcription of the vesicular dopamine transporter (VMAT2) was upregulated by corticosterone 
administration. It has been shown previously that an increase in VIVIAT2 expression produces 
an increase in the amount of dopamine released per depolarisation event (Pothos et al. 2000) 
further supporting this as a potential mechanism. Under these conditions the number of vesicles 
undergoing exocytosis following depolarisation of the terminal would be the same in both 
treatment groups. The fact that potassium stimulation produced the same percentage increase 
over baseline bupropion stimulated dopamine levels in vehicle and corticosterone treated 
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animals is consistent with such a mechanism. The evidence therefore suggests that increased 
vesicular content is a likely candidate to explain the increase in dopamine release seen in 
corticosterone treated animals. 
As calcium entry into the terminal plays a key role in neurotransmitter exocytosis it is possible 
that in the corticosterone treated group an upregulation of calcium signalling was responsible for 
the increase in dopamine release. This aspect of neuronal function was not examined in the 
present study but this mechanism could account for the observed increases in dopamine 
release under both baseline and stimulated conditions. However, the previously mentioned 
hypothesis involving upregulation of vesicular dopamine content successfully accounts for the 
observed increase in dopamine release, and in situ and enzyme assay data support this view. It 
is unknown whether, in addition, changes to calcium signalling occur, and based on the 
available data this possibility can not be ruled out. 
5.4.4. D2 receptor function in corticosterone treated animals 
In light of in-situ data showing an upregulation of D2 receptor gene transcription in the VTA 
following corticosterone treatment, (see Chapter 4), it was postulated that increased D2 receptor 
activity might offset the effects of increased dopamine synthesis and release in the mPFC. 
It was found that local application of the D2 receptor antagonist sulpiride into the mPFC did 
not elevate extracellular dopamine levels in either corticosterone or vehicle treated animals. 
This suggests that there is little or no tonic inhibition of dopamine release by this receptor in the 
mPFC. In fact, dopamine levels appeared to decrease somewhat following sulpiride application 
although this failed to reach statistical significance. This trend towards a run down in dopamine 
release was evident in the preliminary study examining the repeatability of potassium 
stimulation where, in the absence of sulpiride, a non-significant decrease in dopamine release 
occurred following the first potassium stimulation. It is possible that this decrease is due to a 
it run-down" in release following the first potassium stimulation, however, the effect is relatively 
small and appears not to have adversely affected the results. 
Sulpiride had no significant effect on the magnitude of evoked dopamine release produced by 
depolarisation stimulation in the two treatment groups. Given that the D2 receptor is more likely 
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to be occupied under conditions of high doparnine release, the lack of effect of sulpiride 
following potassium stimulation further supports the notion that this receptor is inactive in the 
mPFC. Overall the data indicate that the D2 receptor does not influence bupropion or potassium 
stimulated release in the mPFC and furthermore that the corticosterone induced increase in 
dopamine release is not accounted for by a decrease in receptor sensitivity. 
The result of the present study is in direct contrast with microdialysis data published by Bean 
and Roth (1991) showing that sulpiride (at the same concentration used here) increases 
dopamine release by 94% in the mPFC. Their data therefore suggest that release modulating 
autoreceptors; are present and functional in this region. In support of the present results, some 
studies have shown no effect of locally applied haloperidol (a D2 antagonist) in the mPFC 
(Gessa et al. 2000; Devoto et al. 2001). Furthermore a variety of groups have shown no effect 
of systemic administration of sulpiride on mPFC dopamine release (Moghaddam and Bunney, 
1990; Ago et al. 2005) and studies in slices of rabbit PFC have found that sulpiride only 
potentiates stimulated dopamine release when high rates of stimulation are used (Agneter et al. 
1994). Thus there is some support for a lack of a physiological role for the D2 autoreceptor in 
the mPFC. 
Studies employing doparninergic agonists have been similarly inconsistent with one study 
finding that intra-PFC infusion of apomorphine (a D2 agonist) decreases doparnine release as 
measured by microdialysis (Bean et al. 1990) and another showing inhibition of DA release in 
slices of prefrontal cortex following local application of dopaminergic agonists (Hoffmann et al. 
1998). In contrast, local application of the D2 agonist quinpirole has been shown to have no 
effect on DA release in the PFC (Devoto et al. 2001). Studies with systemically administered D2 
agonists have shown no effect on DA release (Chiodo et al. 1984, White and Wang 1984). 
Hoffman et al. (1998) suggested that in the PFC the D2 receptor is located some distance from 
the synapse as electrically evoked DA release was found to be less effective at increasing D2 
agonist efficacy than in the striaturn despite a greater evoked DA outflow. Consequently it is 
possible that under physiological conditions in-vivo D2 autoinhibition does not occur due to 
doparnine not diffusing far enough to reach receptor sites (see Cubbedu et al. 1990). 
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Given the lack of efficacy of systemically administered sulpiride on PFC dopamine release 
(Moghaddam and Bunney, 1990; Ago et al. 2005) it is interesting to note that intra-VTA 
application of sulpiride has been found to increase dopamine release in the PFC (Westerink et 
al. 1998) suggesting the presence of functional somatodendritic autoreceptors. It may be the 
case that following systemic administration, sulpiride modulation of afferent input to the VTA 
masks the autoreceptor effect whereas under normal conditions it is functional. Given that in the 
present study no evidence for a change in firing rate of doparnine neurones was found, it is 
likely that corticosterone treatment had no effect on somatodendritic autoreceptor function. 
In the previous chapter an increase in D2 receptor mRNA was found at the level of the VTA 
following corticosterone administration. Given that the present results (namely an increase in 
DA synthesis and release) are inconsistent with an upregulation of either somatodendritic or 
terminal D2 receptors it is likely that corticosterone treatment did not increase D2 receptor 
protein expression in mesocortical neurones. 
One possible explanation for this is that the upregulation of D2 mRNA transcription did not 
occur in mesocortical neurones. It has been suggested that mPFC projections arise in the 
dorsal VTA which exhibited a much smaller increase in D2 mRNA following corticosterone 
treatment than the ventral VTA, indeed, the dorsolateral region showed no increase in D2 
transcription at all. 
Another possibility is that protein synthesis and/or trafficking in mesocortical neurones is not 
upregulated in response to elevated levels of D2 mRNA to increase the number of functional 
autoreceptors. If this were the case it might represent a further contrast with mesolimbic 
neurones as increased D2 receptor function was postulated to underlie the post-translational 
inhibition of tyrosine hydroxylase in this region seen in the tissue homogenate TH assay. 
A further possibility is that D2 receptor protein expression is increased in the PFC following 
corticosterone treatment but the receptor is not functional. The lack of effect of sulpiride in 
vehicle treated animals supports a lack of functionality. However, if this were the case, one 
might expect a concomitant increase in somatodendritic D2 receptor expression, and hence a 
change in neuronal firing rate. No evidence of a change in basal firing rate was suggested by 
comparing baseline bupropion stimulated dopamine release with potassium stimulated release. 
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It is more likely that corticosterone has no effect on transcription in these neurones or that some 
translational/trafficking deficit accounts for the lack of effect. 
Overall, these results suggest that (i) terminal D2 autoreceptors do not function in the mPFC 
and (ii) corticosterone treatment does not upregulate D2 receptor expression in mesocortical 
doparninergic terminals such that autoinhibition occurs. 
5.4.5. Functional implications of elevated dopamine release in the PFC 
The prefrontal cortex is involved in a number of executive brain functions including working 
memory, selective attention, goal directed behaviours, behavioural inhibition and visceromotor 
control (see reviews by Arnsten, 1997; Vertes, 2006). In particular the regions of the PFC 
looked at in the present study, namely the prelimbic and infralimbic cortices, are thought to be 
involved in working memory and attention regulation, with the prelimbic cortex associated with 
action-outcome contingency detection and visual attention selectivity (Dalley et al. 2004). 
Doparninergic regulation plays a critical role in these processes with many of them sensitive to 
manipulation by cloparninergic agonists and antagonists. Indeed it has been suggested that 
dopamine is the major monoamine influencing prefrontal cortical function (Grafton et al. 1989). 
The majority of the work on dopaminergic regulation of prefrontal cognitive function has been 
carried out in experiments investigating working memory, where it has been shown that a 
reduction in post-synaptic doparninergic activity using dopamine antagonists impairs working 
memory, whilst modest elevation of doparninergic activity improves cognitive function (reviewed 
by Arnsten, 1997; Robbins, 2005). It has been shown, however, that supranormal DA 
stimulation results in impairment of spatial working memory and this can be produced by both 
doparninergic agonists and drugs which induce PFC doparnine release such as ketamine. 
Furthermore, acute stress can raise dopamine levels to a point where they are detrimental to 
cognitive function (reviewed by Arnsten, 1997; Robbins, 2005). Overall these data suggest that 
the doparnine response curve is bell-shaped with respect to cognition and that alterations in DA 
release can have significant effects on cognitive function. 
At the cellular level the predominant action of dopamine in the prefrontal cortex is thought to 
be inhibitory with dopaminergic agonists having been shown to exert an inhibitory effect on 
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prefrontal glutamatergic pyramidal cells (Sesack and Bunney, 1989; Godbout et al. 1991). The 
receptor subtype responsible for the cognitive effects of post-synaptic doparninergic signalling is 
thought to be the D, receptor subtype with working memory showing the aforementioned bell- 
shaped dose response curve in response to D, selective agonists (Arnsten, 1997; Dalley et al. 
2004). 
The post-synaptic D2 receptor also appears to play a role as some groups have shown that 
doparninergic inhibitory responses in the PFC are antagonised by D2 selective but not D, 
selective antagonists (Sesack and Bunney, 1989; Godbout et al. 1991). In addition, D2 selective 
agonists have been shown to be more potent than D, selective agonists at producing inhibitory 
responses in the PFC (Parfift et al. 1990). The role of this in cognitive function is put into 
question, however, by studies showing that whilst a D2 selective agonist can improve working 
memory function at a dose sufficient to stimulate post-synaptic receptors, D2 antagonists do not 
impair cognitive function when applied directly into the PFC (Arnsten, 1997). 
It has been suggested that dopamine concentrations are a critical determinant of the relative 
contributions of Dj/D2 receptors to signalling in the PFC and that D2 mediated signalling 
predominates at high dopamine concentrations (Trantham-Davidson et al. 2004). Overall it can 
be seen that whilst the exact mechanism of dopamine's postsynaptic effect is unclear, 
prefrontocortical function is critically regulated by doparnine levels and increased or decreased 
dopamine release can have detrimental effects on executive function. The functional 
consequences of the corticosteroid induced elevation in doparnine seen in the present study are 
difficult to predict, but they may result in an impairment of cognitive function due to an elevated 
basal doparnine level (this is discussed further in chapter 6. ). 
Dopaminergic prefrontocortical inhibition not only affects brain functions mediated by the PFC 
itself, but in addition it affects numerous other brain areas via cortical afferents. Of particular 
relevance to the present study is the presence of cortico-limbic afferents which feed-forward to 
control dopaminergic projections terminating in the nucleus accumbens. The presence of a 
projection originating in the PFC and targeting the nucleus accumbens was first demonstrated 
by Beckstead in 1979. It was subsequently shown that doparninergic activity in the PFC exerts 
an inhibitory influence on dopamine release in the nucleus accumbens (Thompson and Moss, 
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1995; Doherty and Grafton, 1996). This suggests that another functional implication of the 
observed increase in doparnine release in the PFC seen in the present study could be an 
inhibition of meso-accumbens doparninergic activity. This effect combined with the evidence 
from the tyrosine hydroxylase activity assay that dopamine synthesis is not increased in the 
nucleus accumbens provides further support for the hypothesis that corticosteroids can induce a 
functional "imbalance" between mesocortical and mesolimbic doparninergic function. 
5.5. Conclusion 
The available data suggest that dysregulation of the HPA axis such as that seen in bipolar 
disorder and modelled in the present study produces an increase in the synthesis and release 
of doparnine in the prefrontal cortex, whilst producing no increase in synthesis in the nucleus 
accumbens. This may adversely affect cognitive function by elevating dopamine release in the 
prefrontal cortex. Cognitive function may also be relatively more impaired by acute stressors 
due to an exaggerated doparnine response caused by corticosteroid dysregulation. This 
suggests that a hyperdoparninergic state in the prefrontal cortex arising from dysregulation of 
the HPA axis could be responsible for some of the symptoms of bipolar and other affective 
disorders and may be implicated in the triggering of psychiatric events following exposure to 
stress. 
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Chapter 6. General Discussion 
The aim of the studies in this thesis has been to investigate the hypothesis that changes to 
the diurnal corticosteroid rhythm of the type seen in bipolar disorder produce changes in 
mesocorticolimbic dopaminergic function. This hypothesis stems from the theory that HPA 
axis abnormalities are a causative factor in bipolar disorder, and from the evidence that 
dysregulation of dopaminergic systems plays a role in the mood states characteristic of the 
disorder. 
HPA axis abnormalities in bipolar disorder have been demonstrated in a variety of studies 
looking at diurnal secretion profiles and feedback responsiveness. Of particular interest is 
the altered corticosteroid rhythm in bipolar patients (Sachar, 1975; Akesocle et al. 1976; 
Linkowski et al. 1985; Souetre et al. 1989; Linkowski et al. 1994; Cervantes et al. 2001) 
which takes the form of an elevated level of secretion during the daily nadir which reduces 
the amplitude of the diurnal cycle. Of relevance to these findings are observed abnormalities 
in feedback function within the HPA axis in bipolar disorder with a large proportion of patients 
exhibiting non-suppression of HPA axis activity following administration of the glucocorticoid 
agonist dexamethasone. Such findings may in part explain the elevated levels of 
corticosteroid release during the diurnal cycle in bipolar patients, the effects of which have 
been investigated in this thesis. 
A role for cloparnine in the aetiology of bipolar disorder has been postulated based on a 
number of strands of evidence. A general dysregulation of doparninergic function in the 
disorder has been suggested by studies looking at dopamine metabolites in the CSF of 
bipolar patients. These studies have shown elevations in HVA levels during manic episodes 
(Swann et al. 1983; Gerner et al. 1984; Tandon et al. 1988) whilst depressed bipolar patients 
have shown decreased levels of this metabolite (Asberg et al. 1984; Reddy et al. 1992, 
Bottiglieri et al. 2000). A second strand of evidence is the ability of doparninergic drugs to 
replicate features of mood states from the disorder. Thus administration of drugs which 
increase doparninergic neurotransmission such as amphetamine, levodopa and 
bromocriptine can induce manic-like states in healthy individuals (reviewed by Silverstone, 
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1985) whilst decreasing doparninergic neurotransmission via tyrosine depletion (McLean et 
al. 2003) or reserpine administration (Schildkraut, 1965) can produce depressive symptoms. 
Of further relevance is the ability of mood stabilising drugs to alter doparninergic function in 
pre-clinical studies. These have shown that lithium (Hesketh et al. 1978; Koyama, 1987; 
Gottberg et al. 1989), valproate (Ichikawa and Meltzer, 1999) and carbamazepine (Okada et 
al. 1997) can alter the release of dopamine in its terminal regions, whilst antipsychotic drugs 
which antagonize dopamine receptors are efficacious in the prophylactic and acute treatment 
of mania and depression (Wilson et al. 1998; Brambilla et aL 2003; Kapur and Mamo, 2003). 
It is the central hypothesis of this thesis that the altered diurnal corticosteroid secretion 
profile in bipolar disorder is responsible for alterations in dopaminergic function in the central 
nervous system, and in particular the mesocorticlimbic dopaminergic neurons originating in 
the ventral tegmental area. Corticosteroids circulate throughout the body and readily enter 
the brain, and a number of studies in rats have demonstrated the ability of corticosteroids to 
alter mesocorticolimbic function. Whilst these studies support the hypothesis in as much as 
they demonstrate that corticosteroids can affect this system, their relevance is limited by the 
fact that they either utilised high doses of corticosterone (Wolkowitz, 1994; Inoue and 
Koyama 1996; Pacak et al. 2002; Czyrak et al. 2003) or adrenalectomy (Pia=a et al. 1996; 
Shoaib and Shippenberg, 1996; Lindley et al. 1999; Barrot et al. 2000; Nakahara et al. 2000; 
Barrot et al. 2001; Mizoguchi et al. 2004) - manipulations which do not model the more 
subtle changes in corticosteroid levels observed in bipolar disorder. A more clinically relevant 
manipulation was used in the present study by modelling the pattern of corticosteroid 
secretion observed in bipolar disorder through administration of low doses of corticosterone 
to rats in their drinking water. This method has previously been shown to produce a flattened 
corticosteroid rhythm with many of the features observed in bipolar disorder (G. Fairchild, 
doctoral thesis 2004) and by measuring the effects of this manipulation on mesocorticolimbic 
function it was hoped to gain some insight into the neurobiological mechanisms of bipolar 
disorder. 
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6.1. Summary of results 
6.1.1. Corticosteroid receptor expression in the mesocorticolimbic system 
The central hypothesis, in its simplest interpretation, requires corticosteroids to act directly 
on receptors within dopaminergic cells to modulate their function. In this context the existing 
literature lacked clarity regarding the presence of corticosteroid receptors in dopaminergic 
neurons of the VTA and whilst mapping studies had demonstrated the presence of GR 
(Ahima and Harlan, 1990; Cintra et al. 1994; Morimoto et al. 1996) and MR (Ahima et al. 
1991) in this region their cellular location remained unclear. Two studies with conflicting 
results have been published demonstrating the presence (Harfstrand et al. 1986) and 
absence (Czyrak and Chocyk, 2001) of GR within doparninergic cells, whilst MR expression 
within these cells has not been examined. This prompted the initial studies in this thesis 
which utilised immunohistochemistry to demonstrate the presence of both MR and GR in 
VTA dopaminergic cells. 
The present study showed that both GR and MR are expressed in dopaminergic neurones 
within the VTA. Close to half of the sampled tyrosine hydroxylase positive cells in this region 
were found to express GR, whilst all of tyrosine hydroxylase expressing cells co-expressed 
MR. This presence of GR and MR in dopaminergic cells of the VTA supports the central 
hypothesis as it allows for direct corticosteroid modulation of dopaminergic 
neurotransmission, via alterations in the transcription of regulatory genes and their proteins 
within dopaminergic cells. This is certainly true of the subset of dopaminergic cells which 
express GR and MR, where the presence of the low affinity GR suggests that these cells 
would be responsive to supranormal levels of corticosteroids. In addition, the ability of GR 
and MR to form heterodimers as suggested by a variety of studies (Trapp et al. 1994; Liu et 
al. 1995; Ou et al. 2001) allows for some diversity in corticosteroid receptor signalling within 
these cells, although the implications of this are unknown. Studies investigating 
corticosteroid receptor occupancy have found that the MR is close to fully occupied by 
normal physiological levels of corticosterone (Reul and de Kloet, 1985) although this has 
been questioned (Pace and Spencer, 2005). If Reul and de Kloet are correct, the subset of 
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cloparninergic neurones expressing MR but not GR are unlikely to play a role in 
pathophysiological processes resulting from elevated corticosteroid levels. It is likely, 
however that the MR exerts a tonic regulatory role within VTA doparninergic neurones, and 
that decreases in corticosteroid secretion may adversely affect the functioning of these cells. 
It had been hoped that combining retrograde tracing with the aforementioned 
immunohistochernistry would reveal whether there are differences between mesocortical and 
mesolimbic neurones in their expression of these receptors. This was not possible, and a 
further aftempt to compare the spatial distribution of retrogradely labelled cells from the two 
projections with the pattern of GR expression also failed. This failure was due to the fact that 
retrogradely labelled cells from both terminal regions were found intermingled throughout the 
VTA. This result was somewhat disappointing as data from other groups suggests that these 
cells may originate in distinct regions of the VTA (Albanese & Minciacchi, 1983; Fallon et al. 
1978; Brog et al. 1993; Datiche and Caftarelli , 1996; Williams & Goldman-Rakic, 1998; 
Hasue & Sham m ah-Lagnado, 2002). It is possible that this was due to a methodological 
error, however other groups have shown similar results to those presented here (Margolis et 
al. 2006). If mesolimbic and mesocortical neurones are intermingled within the VTA the 
present results do not preclude the possibility that GR is preferentially expressed in either 
mesocortical or mesolimbic cells. However on the basis of the available data no firm 
conclusions can be drawn. 
6.1.2. Effects of corticosteroid rhythm dysregulation on gene transcription in the VTA 
Following the finding that corticosteroid receptors are expressed in VTA dopaminergic cells 
it was hypothesized that altering the corticosteroid rhythm would alter the transcription of 
genes within these cells. In situ hybridization histochernistry was used to compare mRNA 
levels within the VTA in tissue from animals which had undergone corticosterone treatment 
and untreated animals. A number of genes were selected based on their role in DA synthesis 
(tyrosine hydroxylase), release (VMAT2), reuptake (DAT) and metabolism. In addition gene 
expression of the D2 autoreceptor, subunits of the NMDA and AMPA receptors and the 5- 
HT2c receptor were investigated. The proteins coded for by these genes play important roles 
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in regulating dopaminergic neurotransmission and were thought to be likely candidates to 
mediate corticosteroid effects on dopaminergic function. 
The results of these experiments demonstrated that modulating the corticosteroid rhythm in 
rats resulted in increased mRNA expression of the dopaminergic synthetic enzyme tyrosine 
hydroxylase, the vesicular monoamine transporter VMAT2, and the D2 autoreceptor. 
Decreases were found in the GluRl subunit of the glutamatergic AMPA receptor and the 5- 
HT2c receptor. These results suggested that both upregulation and downregulation of 
doparninergic transmission might occur following corticosteroid induced transcriptional 
changes. If changes in mRNA levels are reflected at the protein level then both dopamine 
synthesis, and vesicular transport (and therefore vesicular content) would increase leading to 
an increase in dopamine release in terminal regions. Further to this the decrease in 
expression of the 5-HT2c receptor which inhibits dopaminergic neurotransmission would 
augment this effect. This would likely be a result of a decrease in the firing rate of the 
GABAergic interneurons on which this receptor is thought to be located, and thus 
disinhibiting doparninergic neuronal firing. 
In contrast to these results, the increase in D2 receptor transcription suggests a greater 
degree of autoreceptor inhibition of neuronal firing and dopamine release which would not 
only counter the any increase in neuronal firing resulting from the decrease in 5-HT2C 
receptor transcription via somatodendritic receptors, but also the increase in tyrosine 
hydroxylase expression via receptors at the terminal. The terminal D2 receptor regulates the 
phosphorylation state of tyrosine hydroxylase and inhibits enzyme activity. Thus even with 
an increase in TH protein as suggested by these results, the concomitant increase in D2 
protein would act to limit increases in dopamine synthesis. This would also limit the effect of 
VMAT2 upregulation due to lower neurotransmitter availability, and additionally an increased 
concentration gradient between dopamine containing vesicles and the cytoplasm, thus 
favouring leakage of dopamine to the cytoplasm. Furthermore the decrease in transcription 
of the GluRl subunit of the AMPA receptor would lead to a decreased excitatory drive on 
dopaminergic neurons decreasing their firing rate. 
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Analysis of sub-regional differences in mRNA expression within the VTA was performed in 
an attempt to determine whether there are differences in transcriptional regulation between 
mesolimbic and mesocortical neurones. Whilst the retrograde tracing experiment in the initial 
study had failed to find evidence that mesolimbic and mesocortical projections arise in 
different regions of the VTA, there is some evidence in the literature to support this notion 
(Albanese & Minciacchi, 1983; Fallon et al. 1978; Brog et al. 1993; Datiche and Caffarelli , 
1996; Williams & Goldman-Rakic, 1998; Hasue & Shammah-Lagnado, 2002). The principal 
findings here were that D2 receptor transcription was increased to a greater degree in the 
ventral region of the VTA, a region from which it has been suggested that the majority of 
dopaminergic neurons project to limbic areas. This suggests that the type of counter- 
regulatory effects of increased D2 transcription discussed in the previous paragraph occur to 
a greater degree in mesolimbic cells compared to mesocortical cells. Further support for this 
hypothesis is given by reports that the terminal synthesis regulating autoreceptor is less 
effective in mesocortical cells compared to mesolimbic cells (Hoffmann et al. 1988; 
Moghaddarn and Bunney, 1990; Agneter et al. 1994; Kuroki et al. 1999; Gessa et al. 2000; 
Devoto et al. 2001; Ago et al. 2005) suggesting that increases in D2 receptor transcription 
would have less of an impact on DA synthesis in this projection. This does not however 
preclude the possibility that the increase in transcription of D2 mRNA brings the terminal 
receptor "on-line" in the mesocortical system or that there is an increase somatodendritic D2 
mediated inhibition of firing. 
Sub regional analysis of the effect of corticosterone on 5-HT2c receptor expression 
revealed that in the ventromedial VTA no effect of cortiosterone was found. As the 
ventromedial region contains mesolimbic neurons projecting to the nucleus accumbens, it 
might be expected that the decreased inhibitory tone predicted for neurons in other regions 
of the VTA may not occur in a subset of mesolimbic neurons. This was taken as further 
evidence that neurotransmission increases by a greater extent in mesocortical neurons 
following corticosterone treatment 
Another finding of the sub-regional analysis was a significantly greater decrease in GluRl 
mRNA in the dorsolateral VTA than other regions. This part of the VTA has been suggested 
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to contain a high density of mesocortical cells, and the consequence of this could be a 
relatively greater loss of excitatory tone in this group of neurons compared to mesolimbic 
cells. It would appear that this finding is anomalous in the broader context of these results as 
far as they concern the mesocortical system, with the balance of evidence pointing to an 
upregulation of neurotransmission in this projection, however some attenuation of this effect 
may occur as a result of AMPA receptor downregulation. 
Overall it was hypothesized that in the mesocortical system the effects of corticosteroid 
dysrhythmia on gene transcription in the VTA would lead to an increase doparnine release 
as a result of increased synthesis, vesicular content, and decreased 5-HT2C mediated 
inhibitory tone, with some amelioration of these effects by the decreased excitatory drive 
resulting from AMPA receptor downregulation and increased somatodendritic D2 mediated 
inhibition. 
In contrast it was hypothesized that mesolimbic neurons would undergo an increase in TH 
transcription but the functional effects of this would be limited by an increase in terminal D2 
receptor expression, which would also serve to limit the effects of increased VMAT2 
expression and neurotransmitter release. The lesser decrease in 5-HT2c receptor expression 
in regions of the VTA containing mesolimbic neurons, the decrease in AMPA receptor 
function and the increased somatodendritic D2 receptor expression would lead to an overall 
decrease in the excitatory drive of these cells and reduce the firing rate. Thus the evidence 
suggests that mesolimbic neurotransmission would decrease following corticosteroid 
dysrhthymia of the type seen in bipolar disorder. 
6.1.3. Effects of corticosteroid rhythm dysregulation on dopaminergic function in 
mesocorticolimbic terminal regions. 
Based on the hypotheses generated by the in situ hybridization experiments, the functional 
effects of corticosteroid dysrhythmia were investigated. The first experiment was an assay of 
tyrosine hydroxylase activity in the nucleus accumbens and the prefrontal cortex to 
investigate the theory that this enzyme is differentially regulated by corticosteroids in the 
mesolimbic and mesocortical systems. The results provided some support for this hypothesis 
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however they were not conclusive. Tyrosine hydroxylase activity as measured by DOPA 
accumulation was almost doubled in the prefrontal cortex following corticosterone treatment 
however the results failed to reach statistical significance. In the nucleus accumbens the 
results were again inconclusive with a 50% decrease in DOPA accumulation in 
corticosterone treated animals following 20 minutes of DOPA clecarboxylase inhibition (a 
finding consistent with a previous study, Pacak et al. 2002), but no effect following 2 hours of 
treatment. Despite the lack of conclusive results these data provided some evidence that TH 
activity is differentially regulated in mesolimbic and mesocortical neurons. They also gave 
some support to the hypothesis that the increase in TH mRNA within the VTA would be 
reflected in an increase in function in the prefrontal cortex but not the nucleus accumbens as 
a result of differential D2 receptor function in the two systems. However the nature of these 
differential effects is yet to be fully elucidated. 
The second investigation employed in vivo microdialysis to evaluate doparnine efflux in the 
prefrontal cortex following corticosteroid dysrhythmia to determine whether changes in 
mRNA transcription in the VTA do, as hypothesized, increase doparnine release in this 
region. The results demonstrated that dopamine efflux was elevated by -50% in the 
presence of bupropion in corticosterone treated animals and additionally that potassium 
stimulated release increases dopamine levels to a greater degree following corticosterone 
treatment, with stimulated DA levels -50% greater than those seen in untreated animals. 
This was interpreted as evidence for an increase in doparnine release occurring without a 
change in the neuronal firing rate. Thus it would appear that as far as mesocortical neurons 
are concerned, the corticosterone induced alterations in GluR1,5-HT2C, and somatodendritic 
D2 receptor transcription seen in the in situ study did not affect the neuronal firing rate as had 
been originally hypothesized. 
In contrast, the demonstration of corticosterone induced increases in TH and VMAT2 
transcription in the in situ study provide a possible explanation for the observed increase in 
dopamine release. By increasing dopamine synthesis and vesicular uptake, it was 
hypothesized that vesicular content would increase in corticosterone treated animals. 
Increased vesicular content would account for the elevated release of dopamine seen in 
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treated animals in the microdialysis study and could increase release in the absence of 
changes to neuronal firing rate. 
D2 receptor function in the prefrontal cortex was also probed to determine whether the 
increase in D2 mRNA following corticosterone treatment affects terminal autoreceptor 
function. It was found that intra-PFC application of a D2 receptor antagonist had no effect on 
either bupropion or potassium stimulated dopamine release in treated and control animals. 
This replicates the findings of previous studies which have found little evidence for functional 
D2 terminal autoreceptors in this region (Moghaddam and Bunney, 1990; Kuroki et al. 1999; 
Gessa et al. 2000; Devoto et al., 2001; Ago et al. 2005). Furthermore it confirms the theory 
that the observed increase in D2 mRNA would have little impact on terminal receptor 
function. 
This is consistent with the tyrosine hydroxylase assay results where evidence for an 
increase in enzyme activity was found in the PFC but not the nucleus accumbens following 
corticosterone treatment. To summarize, the results can be taken as supporting the theory 
that in mesocortical neurones increased TH transcription following corticosterone treatment 
led to increased dopamine synthesis. Furthermore the lack of functional D2 receptors at the 
terminal meant that this increase in synthesis was not restrained by autoinhibition. The lack 
of an increase in TH function in the nucleus accumbens suggests that the concomitant 
increase in D2 receptor transcription following corticosterone treatment led to an increase in 
autoinhibition. This in turn attenuated synthesis in these neurons. The result of this was that 
increased TH transcription in mesolimbic neurons did not lead to an increase in dopamine 
synthesis. 
Whilst the hypothesis regarding mesocortical function which developed from the results of 
the in situ experiments is supported by the present data, mesolimbic function was not fully 
investigated. Ideally microdialysis would have been performed in the nucleus accumbens to 
compare dopamine release and autoreceptor function with the prefrontal cortex however this 
was not possible due to time constraints. The tyrosine hydroxylase assay did provide some 
evidence to support the theory that dopamine transmission is inhibited due to reduced 
doparnine synthesis, and it could be argued that as a result the increase in VMAT2 
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transcription would have limited effect, especially in the long term where dopamine 
availability is reduced. Furthermore, if it is indeed the case that increased terminal D2 activity 
was responsible for the lack of an increase in TH function, this would inhibit neurotransmitter 
release as well, thus negating the effects of increased VMAT2 transcription. There is some 
evidence in the literature suggesting that chronic administration of corticosteroids may 
attenuate dopamine release in the nucleus accumbens (Pacak et al. 2002). This attenuation 
of dopamine release may result not only from transcriptional changes but also from 
corticolimbic afferents which inhibit doparnine release in the nucleus accumbens in response 
to increases in dopamine in the pre-frontal cortex (Thompson and Moss, 1995; Doherty and 
Gratton, 1996). Consequently it may well be the case that doparninergic function is 
differentially regulated by corticosteroids in the mesocortical and mesolimbic systems. 
Overall the findings of this study provide evidence that corticosteroid dysrhythmia of the 
type seen in bipolar disorder increases mesocortical dopamine release and that this probably 
occurs as a result of increased neurotransmitter synthesis and vesicular packaging. 
Furthermore there was some evidence that mesolimbic and mesocortical neurons are 
differentially regulated by this dysrhythmia in terms of their tyrosine hydroxylase activity 
possibly as a consequence of their differential regulation by the terminal D2 autoreceptor. 
These findings are of potential importance in our understanding of mesocorticolimbic 
doparninergic function in bipolar disorder. 
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6.2. Methodological considerations 
6.2.1. Immunocytochemistry and retrograde tracing 
Immunocytochernistry was used in this study to determine whether corticosteroid receptors 
are present on dopaminergic cells in the VTA. This is a powerful and reliable technique for 
the detection of proteins within tissue provided appropriate steps to maintain labeling 
specificity are used. In the protocol used here a number of methods including peroxidase 
treatment and blocking steps with rat serum, BSA, and biotin/(strept)avidin were used to 
ensure labelling was specific to the protein of interest. This was confirmed by carrying out 
experiments in the absence of primary antibody in which labeling was not seen. As a 
consequence it is believed that the results obtained here are reliable. 
The principle criticism of the immunocytochernistry study would be the limited number of 
animals used. Whilst it was demonstrated that both MR and GR are expressed in VTA 
doparninergic cells, and this result is not in question, there is less certainty over the 
proportion of cells expressing these receptors. It is possible that GR/TH co-expression varies 
between animals, hence using more animals would have provided more accurate data. It is 
the case however that the proportion of GR/TH co-expressing found here was similar to that 
reported previously (Harfstrand et al. 1986). 
In the case of the GR, the fact that it was only found in a proportion of DA cells was 
interpreted as meaning that those cells where it was not observed do not express GR. These 
cells may, however, express this protein at a much lower level than those cells where 
labeling was evident. Labelling of GR required high concentrations of primary antibody 
compared to labeling for TH and signal amplification steps were required to improve 
visualization. Given this lack of sensitivity low levels of GR may not have been detectable in 
our experiments, and as a consequence it may not be accurate to state that those cells in 
which it was not observed do not express this receptor. 
Retrograde tracing was used in an attempt to determine the origin within the VTA of cells 
projecting to the prefrontal cortex and nucleus accumbens. The results of this study 
disagreed with a body of literature suggesting that these projections arise in different regions 
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of the VTA (although two published reports agreed with the results). Consequently no 
conclusions were drawn from these experiments, principally because there was some doubt 
over the accuracy of the tracer injections given the proximity of the PFC and NAcc at their 
respective caudal and rostra[ extents. These results were not used to derive any hypotheses 
for later work and are not thought to be detrimental to the rest of the study or any of the 
conclusions drawn. 
6.2.2. In situ hybridization 
In situ hybridization was used to quantitavely determine changes in levels of mRNA coding 
for specific proteins in the VTA. The probes used are of high specificity being complimentary 
to the mRNA of interest and a significant advantage of this technique is that probes can be 
designed for any known gene sequence. In this study measuring changes to mRNA levels 
was considered particularly appropriate given that corticosteroid receptors act as 
transcriptional regulators. 
There are a number of types of probe and various labels which can be used in in situ 
hybridization. In the present study oligonucleoticle probes labeled with [35 S]-dATP at the 3' 
tail were used to visualize mRNA. A drawback of this technique is the relatively low signal 
obtained from the probe, and as a consequence low abundance mRNAs are difficult to 
detect. Furthermore, where signal is detectable, if mRNA expression is low then changes in 
expression are more difficult to detect. An alternative to the use of an oligoprobe is to use a 
riboprobe which can be labeled at multiple sites and gives a better signal, however it has 
been reported that oligoprobes are more accurate at determining relative levels of mRNA in 
different brain regions (Broide et al. 2004). Furthermore oligoprobes are easier to label and 
cheaper to produce making them the better choice for this study. 
A major, and often cited, drawback of in situ hybridization is that it does not give an 
accurate measure of protein expression. Wide discrepancies have been demonstrated 
where changes in mRNA levels have been compared with protein expression (Gygi et 
al. 1999) and this makes extrapolating functional consequences from in situ hybridization 
results difficult. Further to this, the absence of changes to mRNA expression does not offer 
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any evidence that protein levels are not altered as a consequence of a particular treatment 
as demonstrated by studies in our laboratory (L. Ferrie, doctoral thesis 2005). In defence of 
the use of this technique in the present study, the fact that corticosteroid receptors are 
transcriptional regulators means that their primary effects are via changes in mRNA 
expression. Measures of mRNA are therefore of value in demonstrating that these receptors 
are present and functional in the VTA in support of the results from the immunocytochemistry 
experiments. 
A further drawback of in situ hybridization is that it does not give any information regarding 
the phenotype of the cells in which a particular mRNA is expressed. In the present study it 
was, with one exception (the 5-HT2c receptor), assumed that the changes in mRNA 
expression occurred in doparninergic neurons, however the presence of corticosteroid 
receptors in other cells within the VTA as demonstrated by ICC offers the possibility that 
other types of cell were involved. In fact this is only likely to be true for the GluRl subunit of 
the AMPA receptor and possibly the D2 receptor (see Pickel et al. 2002). All other probes 
targeted mRNA coding for proteins specifically related to dopaminergic function (TH, 
VMAT2, DAT). In the case of the 5-HT2c receptor it was assumed based on evidence from 
the literature that this receptor was present on GABAergic interneurons, although the 
evidence to support this is indirect. 
6.2.3 Tyrosine Hydroxylase assay 
Tyrosine hydroxylase enzyme function was measured in the nucleus accumbens and 
prefrontal cortex of rats by inhibiting DOPA decarboxylase activity for a period of either 20 
minutes or 2 hours prior to sacrifice and subsequently measuring DOPA accumulation in 
homogenised tissue from the regions of interest. This method gives a measure of the rate of 
dopamine synthesis as TH is the rate limiting enzyme in this pathway. 
DOPA concentrations were calculated by measuring total DOPA tissue content with high 
performance liquid chromatography. A limitation of this method was the sensitivity of the 
HPLC assay. In tissue from the prefrontal cortex, 20 minutes of DOPA decarboxylase 
inhibition did not result in measurable levels of DOPA, whilst after 2 hours levels were 
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measurable but very low. The results indicated that TH activity was increased following 
corticosterone treatment in this region but statistical significance was not reached and this is 
likely to be a direct consequence of the extremely low levels present. As such, limitations in 
the assay are thought to be responsible for the inconclusive results obtained. 
A further reason for the variability in the data, which was also seen in the nucleus 
accumbens, was the method used to dissect the tissue. The dissection was relatively 
inaccurate in both regions consisting of tissue blocks containing the region of interest. This 
offers an explanation for the variable tissue levels recorded, given that the tissue blocks 
might have contained varying amounts of the adjacent regions. Overall limited conclusions 
could be drawn from the data although some indication of differential effects of 
corticosterone in the two brain areas was evident. 
6.2.4. In-vivo microdialysis 
In vivo microdialysis is a useful method for measuring neurotransmission in the brains of 
intact animals. It allows measurement of basal neurotransmitter release, as well as the 
effects of local application of drugs and solutions to probe neuronal function. In this thesis 
microdialysis was used to measure dopamine efflux under a variety of conditions in rats 
treated with corticosterone and control animals. 
An important factor in interpreting microdialysis data is the invasive nature of the technique. 
Insertion of a microdialysis probe into the brain causes damage to a number of brain regions 
en-route to the region of interest. In this study the probe was placed in the infralimbic cortex 
and passed though more dorsal regions of the PFC during implantation. There is the 
possibility that this may have affected afferent input to the infralimbic cortex with potential 
consequences for neurotransmission in this region. In addition there is evidence that probe 
implantation damages the blood brain barrier (Groothuis 1998). It has been reported that 
between one and two hours after probe implantation neurotransmitter levels are restored to 
their normal levels (Benveniste and Huttemeier 1990) and as a consequence in the present 
studies samples were not taken for at least one hour after surgery. 
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Another important factor is the use of anaesthetized animals in the present study. Urethane 
has been reported to decrease neurotransmission in doparninergic terminal regions such as 
the striaturn (Warenycia and McKenzie, 1988, West, 1998) and as a consequence it has 
been suggested that anaesthetics are a confounding factor when extrapolating data from 
studies in anaesthetized animals. The converse argument to this is that anaesthetized 
animals have reduced sensory input, are not moving around, and show no behavioural 
responses to drug administration, factors which could complicate the interpretation of results 
from awake animals. Whilst it is true that the function of the dopaminergic neurons examined 
in this study might be significantly different to that in an awake animal, the fact that 
differences were seen in dopamine efflux between treated and control animals remains a 
valid finding. Given that the changes observed are likely to be the result of increased 
synthesis and vesicular uptake of dopamine rather than a change in neuronal firing rate 
(which is more likely to be affected by anesthesia due to alterations in afferent input), one 
would expect a similar effect of corticosterone on dopamine release in awake animals. The 
findings do therefore provide evidence that corticosterone dysregulation produces an 
increase in doparninergic neurotransmission within the prefrontal cortex. 
6.2.5. Corticosterone treatment model 
The corticosterone treatment model used in this thesis, in which corticosterone was 
administered to animals via their drinking water, has been validated in previous studies 
carried out in our laboratory (G. Fairchild, doctoral thesis 2004). Repeated blood sampling 
over a twenty four hour period has shown that this treatment leads to an increase in 
corticosterone levels during the diurnal nadir (approximately 5-8 fold greater than those seen 
in vehicle treated animals) whilst leaving the diurnal peak relatively unchanged. This pattern 
of secretion is similar to that seen in bipolar disorder patients with HPA axis abnormalities 
(Akesocle et al. 1976; Linkowski et al. 1985; Linkowski et al. 1994; Souetre et al. 1991; 
Cervantes et al. 2001). Corticosterone administration via drinking water offers several 
advantages over administration via osmotic minipump or corticosterone pellet. First it is non- 
invasive avoiding the stress of surgery and recovery and the confounding influence of 
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anaesthetic treatment. Furthermore it is highly flexible allowing the withdrawal and 
reinstatement of treatment at any time and as such can be adapted to model episodic as well 
as chronic dysregulation of corticosterone treatment. It should be noted, however, that this 
model does not mimic other aspects of HPA axis dysregulation seen in bipolar disorder (see 
1.2.3. ) including reduced negative feedback regulation, ACTH secretion hypo- 
responsiveness to CRH, or ACTH hyper-responsiveness to combined dexamethasone/CRH. 
As such what is modeled is not the HPA axis dysfunction itself, but rather the corticosterone 
secretion profile seen with this dysfunction. Whilst it is believed this has validity for the study 
of corticosteroid effects on CNS function in bipolar disorder, the limitations of the model must 
nevertheless be taken into consideration. 
6.2.6. Rodent modefling of human disease states 
The use here of a rodent model to investigate mechanisms which might be responsible for 
bipolar disorder in humans has two principal limitations. The first of these is the validity of the 
model i. e. what is actually being modeled and how can that be interpreted in a clinical 
context. The second limitation is the question of whether a rat model has validity for the 
study of human disease processes. 
The issue of what is actually being modeled is extremely important, and has to a certain 
extent been discussed in section 6.2.5. Here it was stated that the corticosterone treatment 
paradigm only models the pattern of corticosterone secretion seen in bipolar disorder, but 
not the HPA axis dysfunction itself. More fundamentally, this treatment does not produce a 
model of bipolar disorder. Rather, it may model a vulnerability towards bipolar disorder in 
individuals with HPA axis dysfunction, which with the right interplay of genes and 
environment can trigger the condition in some individuals. The fact that very similar HPA axis 
abnormalities are found in some patients with unipolar depression (Yehuda et al. 1996; 
Deuschle et al. 1997) further argues against this as a model of bipolar disorder specifically 
but possibly a vulnerability model for affective disorders in general. A common aetiological 
mechanism for affective disorders would fit with the notion that bipolar disorder and 
depressive disorders are not distinct but exist on a continuum with mood states ranging from 
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pure mania to outright depression (see Akiskal, 2002; Muller-Oerlinghausen, 2002). In the 
context of more categorical definitions of affective disorders, the HPA axis abnormalities are 
likely to interact with environmental and genetic factors which determine the specific type of 
affective disorder triggered in a susceptible individual, with bipolar disorder representing one 
of many possible outcomes. In light of these considerations it can be seen that simply 
administering corticosterone will not produce a cage full of bipolar rats any more than 
corticosterone administration to humans will induce bipolar disorder. In defence of the model 
it was never the intention to replicate bipolar disorder but to investigate the effects of 
corticosteroid dysrhythmia on dopaminergic function. This has relevance to bipolar disorder 
due to the HPA axis and dopaminergic abnormalities which have been observed in the 
illness and is likely to have some value in aiding our understanding of doparninergic aspects 
of the disease process. 
The reason a model of the disease itself was not attempted stems from the incredibly 
complex nature of the illness and our lack of understanding of it. In the past, attempts have 
been made to model mania in rats using stimulant drugs, sleep deprivation, brain lesions and 
electrical stimulation, whilst models of depression have utilised stress paradigms, brain 
lesions, neurochernical manipulation, and rats bred to exhibit depressive behaviours 
(reviewed by Machado-Vieira et al. 2004). Although these models produce certain 
behaviours which are thought to be analogous to those seen in human mania or depression 
they have consistently failed to replicate anything like the full spectrum of affective and 
cognitive disturbances characteristic of the illness. Furthermore there has never been a 
model which produces one of the most important characteristics of bipolar disorder which is 
mood cycling. As a consequence whilst these models might provide insights into the 
generation of mood and its dysregulation, they cannot be described as models of bipolar 
disorder. 
A more fundamental problem with any animal model of bipolar disorder is how closely 
cognitive and emotional dysregulation, as measured by relatively primitive behaviours, can 
be related to the symptoms of the disease in humans. This is particularly true of rodent 
models where cognitive and emotional processing is far less advanced than in humans - 
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indeed it is questionable whether rodents can develop bipolar disorder at all, and if they can 
would we recognize it as such? In the present study these problems were avoided by 
attempting to model what may be a causative factor or vulnerability trait for bipolar disorder, 
looking at the effects of this on neuronal function, and attempting to relate the results to 
neuronal abnormalities which are thought to contribute to bipolar disorder in humans. At the 
neuronal level a rodent model can provide insight into human brain function given the broad 
similarities in basic function and anatomy between mammalian brains. Even at this level 
however there are questions over the validity of rodent models. 
In the present study increases in dopamine release were found in the medial prefrontal 
cortex of rats following corticosterone treatment and in the following section the potential 
clinical implications for humans will be discussed. It is the case, however, that the presence 
of a rat prefrontal cortex analogous to and serving the same functions as the human/primate 
prefrontal cortex has been questioned (Preuss, 1995). Anatomically, the prefrontal cortex is 
defined as the regions of the frontal lobe receiving afferents from the mediodorsal thalamic 
nucleus (Rose and Woolsey, 1948). In primates this includes the dorsolateral, medial and 
orbital frontal cortices, whilst in rats only the medial and orbital cortices receive these 
projections. As a consequence of this it has been suggested that the primate dorslateral 
cortex is functionally unique, which, were it to be true, would make the extrapolation of data 
from the rat PFC to humans somewhat difficult. There is evidence to suggest, however, that 
dorsolateral functions in humans are carried out in other regions of the PFC in rats. In 
humans the dorsolateral prefrontal cortex is associated with so called "executive" cognitive 
processes including working memory, aftentional control, reasoning and decision-making, 
and the temporal organization of behaviour (Brown and Bowman, 2002). In rats, similar 
functions have been found associated with the medial prefrontal cortex (reviewed in Brown 
and Bowman, 2002), suggesting that despite the lack of a dorsolateral PFC, its cognitive 
functions are preserved. A good demonstration of this is the role of these regions in the 
formation of higher order rules for guiding behaviour. In humans this can be tested using the 
Wisconsin Card Sort Test which measures attentional set-shifting and is dependent on 
visual-processing, attention, and working-memory. Studies in humans have shown that 
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lesions of the frontal lobe, including dorsolateral PFC lesions, impair performance on this 
test with a greater number of perseverative errors due to an inability to shift attention from 
one aspect of a complex stimulus (e. g. colour) to another (e. g. shape) (reviewed by Alvarez 
and Emory, 2006). In rats an analogous test has been devised which involves the animals 
digging for food in bowls where stimuli vary in terms of odour, digging medium or surface 
texture (Birrell and Brown, 2000). In this test, lesions of the medial prefrontal cortex result in 
impairments of set-shifting analogous to those seen with dorsolateral prefrontal cortex 
lesions in humans. The similarities in cognitive function between human dorsolateral PFC 
and rodent mPFC suggest that changes to PFC function in rats can be related to PFC 
function in humans including those processes associated with the dorsolateral PFC. As a 
consequence it can be argued that any discussion of mPFC dysfunction as it relates to 
cognition in rats can be extrapolated to cognitive function in humans, and furthermore that 
the results from the present study have clinical relevance as far as the effect of HPA axis 
dysregulation on prefrontocortical function is concerned. 
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6.3. Clinical Implications 
The results presented in this thesis demonstrate that flattening of the corticosteroid rhythm 
results in an increase in the release of doparnine in the prefrontal cortex. This is likely to 
result from corticosteroid action at receptors within VTA doparninergic cells which increase 
the transcription of genes coding for tyrosine hydroxylase and the vesicular monoamine 
transporter in response to elevated cortisol levels during the diurnal nadir in secretion. An 
increase in doparnine release in this region is consistent with the current monoamine 
hypothesis of bipolar disorder which states that doparninergic hyperfunction is in part 
responsible for the emotional and cognitive impairments characteristic of the disease (see 
chapter 1). The following section considers in more detail how excess dopamine release in 
the prefrontal cortex might be involved in these impairments and examines the evidence that 
HPA axis dysfunction is a pre-morbid vulnerability trait for affective disorders. 
6.3.1. Prefrontocortical cognitive function 
In chapter 5 the implications of increased dopamine release in the prefrontal cortex were 
discussed in relation to the known functions of this part of the brain. The microdialysis study 
measured dopamine levels in the pre- and infralimbic cortices which have been associated 
with "executive functions" such as working memory, aftentional regulation, action-outcome 
contingency detection and visual attention selectivity in rats (Dailey et al. 2004). In studies of 
working memory in rodents modest elevations in dopaminergic activity using DA agonists 
were shown to improve working memory, whilst supranormal DA activity impaired working 
memory (reviewed by Arnsten, 1997; Robbins, 2005). Furthermore, stress induced 
elevations in dopamine release produce impairments of working memory in a similar fashion 
to those induced by DA agonists (reviewed by Arnsten, 1997; Robbins, 2005). The increase 
in dopamine levels seen in the present study was relatively modest (-50% increase) 
compared to the levels which have been shown to produce working memory impairments 
(-150-250% increase; Murphy et al. 1996; Verma and Moghaddam, 1996) and it is possible 
that cognitive function improves with such an increase. It is currently unclear, however, at 
what level of dopaminergic stimulation cognition is impaired and it could equally be the case 
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that the increase in DA release seen here is detrimental to working memory and other 
executive functions. 
An impairment of prefrontal cognitive function as a consequence of elevated dopamine 
levels would be consistent with neuropsychological findings in bipolar disorder. A number of 
studies have demonstrated impairments to executive function in bipolar patients (reviewed 
by Quraishi and Frangou, 2002; Savitz et al 2005) and these deficits are present in 
depressed, manic, and hypomanic phases of the illness (Martinez-Aran et al. 2004; Malhi et 
al. 2007) as well as during the euthymic phase when mood symptoms are absent (Martinez- 
Aran et al. 2004; Thompson et al. 2005; Kolur et al. 2006). The presence of neurocognitive 
deficits in euthymic patients suggests that the impairment is independent of mood state and 
may represent a trait marker for bipolar illness. Further evidence for this is given by the fact 
that whilst the degree of neurocognitive impairment correlates with severity and length of 
illness (Robinson and Ferrier, 2006), significant deficits are present at first hospitalization 
(Gruber et al. 2007) making it possible that the impairment was present prior to the onset of 
affective symptoms. As circadian corticosteroid secretion is abnormal in all phases of bipolar 
illness (Akesocle et al. 1976; Linkowski et al. 1985; Linkowski et al. 1994; Souetre et al. 
1991; Cervantes et al. 2001) such persistent neurocognitive deficits support the theory that 
HPA axis abnormalities play a role in their generation. Further to this the ability of 
corticosteroids to modulate neurocognitive function in healthy individuals has been 
demonstrated in studies where corticosteroid administration was found to impair verbal and 
working memory (Lupien et al. 1999; Newcomer et al. 1999). It may be the case that 
elevated dopamine, levels caused by chronic HPA axis dysrhythmia are responsible for 
deficits in executive function which are entirely independent of mood state and may precede 
the onset of affective symptoms, thus implicating both HPA axis abnormalities and dopamine 
induced neurocognitive deficits as vulnerability factors for bipolar disorder. 
Such a theory depends on the elevation of dopamine levels being sufficient to impair 
cognitive function in itself, and, as discussed previously, this may not in fact be the case. 
Under these circumstances an alternative interpretation of the present results is that the 
threshold for cognitive impairment is reached more readily under conditions of stimulated 
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dopamine release in people with HPA axis abnormalities due to an elevated basal level of 
dopamine. In addition the fact that potassium stimulated release produced a greater peak 
concentration of DA in treated animals indicates that there is a greater capacity for dopamine 
release in these animals than in controls. As a consequence it is possible that not only is the 
threshold for cognitive impairment reached more readily in people with a flattened 
corticosteroid rhythm, but that the cognitive impairment produced is more severe due to 
more dopamine being released following an appropriate stimulus. 
These types of effects are likely to manifest themselves during stress induced increases in 
prefrontal dopamine. The ability of acute stress to increase dopamine release in the 
prefrontal cortex has been hypothesised to be of benefit in the "fight or flight" response 
where fast habitual responding is required to deal with perceived threats. Elevated doparnine 
levels which produce an impairment of PFC cognitive function actually serve to take the PFC 
ssoffline" via inhibition of cortical pyramidal cells during stressful events, and it has been 
shown that these elevations of doparnine in the PFC improve performance at simple well- 
rehearsed tasks which are presumably controlled by lower order brain functions (Arnsten, 
1997). It could be suggested therefore that the elevated basal DA levels put the PFC into a 
state where it is primed to over-respond to stressors, increasing the likelihood of triggering a 
"fight or flight" response where it is inappropriate. Such a priming mechanism might play a 
role in the well documented ability of stressful events to trigger both first-onset and repeated 
episodes of bipolar disorder. Thus whilst corticosteroid dysrhythmia may not be directly 
responsible for neurocognitive deficits, the doparninergic hyper-responsiveness it produces 
may predispose individuals to this type of impairment, again implicating it as a vulnerability 
factor in bipolar disorder. 
6.3.2. Prefrontocortical regulation of emotion 
Whilst HPA axis dysfunction might be responsible for neurocognitive deficits in bipolar 
disorder, or act as a priming mechanism for such deficits, linking it to emotional aspects of 
the illness is more problematic. The fact that the pattern of corticosteroid secretion is not 
predictive of mood state indicates that other mechanisms are involved in the generation of 
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the fundamentally different symptoms characteristic of mania and depression. Despite this 
there is evidence that the prefrontal cortex is involved in the regulation of emotion although 
the processes involved are poorly understood. 
Lesions of the medial prefrontal cortex in humans impair the ability of subjects to anticipate 
future negative and positive consequences of their actions and to cope emotionally with 
different situations (reviewed in Davidson and Irwin, 1999; Bandler et al. 2000) and it has 
been suggested that damage to the PFC impairs the ability to sustain emotion so it can be 
used to guide future behaviour (Davidson and Irwin, 1999). Adaptive responding to 
emotional experiences is dependent on the ability to regulate emotion via cognitive 
processes (Urry et al. 2006) and a number of imaging studies have shown that the prefrontal 
cortex is involved in this regulatory mechanism via modulation of amygdala activity during 
conscious suppression of emotion (Beauregard et al. 2001; Levesque et al. 2003; Ochsner 
et al. 2004; Ohira et al. 2006; Urry et al. 2006). Afferents from the medial prefrontal cortex to 
the amygdala have been demonstrated in both rats (Gabott et al. 2005) and primates 
(Stefanacci and Amaral, 2002) and lesions of the medial prefrontal cortex in rats impair the 
extinction of conditioned responses to aversive stimuli (Morgan et al. 2003). The role of 
dopamine in this process has been demonstrated by selectively lesioning DA neurones in 
the prefrontal cortex, the result of which is to delay the extinction of fear conditioning 
(Morrow et al. 1999; Fern andez-Espejo, 2003) in a similar fashion to that seen with gross 
lesions of the mPFC. These effects parallel the findings in the human imaging studies 
mentioned previously in as much as the ability of the animal to suppress the fear response to 
the conditioned stimulus once it is no longer presented with a painful stimulus is impaired 
following prefrontal lesions. The elevated dopamine levels seen in the present study may 
have an analogous effect to gross lesions as a result of their ability to reduce 
prefrontocortical function (Arnsten, 1997) and this may impair emotional processing in a 
similar fashion. This makes it possible that the changes to prefrontocortical function seen in 
the present study affect the ability of the PFC to regulate emotional adaptation and this 
implicates such changes in the affective dysregulation characteristic of bipolar disorder. 
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Evidence for prefrontocortical-amygdala dysfunction in bipolar disorder to support this 
theory is provided by studies which have examined facial emotion recognition in bipolar 
patients, a process associated with activity in the prefrontal cortex and the amygdala 
(O'Doherty et al. 2003; Ochsner, 2004). Abnormalities in facial emotion processing have 
been found in rernifted (Bozikas et al. 2006; Pavaluri et al. 2007), depressed (Lawrence et al. 
2004) and manic (Lennox et al. 2004) bipolar subjects suggesting that this may be a trait 
marker for bipolar illness. The evidence that this deficit is present in all mood states supports 
the theory that HPA axis dysfunction may play a causative role, given that the pattern of 
circadian cortisol secretion in bipolar patients is abnormal across mood states (Akesode et 
al. 1976; Linkowski et al. 1985; Linkowski et al. 1994; Souetre et al. 1991; Cervantes et al. 
2001). As such it is possible that HPA axis dysregulation adversely affects prefrontocortical 
function, in turn impairing emotional processing in the amygdala. 
Such an involvement of the HPA axis in these processes is given further credence by the 
previously mentioned imaging study by Urry et al. (2006) which looked at suppression of 
negative emotions in human subjects. By taking salivary cortisol samples throughout the day 
it was demonstrated that subjects with a flattened cortisol secretion profile performed less 
well in their ability to suppress negative emotions than subjects with a normal profile, an 
intriguing finding given that the data in this thesis could provide the "missing link" between 
the flattened cortisol profile and the PFC-amygdala dysfunction associated with negative 
affect suppression. It is possible that flattening of the cortisol rhythm increases PFC 
doparnine (as shown in the present study), which in turn alters prefrontocortical regulation of 
the amygdala to produce the impairments of emotion seen in bipolar disorder. 
6.3.3. Implications of potential changes to dopaminergic transmission in the nucleus 
accumbens 
Doparnine release in the nucleus accumbens is thought to play a central role in the brain 
reward circuit and increases in doparnine release in this region are associated with the 
rewarding properties of intracranial self stimulation, drugs of abuse, food, sex, and social 
interactions (reviewed by Salamone et al. 2002a). The exact role doparnine plays in reward 
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related processes is somewhat controversial, but there is evidence that dopamine is involved 
in anticipatory and "wanting" aspects of reward rather than the rewarding properties of a 
stimulus per se (Salamone and Correa, 2002). Evidence for this is provided by studies which 
have shown that dopamine depletion or administration of dopamine antagonists in the NAcc 
reduces the amount animals are willing to work for a rewarding stimulus but do not impair the 
appetite for that stimulus (Aberman et al. 1999; Nowend et al. 2001; Correa et al. 2002; 
Salamone et al. 2002). The results of the tyrosine hydroxylase assay in chapter 5 suggest 
that dopamine synthesis in the nucleus accumbens may be decreased by flattening the 
corticosteroid rhythm and this is supported by experiments performed by Pacak et al. (2002) 
showing that chronic hypercortisolaemia inhibits dopamine synthesis and turnover in this 
region. Furthermore there is evidence that an increase in dopamine release in the prefrontal 
cortex, such as that seen in the present study, can inhibit dopamine release in the nucleus 
accumbens (Thompson and Moss, 1995; Doherty and Grafton, 1996). A role for 
glucocorticoids in regulating reward processes is suggested by studies showing that 
adrenalectomy attenuates the release of dopamine in the NAcc in response to cocaine 
(Barrot et al. 2000) and that this occurs selectively in the nucleus accumbens., whilst 
administration of corticosteroids to replicate stress levels promotes the self administration of 
drugs of abuse (Piazza et al. 1991; Mantsch et al. 1998). Although the effects of flattening 
the corticosteroid rhythm on dopamine release in the NAcc are unknown, the literature 
suggests that a functional consequence might be a disruption of dopamine mediated 
motivational processes in the reward pathway. Disruption of systems involved in the 
generation of reward has been implicated in anhedonic and motivational aspects of major 
depression (Nestler and Carlezon, 2006) and deficits in these functions accord with the 
symptoms of depressive states in bipolar disorder. The high comorbidity of substance abuse 
disorders with bipolar disorder (see Krishnan, 2005; Hirshfeld and Vornik, 2005; Pini et al. 
2005) further supports the notion that dopaminergic aspects of the reward system are 
dysfunctional in the illness increasing the susceptibility of individuals to self administer drugs 
of abuse which activate this system. This active seeking of rewarding stimuli is also 
consistent with the symptoms of mania in which there is compulsive reward seeking 
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behaviour in conjunction with a disregard or inability to predict the consequences of such 
behaviour. Without knowing the effect of flattening the corticosteroid rhythm on dopamine 
release in the nucleus accumbens, and given the complex role of dopamine in these 
processes, it is difficult to predict the consequences for human reward functions. The 
evidence suggests, however, that the flattening of the corticosteroid rhythm seen in bipolar 
disorder may induce changes in nucleus accumbens doparninergic function that play a role 
in the affective symptoms of the illness via interfering with the brain reward system. 
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6.4. Conclusion 
In conclusion the present thesis demonstrates that flattening of the corticosteroid rhythm 
results in changes to mRNA transcription in the VTA which produces differential effects on 
dopamine synthesis in the mesocortical and mesolimbic pathways whilst upregulating 
dopaminergic neurotransmission in the prefrontal cortex. Furthermore the finding that MR 
and GR receptors are present in dopaminergic cells of the VTA suggests that these effects 
result from a direct modulation of gene transcription in these cells rather than indirect 
interactions with other brain systems. 
This increase in dopamine release in the prefrontal cortex is consistent with alterations to 
neurocognitive function and emotional processing which are thought to be trait markers for 
bipolar illness which, when taken into consideration with the evidence that the cortisol profile 
is altered in euthymic bipolar individuals and across all mood states, suggests that flattening 
of the 24 hour cortisol profile may be responsible for such deficits and may in itself be a trait 
marker for bipolar disorder. 
The implications for nucleus accumbens doparninergic function were consistent with 
affective dysregulation resulting from decreased dopaminergic activity in this region. This is 
certainly consistent with anhedonic aspects of depressive phases of the illness and may also 
account for the pleasure seeking aspects of mania which may be a compensatory strategy 
for such a deficit. 
Overall the data presented in this thesis suggests that a flattened cortisol rhythm may be a 
vulnerability factor for bipolar disorder which disrupts dopaminergic neurotransmission and 
may account for alterations in brain function associated with deficits in cognitive and 
emotional processing present in bipolar individuals. 
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